EP0799020A1 - Cosmetic and dermatological preparations with flavonoids - Google Patents

Cosmetic and dermatological preparations with flavonoids

Info

Publication number
EP0799020A1
EP0799020A1 EP95941094A EP95941094A EP0799020A1 EP 0799020 A1 EP0799020 A1 EP 0799020A1 EP 95941094 A EP95941094 A EP 95941094A EP 95941094 A EP95941094 A EP 95941094A EP 0799020 A1 EP0799020 A1 EP 0799020A1
Authority
EP
European Patent Office
Prior art keywords
group
hair
alpha
skin
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP95941094A
Other languages
German (de)
French (fr)
Inventor
Ghita LANZENDÖRFER
Franz STÄB
Sven Untiedt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beiersdorf AG
Original Assignee
Beiersdorf AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6535603&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0799020(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Beiersdorf AG filed Critical Beiersdorf AG
Priority to DE29522372U priority Critical patent/DE29522372U1/en
Publication of EP0799020A1 publication Critical patent/EP0799020A1/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365Hydroxycarboxylic acids; Ketocarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37Esters of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60Sugars; Derivatives thereof
    • A61K8/602Glycosides, e.g. rutin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52Stabilizers
    • A61K2800/522Antioxidants; Radical scavengers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/001Preparations for care of the lips
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/19Sheets or webs edge spliced or joined
    • Y10T428/192Sheets or webs coplanar
    • Y10T428/193Double faced corrugated sheets or webs connected
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/19Sheets or webs edge spliced or joined
    • Y10T428/192Sheets or webs coplanar
    • Y10T428/195Beveled, stepped, or skived in thickness

Definitions

  • the present invention relates in particular to cosmetic and dermatological preparations containing flavonoids, their glycosides and, if appropriate, their combinations with cinnamic acid derivatives or antioxidants.
  • the damaging effect of the ultraviolet part of solar radiation on the skin is generally known. While rays with a wavelength shorter than 290 nm (the so-called (JVC range) are absorbed by the ozone layer in the earth's atmosphere, rays in the range between 290 nm and 320 nm, the so-called UVB range, cause erythema, a simple sunburn or even more or less severe burns.
  • JVC range the so-called (JVC range)
  • the narrower range around 308 nm is given as a maximum of the erythema effectiveness of sunlight.
  • UVB radiation which are derivatives of 3-benzylidene camphor, 4-aminobenzoic acid, cinnamic acid, salicylic acid, benzophenone and also 2-phenylbenzimidazole. It is also important to have filter substances available for the range between about 320 nm and about 400 nm, the so-called UVA range, since their rays can cause reactions in light-sensitive skin. It has been proven that UVA radiation leads to damage to the elastic and collagen fibers of the connective tissue, which causes the skin to age prematurely, and that it is to be seen as the cause of numerous phototoxic and photoallergic reactions. The damaging influence of UVB radiation can be intensified by UVA radiation.
  • UV radiation can also lead to photochemical reactions, in which case the photochemical reaction products interfere with the skin's metabolism.
  • Such photochemical reaction products are predominantly free radical compounds, for example hydroxy radicals.
  • Undefined radical photo products which are created in the skin itself, can also display uncontrolled subsequent reactions due to their high reactivity.
  • singlet oxygen a non-radical excited state of the oxygen molecule can occur with UV radiation, just as short-lived epoxies and many others.
  • Singlet oxygen for example, is characterized by increased reactivity compared to the triplet oxygen normally present (radical ground state).
  • UV radiation also belongs to ionizing radiation. There is therefore a risk that ionic species also develop when exposed to UV rays, which in turn can oxidatively intervene in the biochemical processes.
  • antioxidants or free radical scavengers can be incorporated into cosmetic or dermatological formulations.
  • vitamin E a substance with a known antioxidative effect, in light protection formulations, but the effect achieved here also falls far short of the hoped-for effect.
  • the effect of solar radiation on the skin is, besides the formation of light swellings and tanning, mainly caused by the UVB area, a slow and progressive degradation of the connective tissue under the epidermis, caused by the longer-wave area of UVA sunlight, in which the elastic areas are exposed to radiation and strengthening fibers are destroyed.
  • the weakening strength of the connective tissue leads to increased wrinkling and in extreme cases can lead to so-called "farmer's skin” or actinic keratosis. Wrinkles, wrinkles and dry skin that occur before the actual biological age due to environmental influences and the symptom of "premature skin aging" are considered as cosmetic undesirable " are.
  • Antioxidants are mainly used as protective substances against the spoilage of the preparations containing them. Nevertheless, it is known that undesirable oxidation processes can also occur in human and animal skin. Such processes play an essential role in skin aging.
  • the object of the invention was therefore to provide cosmetic and dermatological active ingredients and preparations and light protection formulations which are used for the prophylaxis and treatment of light-sensitive skin, but also normal skin exposed to the sun.
  • the lips are an area of the face, which due to its structure and exposure is strongly exposed to and influenced by external influences.
  • the naturally red color of the lips stems from the fact that lip skin, in contrast to "normal" skin, is much thinner, sweat and sebum glands are also missing. Melanin is significantly less present.
  • the lack of some of the natural protection of the skin leads to lips being underneath Cold, heat and solar radiation are more exposed than normal skin, so protection and care of the lips are necessary in order to maintain a smooth, rosy appearance of the lips.If the lips were not adequately protected during exposure, the symptoms mentioned above can be seen Relief and elimination can also be seen as a cosmetic concern.
  • the invention relates to preparations with extremely low so-called "stinging potential" and preparations against non-specific non-pathological itching.
  • the skin especially the epidermis, as a barrier organ of the human organism, is particularly exposed to external influences.
  • the skin represents an immunological organ, which as an immunocompetent peripheral compartment plays its own role in inductive, effective and regulative immune processes of the whole organism.
  • the epidermis is rich with nerves and nerve end devices such as Vater-Pacini lamellar bodies, Merkel-cell-neurite complexes and free ones Nerve endings equipped for pain, cold, warmth and itching.
  • nerve end devices such as Vater-Pacini lamellar bodies, Merkel-cell-neurite complexes and free ones Nerve endings equipped for pain, cold, warmth and itching.
  • This "sensitive skin” differs fundamentally from “dry skin” with thickened and hardened horny layers.
  • Typical reactions of "stinging" to sensitive skin are reddening, tension and burning of the skin as well as itching.
  • Typical disturbing neurosensory phenomena associated with the terms "stinging” or “sensitive skin” are reddening of the skin, tingling, tingling, tensing and burning of the skin and itching.
  • the itching in atopic skin is to be regarded as a neurosensory phenomenon, as well as itching in skin diseases, which is only a symptom of these diseases and vice versa but also unspecific, i.e. without a clinical finding of a skin disorder, infection or irritation.
  • unspecific itching is a first sign of a possible hidden general illness, it can also be triggered by stress or other environmental influences.
  • “Stinging” phenomena can therefore generally be regarded as disorders to be treated cosmetically. Severe itching, on the other hand, particularly severe itching of the skin that occurs in atopy, can also be described as a more serious dermatological disorder, while itching that occurs during stinging or nonspecifically without a disease can also be regarded as a cosmetically treatable disorder.
  • a "permeable" barrier is discussed, which is reflected in an increased TEWL.
  • occlusive or lipid-substituting ones are used Products recommended that lower the TEWL after application.
  • P.Elias even describes various lipid mixtures that cause barrier regeneration on mouse skin that has been damaged with acetone.
  • the topical application of RRR-a-tocopherol has also been shown to improve the skin barrier.
  • the dye chromophore is formed by the reaction of precursors (phenols, aminophenols, more rarely diamines) and bases (mostly p-phenylenediamine) with the oxidizing agent, mostly hydrogen peroxide. Hydrogen peroxide concentrations around 6% are usually used.
  • the hydrogen peroxide also has a bleaching effect. Similar to bleached hair, microscopic holes in the areas where melanin granules were present can be detected in oxidatively colored human hair.
  • the oxidizing agent hydrogen peroxide not only reacts with the color precursors, but also with the hair substance and can cause damage to the hair.
  • Derivatives of thioglycolic acid are used in the permanent wave treatment of hair, which reduces the S-S bond of keratin and thus enables the hair to be deformed. Then the S-S bonds must be closed again by a so-called strengthener so that the deformation is retained.
  • the permanent wave treatment takes place in an alkaline, neutral or acidic environment, in which the hair and scalp swell and react very sensitively.
  • the scalp is also influenced during the dyeing process and during the perm.
  • the skin keratin is attacked as well as the hair keratin.
  • the skin of the hands can also be affected, because despite the recommended precautionary measures taken by the manufacturers of these products Gloves are worn or your hands come into contact with them when you rinse out the colors or permanent wave liquid.
  • hair and scalp form a part of the body that is exposed to a considerable amount of UV radiation due to its position when staying outdoors. So far there are only a few products that take hair protection into account. Products that are applied to the hair and scalp after exposure to light, are known to alleviate the negative effects and thus keep the hair shiny and smooth, and to prevent or relieve scalp dandruff.
  • Antioxidants are substances which prevent oxidation processes or which prevent the autoxidation of fats containing unsaturated compounds.
  • Antioxidants which are also used in the fields of cosmetics and pharmacy are, for example, ⁇ -tocopherol, in particular in the form of ⁇ -tocopheryiacetate, sesamol, bile acid derivatives, butylated hydroxyanisole and butylated hydroxytoluene.
  • Antioxidants or radical scavengers can also be incorporated into cosmetic formulations for the reason of preventing such reactions.
  • antioxidants and radical scavengers are known. It has already been proposed in US Pat. Nos. 4,144,325 and 4,248,861 and from numerous other documents to use vitamin E, a substance with a known antioxidative action in light protection formulations, but the effect achieved here still falls far short of the hoped-for effect.
  • An object of the present invention was to eliminate the disadvantages of the prior art.
  • active ingredients or cosmetic and dermatological preparations containing such active ingredients should be made available, the use of which at least reduces, if not completely prevents, damage to the skin and / or hair by oxidative influence.
  • Another object of the present invention was to provide cosmetic preparations which, before or after treatment of the hair with hair dye preparations or permanent wave products, even those containing strong oxidizing agents such as hydrogen peroxide, counteract their damaging oxidizing action.
  • active ingredients and preparations containing such active ingredients should be made available for cosmetic and dermatological treatment and / or prophylaxis of the appearance of the "stinging".
  • the invention relates to cosmetic and dermatological preparations
  • a content of an active ingredient combination comprising a compound or more compounds selected from the group of flavonoids in combination with a compound or more compounds selected from the group of cinnamic acid derivatives and
  • Active ingredient combinations b), their use and preparations containing them are preferred.
  • Topical preparations are preferred.
  • the flavonoids according to the invention are also referred to below with A), the cinnamic acid derivatives according to the invention also with B) and the antioxidants according to the invention also with C).
  • Preferred flavonoids according to the invention are, for example, hydroxylated flavones, flavanones, isoflavones or chalcones and in each case also their glycosides, but also these non-hydroxylated basic structures or parent substances.
  • the flavonoids A) are preferably selected from the group of substances of the generic structural formulas
  • Zi - Z 5 are selected independently of one another from the group H, OH and O-alkyl, where the alkyl groups can be branched and unbranched and can have 1-18 C atoms, and wherein Gly is selected from the group of the mono-, di - And oligoglycoside residues or H can represent.
  • Gly residues can be, for example, the residues specified for Gly1-Gly 3.
  • Gly residues can be, for example, the residues specified for Glyi-Gly3.
  • the flavonoid (s) A) from the group quercitin, chrysin, kaempferol, myricetin, apigenin, naringenin, hesperitin, morin, fisetin, vitexin, isovitexin, flavon and genistein.
  • flavone glycosides A) from the group of rutin, rhamnetin, luteolin, naringin, hesperidin, phloridzin, diosmin, neohesperidin-dihydrochalcone.
  • Chrysin, Naringin, Hesperidin, Naringenin, Hesperetin, Morin, Phloridzin, Diosmin, Neohesperidin-Dihydrochalkon, Flavon are particularly preferred.
  • flavonoids A according to the invention are advantageously selected from the group of substances with the generic structural formulas:
  • Zi - Z5 have the meaning given above and represent Glyi, Gly2 and Gly 3 monoglycoside residues.
  • Gly 1t Gly 2 and Gly 3 are preferably selected independently of one another from the group of the hexosyl radicals or pentosyl radicals.
  • Residues such as allosyl, altrosyl, apiosyl, arabinosyl, ascorbinyl, biosidyl, galactosyl, gulosyl, glucosyl, glucoronidyl, idosyl, mannosyl, talosyl, dulcityl, fructosyl, mannityl, rhamnosyl, ribosyl, sorbityl and xylosyl are advantageous to use. It is particularly advantageous to use rhamnosyl residues or glucosyl residues.
  • flavone glycoside (s) from the group alpha-glucosylrutin, alpha-glucosylmyrictrin, alpha-glucosylisoquercitrin and alpha-glucosylquercitrin.
  • alpha-glycosyl rutin alpha glycosyl hesperidine, alpha glycosyl naringin, alpha mannosyl rutin, alpha rhamnosyl rutin are particularly preferred.
  • Glyi, Gly 2 , Gly 3 radicals from the group of the oligo- or poly-a- or ⁇ -glycosidic compounds, or from the group of the sugar acids or sugar esters.
  • one or more Glyi, Gly 2 , Gly 3 residues can be selected from the group of substituted sugars, such as N-acetylglucosamine. It can also be of advantage to use flavonoids A) whose glycoside residue is bonded to 07, 04 ' , 03 ' or 05 ' via phenolic OH functions.
  • flavonoids A flavonoids A
  • chalcones the phenolic OH function of which is freely available at 09
  • flavonoids A are: chrysin, naringin, hesperidin, naringenin, hesperetin, morin, phloridzin, diosmin, neohesperidin dihydrochalcone, flavone and in particular alpha-glucosylrutin of the formula:
  • flavonoid-containing plant extracts for the purposes of the invention.
  • These can be aqueous-alcoholic or aqueous-glycolic extracts and dry extracts obtained by the usual methods.
  • the following have proven to be particularly advantageous: citrus fruit peel or kernel extract (e.g. Citricidal / Synthapharm), soy extract (e.g. Phytodermin / Chem. Laboratorium Dr. Kurt Richter GmbH), Sophora Japonica extract (e.g. B. Sophorine / Solabia), women's thistle extract (e.g.
  • Suitable cinnamic acid derivatives are e.g. Hydroxycinnamic acids and their derivatives, the derivatives e.g. which can be defined below.
  • cinnamic acid derivatives of the general formula can preferably be used
  • the groups X, Y and R being able to be selected independently of one another from the group H, branched or unbranched alkyl having 1 to 18 carbon atoms, in particular 1 to 6 carbon atoms.
  • the acids or their salts can be used, preferably the physiologically tolerable salts, for example water-soluble salts (sodium, potassium salts).
  • Ferulic acid is regarded as a particularly advantageous cinnamic acid derivative for the purposes of the present invention.
  • Ferulic acid (4-hydroxy-3-methoxycinnamic acid, caffeic acid-3-methyl ether) is due to the structural formula
  • E-ferulic acid preference is given to using E-ferulic acid.
  • Z-ferulic acid any mixtures of E- and Z-ferulic acid.
  • caffeic acid Another derivative of cinnamic acid preferred according to the invention is caffeic acid, which is distinguished by its structure
  • plant extracts containing cinnamic acid derivatives according to the invention in particular ferulic acid and / or caffeic acid.
  • derivatives of caffeic acid or ferulic acid means their cosmetically or pharmacologically acceptable esters, salts and base adducts, in particular those as described above for the cinnamic acid derivatives.
  • Preferred combinations according to the invention are combinations of one or more substances from the group of the flavonoids listed above or combinations of one or more representatives of the flavonoids with a derivative of cinnamic acid or the combination with several cinnamic acid derivatives.
  • the weight ratio of the cinnamic acid derivatives to the flavonoid (s) is advantageously 25: 1 to 1:25, preferably 5: 1 to 1: 5, particularly preferably about 2: 1 to 1: 2.
  • flavonoids flavonglucosides or flavonoid-containing plant extracts with ferulic acid
  • synthetically modified, in particular glycosylated flavonoids such as alpha-glucosylrutin with cinnamic acid derivatives are particularly preferred according to the invention.
  • Preparations with combinations b) which contain alpha-glucocsylrutin and / or ferulic acid are particularly preferred.
  • the compounds of group A or of the combination of the active compounds A) and B) can be present as the sole active compounds in the preparations according to the invention.
  • the cosmetic and dermatological preparations according to the invention preferably contain 0.001% by weight to 30% by weight, preferably 0.01% by weight to 10% by weight, but in particular 0.1% by weight to 6% by weight , based on the total weight of the preparation of one or more substances A) according to the invention or the combination of A) and B).
  • the preparations according to the invention can preferably also have an antioxidant or more antioxidants C).
  • the antioxidants C) according to the invention can be selected particularly advantageously from the group of tocopherols and their derivatives.
  • the tocopherols also called vitamin E, are derived from the main body tocol ((2-methyl-2- (4,8,12-trimethyltridecyl) chroman-6-ol).
  • the most common and most important tocopherol comes from the configuration 2R, 4'R, 8'R. It is sometimes called RRR- ⁇ -tocopherol.
  • the tocopherol derivatives preferred according to the invention are the ⁇ -tocopherol and its esters, in particular the ⁇ -tocopheryl acetate. Esters of acids with 2 to 18, in particular 2 to 8, carbon atoms are preferred.
  • antioxidants C) from the group consisting of amino acids (eg glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (eg urocanic acid) and their derivatives, peptides such as D, L-carnosine, D-carnosine, L- Camosin and its derivatives (e.g. Anserin), carotenoids, carotenes (e.g. ⁇ -carotene, ⁇ -carotene, lycopene) and their derivatives, chlorogenic acid and their derivatives, lipoic acid and their derivatives (e.g.
  • amino acids eg glycine, histidine, tyrosine, tryptophan
  • imidazoles eg urocanic acid
  • peptides such as D, L-carnosine, D-carnosine, L- Camosin and its derivatives (e.g. Anserin)
  • carotenoids e.g. ⁇ -car
  • thiols e.g. Thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, ⁇ -linoleyl, cholesteryl and glyceryl esters
  • salts and sulfoximine compounds eg buthionine suffoximines, homocysteine sulfoximine, buthionine sulfones, penta-, hexa-, heptathioninsulfoximine
  • Dosages e.g. pmol to ⁇ mol / kg
  • metal chelators e.g. ⁇ -hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin
  • ⁇ -hydroxy acids e.g. citric acid, lactic acid, malic acid
  • humic acid
  • Bile acid Bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and their
  • Trihydroxybutyrophenone, uric acid and its derivatives, mannose and its derivatives, sesamol, sesamolin, zinc and its derivatives e.g. ZnO, ZnSO.
  • Selenium and its derivatives e.g. selenium methionine
  • stilbenes and their derivatives e.g. stilbene oxide, trans-stilbene oxide
  • derivatives suitable according to the invention salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids
  • the amount of the aforementioned antioxidants C) (one or more compounds) in the preparations is preferably 0.001 to 30% by weight, particularly preferably 0.05 to 20% by weight, in particular 1 to 10% by weight, based on the total weight the preparation.
  • vitamin E and / or its derivatives represent the antioxidant (s)
  • the cosmetic and / or dermatological formulations according to the invention can be composed as usual and can be used for prophylaxis and / or for the treatment of the skin in the sense of a dermatological treatment or a prophylaxis and / or treatment in the sense of cosmetics. But they can also be used in make-up products in decorative cosmetics. They preferably contain 0.001% by weight to 30% by weight, preferably 0.01% by weight to 10% by weight, but in particular 0.1% by weight to 6% by weight, based on the Total weight, one or more substances A) according to the invention or the combination of A) and B).
  • the substances or preparations according to the invention containing such substances preferably combinations of flavonoids or their derivatives, cinnamic acid derivatives and, if appropriate, antioxidants are applied to the skin in a sufficient amount in the manner customary for cosmetics or dermatics.
  • JP-OS Hei-06-138,941 describes oral preparations containing water-soluble glycosides, which can be selected, for example, from the group ⁇ -glucosylrutin, ⁇ -glucosylmyrictrin, ⁇ -glucosylisoquercitrin and ⁇ -glucosylquercitrin.
  • JP-OS Hei-04- 363,395 describes a process for preventing the decomposition of perfume components, which is characterized, inter alia, by the addition of ⁇ -glucosylrutin to the corresponding preparations.
  • the documents EP-OS 586 303 and EP-OS 595 694 describe the use of flavonoids as antioxidants or light protection substances in cosmetics.
  • vitamin E and its derivatives according to the invention has not been suggested by the prior art.
  • the active substances or combinations of active substances according to the invention for combating and / or prophylaxis of skin aging and inflammatory reactions caused by oxidative stress, and the effects and uses indicated above and below.
  • the invention therefore also relates to the use of the cosmetic and dermatological preparations
  • Topical application is preferred for this use.
  • the cosmetic or dermatological formulations according to the invention can be composed as usual for these uses and e.g. for the treatment, care and cleaning of the skin and / or hair and as a make-up product in decorative cosmetics. They preferably contain 0.001% by weight to 30% by weight, preferably 0.01% by weight to 10% by weight, but in particular 0.1% by weight to 6% by weight, based on the total weight of the agent, on the active substances according to the invention or their combinations of active substances.
  • the cosmetic and dermatological preparations according to the invention are preferably applied in a sufficient amount to the skin and / or the hair for cosmetics.
  • Cosmetic and dermatological preparations according to the invention can be in various forms.
  • they can be a solution, an anhydrous preparation, an emulsion or microemulsion of the water-in-oil (W / O) or oil-in-water (O / W) type, multiple emulsions, for example of the water- in-oil-in-water (W / O / W), a gel, a solid stick, an ointment or an aerosol.
  • W / O water-in-oil-in-water
  • W / O / W oil-in-water
  • a gel for example of the water- in-oil-in-water (W / O / W)
  • a gel for example of the water- in-oil-in-water (W / O / W)
  • a solid stick for example of the water- in-oil-in-water (W / O / W)
  • an aerosol ointment or an aerosol.
  • active ingredient combinations according to the invention for protecting the skin and / or hair from oxidative stress is therefore also regarded as an advantageous embodiment of the present invention, in particular this use of the active ingredient combinations according to the invention in shampoos and wash formulations.
  • the cosmetic and dermatological preparations according to the invention can contain cosmetic auxiliaries as are usually used in such preparations, e.g. Preservatives, bactericides, perfumes, anti-foaming substances, dyes, pigments that have a coloring effect, thickeners, surface-active substances, emulsifiers, softening, moisturizing and / or moisturizing substances, fats, oils, waxes or other common components of a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
  • cosmetic auxiliaries e.g. Preservatives, bactericides, perfumes, anti-foaming substances, dyes, pigments that have a coloring effect, thickeners, surface-active substances, emulsifiers, softening, moisturizing and / or moisturizing substances, fats, oils, waxes or other common components of a cosmetic or dermatological formulation such as alcohols, polyols, polymers
  • preparations according to the invention can also contain antioxidants.
  • antioxidants suitable or customary for cosmetic and / or dermatological applications can be used as favorable antioxidants.
  • the antioxidants are advantageously selected from the group consisting of
  • Amino acids e.g. glycine, histidine, tyrosine, tryptophan
  • derivatives e.g. glycine, histidine, tyrosine, tryptophan
  • Imidazoles e.g. urocanic acid
  • derivatives peptides such as D, L-camosine
  • D-carnosine, L-carnosine and their derivatives e.g. anserine
  • carotenoids e.g. carotenoids
  • carotenes e.g. ⁇ -carotene, ß-carotene, lycopene
  • chlorogenic acid and its derivatives e.g. dihydroliponic acid
  • lipoic acid and its derivatives e.g. dihydroliponic acid
  • Aurothioglucose, propylthiouracil and other thiols e.g. thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl
  • Lipids, nucleotides, nucleosides and salts) and sulfoximine compounds e.g.
  • Buthioninsulfoximine Homocysteinsulfoximin, Buthioninsulfone, Penta-, Hexa-,
  • Heptathioninsulfoximine in very low tolerable doses (e.g. pmol to ⁇ mol / kg), also (metal) chelators (e.g. ⁇ -hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), ⁇ -hydroxy acids (e.g. citric acid, lactic acid,
  • ⁇ -linolenic acid e.g. ⁇ -linolenic acid, linoleic acid, oleic acid
  • folic acid and its derivatives e.g. ubiquinone and ubiquinol and their derivatives
  • vitamin C and derivatives e.g.
  • Ascorbyl palmitate Mg ascorbyl phosphate, ascorbyl acetate), tocopherols and
  • ZnO, ZnSO- selenium and its derivatives
  • stilbenes and their derivatives e.g. stilbene oxide, trans-stilbene oxide
  • the derivatives salts , Esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids
  • the amount of the aforementioned antioxidants (one or more compounds), which are not identical to the active ingredient combinations according to the invention, in the preparations is preferably 0.001 to 30% by weight, particularly preferably 0.05-20% by weight, in particular 1 - 10 wt .-%, based on the total weight of the preparation. If vitamin E and / or its derivatives represent the antioxidant (s), it is advantageous to choose their respective concentrations from the range of 0.001-10% by weight, based on the total weight of the formulation.
  • vitamin A or vitamin A derivatives or carotenes or their derivatives represent the antioxidant or antioxidants, it is advantageous to use their respective concentrations in the range from 0.001-10% by weight, based on the total weight of the formulation, to choose.
  • Emulsions according to the invention are advantageous and contain e.g. the said fats, oils, waxes and other fat bodies, as well as water and an emulsifier, as is usually used for such a type of formulation.
  • oils such as triglycerides of capric or caprylic acid, but preferably castor oil;
  • Fats, waxes and other natural synthetic and / or partially synthetic fat bodies preferably esters of fatty acids with alcohols of low C number, e.g. with isopropanol, propylene glycol or glycerin, or esters of fatty alcohols with low C number alkanoic acids or with fatty acids;
  • Silicone oils such as dimethylpolysiloxanes, diethylpolysiloxanes, diphenylpolysiloxanes and mixed forms thereof
  • saturated compounds such as hydrocarbons of natural or synthetic origin (petroleum jelly, squalane)
  • the aqueous phase of the preparations according to the invention optionally advantageously contains alcohols, diols or polyols of low C number, and whose ethers, preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ether and similar products, furthermore alcohols of low C number, for example Ethanol, isopropanol, 1, 2-propanediol, glycerol and in particular one or more thickeners, which one or more can advantageously be selected from the group consisting of silicon dioxide, aluminum silicates, polysaccharides or their derivatives, for example hyaluronic acid, xanthan gum, hydroxypropylmethyl cellulose , particularly advantageously from the group of polyacrylates, preferably a polyacrylate from
  • Water can also be a component of alcoholic solvents.
  • Emulsions according to the invention are advantageous and contain e.g. the fats, oils, waxes and other fat bodies mentioned, as well as water and an emuigator, as is usually used for such a type of formulation.
  • Gels according to the invention usually contain low C number alcohols, e.g. Ethanol, isopropanol, 1,2-propanediol, glycerol and water or an oil mentioned above in the presence of a thickening agent which is preferably silicon dioxide or an aluminum silicate in the case of oleo-alcoholic gels and preferably a polyacrylate in the case of aqueous-alcoholic or alcoholic gels.
  • a thickening agent which is preferably silicon dioxide or an aluminum silicate in the case of oleo-alcoholic gels and preferably a polyacrylate in the case of aqueous-alcoholic or alcoholic gels.
  • Suitable propellants for preparations according to the invention which can be sprayed from aerosol containers are the customary, known volatile, liquefied propellants, for example hydrocarbons (propane, butane, isobutane), which can be used alone or in a mixture with one another. Compressed air can also be used advantageously.
  • Preparations according to the invention can also advantageously contain substances which absorb UV radiation in the UVB range, the total amount of the filter substances being, for example, 0.1% by weight to 30% by weight, preferably 0.5 to 10% by weight. , in particular 1.0 to 6.0% by weight, based on the total weight of the preparations, in order to provide cosmetic preparations which protect the hair or the skin from the entire range of ultraviolet radiation. They can also serve as a sunscreen for the hair or skin.
  • the emulsions according to the invention contain UVB filter substances, they can be oil-soluble or water-soluble.
  • Oil-soluble UVB filters which are advantageous according to the invention are, for example:
  • 3-benzylidene camphor derivatives preferably 3- (4-methylbenzylidene) camphor, 3-benzylidene camphor;
  • 4-aminobenzoic acid derivatives preferably 4- (dimethylamino) benzoic acid (2-ethylhexyl) ester, 4- (dimethylamino) benzoic acid amyl ester;
  • Esters of cinnamic acid preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-methoxycinnamic acid isopentiester;
  • esters of salicylic acid preferably salicylic acid (2-ethylhexyl) ester, salicylic acid (4-isopropylbenzyl) ester, salicylic acid homomethyl ester,
  • benzophenone preferably 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone;
  • Esters of benzalmalonic acid preferably 4-methoxybenzalmalonic acid di (2-ethylhexyl) ester, 2,4,6-trianilino- (p-carbo-2'-ethyl-1 '- hexyloxy) -1, 3,5-triazine.
  • UVB filters examples include Salts of 2-phenylbenzimidazole-5-sulfonic acid such as its sodium, potassium or triethanoiammonium salt, and the sulfonic acid itself;
  • Sulfonic acid derivatives of benzophenones preferably 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid and its salts;
  • Sulfonic acid derivatives of 3-benzylidene camphor e.g. 4- (2-oxo-3-bornylidene methyl) benzenesulfonic acid, 2-methyl-5- (2-oxo-3-bornylidene methyl) sulfonic acid and their salts.
  • UVB filters which can be used in combination with the active compound combinations according to the invention, is of course not intended to be limiting.
  • the invention also relates to the use of a combination of the active compounds according to the invention with at least one UVB filter as an antioxidant or the use of a combination of the active compounds according to the invention with at least one UVB filter as an antioxidant in a cosmetic or dermatological preparation.
  • UVA filters which have hitherto usually been contained in cosmetic preparations.
  • These substances are preferably derivatives of dibenzoylmethane, in particular 1- (4'-tert-butylphenyl) -3- (4'-methoxyphenyl) propane-1, 3-dione and 1-phenyl-3- (4 '- isopropylphenyl) propane-1,3-dione.
  • These combinations or preparations containing these combinations are also the subject of the invention.
  • the amounts used for the UVB combination can be used.
  • the invention also relates to the use of a combination of the active compounds according to the invention with at least one UVA filter as an antioxidant or the use of a combination of the active compounds according to the invention with at least one UVA filter as an antioxidant in a cosmetic or dermatological preparation.
  • the invention also relates to the use of a combination of the active compounds according to the invention with at least one UVA filter and at least one UVB filter as an antioxidant or the use of a combination of the active compounds according to the invention with at least one UVA filter and at least one UVB filter. Filters as an antioxidant in a cosmetic or dermatological preparation.
  • Cosmetic and dermatological preparations with an effective content of active substances according to the invention can also contain inorganic pigments which are usually used in cosmetics to protect the skin from UV rays. These are oxides of titanium, zinc, iron, zirconium, silicon, manganese, aluminum, cerium and mixtures thereof, as well as modifications in which the oxides are the active agents. It is particularly preferred to use pigments based on titanium dioxide.
  • UVA filter and pigment or preparations containing this combination are also the subject of the invention.
  • the amounts given for the above combinations can be used.
  • Cosmetic and dermatological preparations for protecting the hair from UV rays according to the invention are, for example, shampooing agents, preparations which are used when rinsing the hair before or after the shampooing, before or after the permanent wave treatment, before or after the coloring or discoloration of the Hair is applied to preparations for blow-drying or pickling hair, preparations for coloring or decolouring, to a styling and treatment lotion, a hair lacquer or to permanent waving agents.
  • the cosmetic and dermatological preparations contain active substances and auxiliaries as are usually used for this type of preparations for hair care and hair treatment.
  • Preservatives, surface-active substances, substances to prevent foaming, thickeners, emulsifiers, fats, oils, waxes, organic solvents, bactericides, perfumes, dyes or pigments serve as auxiliary substances.
  • electrolytes are understood to mean water-soluble alkali metal, ammonium, alkaline earth metal (including magnesium) and zinc salts of inorganic anions and any mixtures of such salts, it being necessary to ensure that these salts are pharmaceutical or distinguish cosmetic harmlessness.
  • the anions according to the invention are preferably selected from the group of chlorides, sulfates and hydrogen sulfates, phosphates, hydrogen phosphates and linear and cyclic oligophosphates as well as carbonates and hydrogen carbonates.
  • Cosmetic preparations which are a skin cleansing agent or shampoo contain preferably at least one anionic, non-ionic or amphoteric surface-active substance, or else mixtures of such substances, active substances according to the invention in an aqueous medium and auxiliaries as are usually used therefor.
  • the surface-active substance or the mixtures of these substances can be present in the shampoo in a concentration of between 1% and 50% by weight.
  • a lotion that is rinsed out and e.g. before or after decolorization, before or after shampooing, between two shampooing steps, before or after permanent waving, these are e.g. around aqueous or aqueous-alcoholic solutions, which may contain surface-active substances, the concentration of which may be between 0.1 and 10% by weight, preferably between 0.2 and 5% by weight.
  • a cosmetic preparation in the form of a lotion that is not rinsed out, in particular a lotion for inlaying the hair, a lotion used for blow-drying the hair, a styling and treatment lotion generally provides an aqueous, alcoholic or aqueous-alcoholic solution represents and contains at least one cationic, anionic, non-ionic or amphoteric polymer or mixtures thereof, as well as active ingredient combinations according to the invention in effective concentration.
  • the amount of the polymers used is, for example, between 0.1 and 10% by weight, preferably between 0.1 and 3% by weight.
  • Cosmetic preparations for the treatment and care of the hair which contain active ingredients according to the invention, can be present as emulsions which are of the non-ionic or anionic type.
  • non-ionic emulsions contain oils or fatty alcohols, which can also be polyethoxylated or polypropoxylated, for example, or also mixtures of the two organic components.
  • These emulsions may contain cationic surface-active substances.
  • cosmetic preparations for the treatment and care of the hair can be in the form of gels which, in addition to an effective content of active compound combinations according to the invention and solvents conventionally used for this, preferably water, or organic thickeners, e.g. Gum arabic, xanthan gum, sodium alginate, cellulose derivatives, preferably methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose or inorganic thickeners, e.g. Aluminum silicates such as bentonites, or a mixture of polyethylene glycol and polyethylene glycol stearate or distearate, contain.
  • the thickener is in the gel e.g. in an amount between 0.1 and 30% by weight, preferably between 0.5 and 15% by weight.
  • the amount of the active compounds according to the invention in an agent intended for the hair is preferably 0.05% by weight to 10% by weight, in particular 0.5% by weight to 5% by weight, based on the total weight of the agent.
  • Aqueous cosmetic detergents according to the invention or low-water or water-free detergent concentrations intended for aqueous cleaning can contain anionic, nonionic and / or amphoteric surfactants, for example
  • Cosmetic preparations which are cosmetic cleaning preparations for the skin, can be in liquid or solid form.
  • they preferably contain at least one anionic, nonionic or amphoteric surface-active substance or mixtures thereof, if desired one or more electrolytes and auxiliaries of the kind normally used for this purpose.
  • the surface-active substance can be present in the cleaning preparations in a concentration of between 1 and 94% by weight, based on the total weight of the preparations.
  • Cosmetic formulations which are shampoos s t hal ⁇ th preferably adjacent an effective content of novel active compounds thereof, an inventive electrolytes and auxiliaries as are customarily used for this purpose at least one anionic, nonionic or amphoteric surfactant or mixtures thereof, if necessary.
  • the surface-active substance can be in a Concentration between 1 wt .-% and 94 wt .-% are present in the shampoo.
  • compositions according to the invention contain water and, if appropriate, the additives customary in cosmetics, for example perfume, thickeners, dyes, deodorants, antimicrobial substances, lipid-replenishing agents, complexing and sequestering agents, pearlescent agents, plant extracts, vitamins, active ingredients and the like.
  • the additives customary in cosmetics for example perfume, thickeners, dyes, deodorants, antimicrobial substances, lipid-replenishing agents, complexing and sequestering agents, pearlescent agents, plant extracts, vitamins, active ingredients and the like.
  • the present invention also encompasses a cosmetic method for protecting the skin and hair from oxidative or photooxidative processes, which is characterized in that a cosmetic agent which contains an effective concentration of active compounds according to the invention is applied to the skin or hair in a sufficient amount applies.
  • the present invention also includes a method for protecting cosmetic or dermatological preparations against oxidation or photo-oxidation, these preparations being e.g. Represent preparations for the treatment and care of the hair, in particular hair colorants, hair lacquers, shampooing agents, color shampooing agents, and also make-up products such as e.g. Nail polishes, lipsticks, complexion bases, washing and shower preparations, creams for the treatment or care of the skin or all other cosmetic preparations, the components of which can cause stability problems due to oxidation or photooxidation during storage, characterized in that that the cosmetic preparations have an effective content of active ingredients according to the invention.
  • these preparations being e.g. Represent preparations for the treatment and care of the hair, in particular hair colorants, hair lacquers, shampooing agents, color shampooing agents, and also make-up products such as e.g. Nail polishes, lipsticks, complexion bases, washing and shower preparations, creams for the treatment or care of the skin or all other cosmetic preparations, the components of which can
  • the amount of active compounds according to the invention in these preparations is preferably 0.001% by weight to 10% by weight, in particular 0.01% by weight to 6% by weight, based on the total weight of the preparations.
  • the invention also relates to the process for the preparation of the preparations according to the invention, which is characterized in that Active ingredients according to the invention are incorporated into cosmetic and dermatological logical formulations in a manner known per se.
  • Paraffin oil, pigments and dyes ad 100.00

Abstract

Cosmetic and dermatological compositions for the treatment or prophylaxis of hyper-reactive or deficient, hypoactive skin, contain active agents (I) which are at least one flavonoid or a combination of flavonoid(s) with cinnamic acid derivative(s) and optionally other conventional active agents. <??>Cosmetic and dermatological compositions for the treatment or prophylaxis of hyper-reactive or deficient, hypoactive skin, contain active agents (I) which are at least one flavonoid or a combination of flavonoid(s) with cinnamic acid derivative(s) and optionally at least one of antioxidants, endogenous energy source metabolites, endogenous enzymatic antioxidant systems or their synthetic derivatives (mimics), antimicrobial or antiviral agents and other conventional active agents.

Description

Beschreibung description
Kosmetische und dermatologische Zubereitungen mit FlavonoidenCosmetic and dermatological preparations with flavonoids
Die vorliegende Erfindung betrifft insbesondere kosmetische und dermatologische Zubereitungen enthaltend Flavonoide, ihre Glycoside und gegebenenfalls deren Kombinationen mit Zimtsäurederivaten oder Antioxidantien.The present invention relates in particular to cosmetic and dermatological preparations containing flavonoids, their glycosides and, if appropriate, their combinations with cinnamic acid derivatives or antioxidants.
Die schädigende Wirkung des ultravioletten Teils der Sonnenstrahlung auf die Haut ist allgemein bekannt. Während Strahlen mit einer Wellenlänge, die kleiner als 290 nm ist (der sogenannte (JVC-Bereich), von der Ozonschicht in der Erdatmosphäre absorbiert werden, verursachen Strahlen im Bereich zwischen 290 nm und 320 nm, dem sogenannten UVB-Bereich, ein Erythem, einen einfachen Sonnenbrand oder sogar mehr oder weniger starke Verbrennungen.The damaging effect of the ultraviolet part of solar radiation on the skin is generally known. While rays with a wavelength shorter than 290 nm (the so-called (JVC range) are absorbed by the ozone layer in the earth's atmosphere, rays in the range between 290 nm and 320 nm, the so-called UVB range, cause erythema, a simple sunburn or even more or less severe burns.
Als ein Maximum der Erythemwirksamkeit des Sonnenlichtes wird der engere Bereich um 308 nm angegeben.The narrower range around 308 nm is given as a maximum of the erythema effectiveness of sunlight.
Zum Schutz gegen UVB-Strahlung sind zahlreiche Verbindungen bekannt, bei denen es sich um Derivate des 3-Benzylidencamphers, der 4- Aminobenzoesäure, der Zimtsäure, der Salicylsäure, des Benzophenons sowie auch des 2-Phenylbenzimidazols handelt. Auch für den Bereich zwischen etwa 320 nm und etwa 400 nm, den sogenannten UVA-Bereich, ist es wichtig, Filtersubstanzen zur Verfügung zu haben, da dessen Strahlen Reaktionen bei lichtempfindlicher Haut hervorrufen können. Es ist erwiesen, daß UVA-Strahlung zu einer Schädigung der elastischen und kollagenen Fasern des Bindegewebes führt, was die Haut vorzeitig altern läßt, und daß sie als Ursache zahlreicher phototoxischer und photoallergischer Reaktionen zu sehen ist. Der schädigende Einfluß der UVB- Strahlung kann durch UVA-Strahlung verstärkt werden.Numerous compounds are known for protection against UVB radiation, which are derivatives of 3-benzylidene camphor, 4-aminobenzoic acid, cinnamic acid, salicylic acid, benzophenone and also 2-phenylbenzimidazole. It is also important to have filter substances available for the range between about 320 nm and about 400 nm, the so-called UVA range, since their rays can cause reactions in light-sensitive skin. It has been proven that UVA radiation leads to damage to the elastic and collagen fibers of the connective tissue, which causes the skin to age prematurely, and that it is to be seen as the cause of numerous phototoxic and photoallergic reactions. The damaging influence of UVB radiation can be intensified by UVA radiation.
Zum Schutz gegen die Strahlen des UVA-Bereichs werden daher gewisse Derivate des Dibenzoylmethans verwendet, deren Photostabilität (Int. J. Cosm. Science 10, 53 (1988)), nicht in ausreichendem Maße gegeben ist.To protect against the rays of the UVA range, certain derivatives of dibenzoylmethane are therefore used, the photostability (Int. J. Cosm. Science 10, 53 (1988)) of which is insufficient.
Die UV-Strahlung kann aber auch zu photochemischen Reaktionen führen, wobei dann die photochemischen Reaktionsprodukte in den Hautmetabolismus eingreifen.However, UV radiation can also lead to photochemical reactions, in which case the photochemical reaction products interfere with the skin's metabolism.
Vorwiegend handelt es sich bei solchen photochemischen Reaktionsprodukten um radikalische Verbindungen, beispielsweise Hydroxyradikale. Auch Undefinierte radikalische Photoprodukte, welche in der Haut selbst entstehen, können aufgrund ihrer hohen Reaktivität unkontrollierte Folgereaktionen an den Tag legen. Aber auch Singulettsauerstoff, ein nichtradikalischer angeregter Zustand des Sauerstoffmoleküls kann bei UV-Bestrahlung auftreten, ebenso kurzlebige Epoxide und viele andere. Singulettsauerstoff beispielsweise zeichnet sich gegenüber dem normalerweise vorliegenden Triplettsauerstoff (radikalischer Grundzustand) durch gesteigerte Reaktivität aus. Allerdings existieren auch angeregte, reaktive (radikalische) Triplettzustände des Sauerstoffmoleküls. Ferner zählt UV-Strahlung zur ionisierenden Strahlung. Es besteht also das Risiko, daß auch ionische Spezies bei UV-Exposition entstehen, welche dann ihrerseits oxidativ in die biochemischen Prozesse einzugreifen vermögen.Such photochemical reaction products are predominantly free radical compounds, for example hydroxy radicals. Undefined radical photo products, which are created in the skin itself, can also display uncontrolled subsequent reactions due to their high reactivity. But also singlet oxygen, a non-radical excited state of the oxygen molecule can occur with UV radiation, just as short-lived epoxies and many others. Singlet oxygen, for example, is characterized by increased reactivity compared to the triplet oxygen normally present (radical ground state). However, there are also excited, reactive (radical) triplet states of the oxygen molecule. UV radiation also belongs to ionizing radiation. There is therefore a risk that ionic species also develop when exposed to UV rays, which in turn can oxidatively intervene in the biochemical processes.
Um diesen Reaktionen vorzubeugen, können kosmetischen bzw. dermatologi¬ schen Formulierungen zusätzliche Antioxidantien oder Radikalfänger einverleibt werden.To prevent these reactions, additional antioxidants or free radical scavengers can be incorporated into cosmetic or dermatological formulations.
Es ist bereits vorgeschlagen worden, Vitamin E, eine Substanz mit bekannter antioxidativer Wirkung in Lichtschutzformulierungen einzusetzen, dennoch bleibt auch hier die erzielte Wirkung weit hinter der erhofften zurück.It has already been proposed to use vitamin E, a substance with a known antioxidative effect, in light protection formulations, but the effect achieved here also falls far short of the hoped-for effect.
Die Wirkung der Sonnenstrahlung auf die Haut ist außer Bildung der Lichtschwiele und Bräunung, hervorgerufen überwiegend durch den Bereich des UVB, eine langsame und fortschreitende Degradation des unter der Epidermis liegenden Bindegewebes, hervorgerufen durch den längerwelligen Bereich des Sonnenlichts UVA, in dem durch Bestrahlung die elastischen und festigenden Fasern zerstört werden. Die nachlassende Festigkeit des Bindegewebes führt zu vermehrter Faltenbildung und kann im Extremfall zur sogenannten „Landmannshaut" oder auch aktinischer Keratose führen. Als kosmetische unerwünscht gelten Falten, Runzeln und trockene Haut, die vor dem eigentlichen biologischen Alter durch Umwelteinflüsse entstehen und das Symptom „vorzeitiger Hautalterung" sind.The effect of solar radiation on the skin is, besides the formation of light swellings and tanning, mainly caused by the UVB area, a slow and progressive degradation of the connective tissue under the epidermis, caused by the longer-wave area of UVA sunlight, in which the elastic areas are exposed to radiation and strengthening fibers are destroyed. The weakening strength of the connective tissue leads to increased wrinkling and in extreme cases can lead to so-called "farmer's skin" or actinic keratosis. Wrinkles, wrinkles and dry skin that occur before the actual biological age due to environmental influences and the symptom of "premature skin aging" are considered as cosmetic undesirable " are.
Hauptsächlich werden Antioxidantien als Schutzsubstanzen gegen den Verderb der sie enthaltenden Zubereitungen verwendet. Dennoch ist bekannt, daß auch in der menschlichen und tierischen Haut unerwünschte Oxidationsprozesse auftreten können. Solche Prozesse spielen eine wesentliche Rolle bei der Hautalterung.Antioxidants are mainly used as protective substances against the spoilage of the preparations containing them. Nevertheless, it is known that undesirable oxidation processes can also occur in human and animal skin. Such processes play an essential role in skin aging.
Im Aufsatz "Skin Diseases Associated with Oxidative Injury" in "Oxidative Stress in Dermatology", S. 323 ff. (Marcel Decker Inc., New York, Basel, Hong Kong, Herausgeber: Jürgen Fuchs, Frankfurt, und Lester Packer, Berke- ley/Californien), werden oxidative Schäden der Haut und ihre näheren Ursachen aufgeführt.In the article "Skin Diseases Associated with Oxidative Injury" in "Oxidative Stress in Dermatology", p. 323 ff. (Marcel Decker Inc., New York, Basel, Hong Kong, editors: Jürgen Fuchs, Frankfurt, and Lester Packer, Berke- ley / California), oxidative damage to the skin and its closer causes are listed.
Aufgabe der Erfindung war es daher, kosmetische und dermatologische Wirkstoffe und Zubereitungen sowie Lichtschutzformulierungen zu schaffen, die zur Prophylaxe und Behandlung lichtempfindlicher Haut, aber auch normaler sonnenexponierter Haut dienen.The object of the invention was therefore to provide cosmetic and dermatological active ingredients and preparations and light protection formulations which are used for the prophylaxis and treatment of light-sensitive skin, but also normal skin exposed to the sun.
Weiterhin sind die Lippen ein Areal des Gesichtes, das durch seinen Aufbau und die Exposition stark den äußeren Einflüssen ausgesetzt und beeinflußt wird. Die natürlich rote Farbe der Lippen rührt daher, daß Lippenhaut im Gegensatz zu „normaler" Haut viel dünner ist, auch fehlen Schweiß- und Talgdrüsen. Melanin ist deutlich weniger vorhanden. Das Fehlen eines Teils des natürlichen Schutzes der Haut führt dazu, daß Lippen unter Kälte, Wärme und Sonnenstrahlung stärker belastet werden als normale Haut. Schutz und Pflege der Lippen sind daher notwendig, um ein glattes, rosiges Aussehen der Lippen zu erhalten. War kein ausreichender Schutz der Lippen bei Exposition vorhanden, zeigen sich die oben genannten Symptome, deren Linderung und Beseitigung ebenfalls als ein kosmetisches Anliegen gesehen werden kann.Furthermore, the lips are an area of the face, which due to its structure and exposure is strongly exposed to and influenced by external influences. The naturally red color of the lips stems from the fact that lip skin, in contrast to "normal" skin, is much thinner, sweat and sebum glands are also missing. Melanin is significantly less present. The lack of some of the natural protection of the skin leads to lips being underneath Cold, heat and solar radiation are more exposed than normal skin, so protection and care of the lips are necessary in order to maintain a smooth, rosy appearance of the lips.If the lips were not adequately protected during exposure, the symptoms mentioned above can be seen Relief and elimination can also be seen as a cosmetic concern.
Darüber hinaus betrifft die Erfindung Zubereitungen mit extrem niedrigem soge¬ nanntem "Stinging Potential" und Zubereitungen gegen unspezifischen nicht krankhaften Juckreiz.In addition, the invention relates to preparations with extremely low so-called "stinging potential" and preparations against non-specific non-pathological itching.
Die Haut, insbesondere die Epidermis, ist als Barriereorgan des menschlichen Organismus in besonderem Maße äußeren Einwirkungen unterworfen. Nach dem heutigen wissenschaftlichen Verständnis repräsentiert die Haut ein immunologisches Organ, das als immunkompetentes peripheres Kompartiment eine eigene Rolle in induktiven, effektiven und regulativen immunprozessen des Gesamtorganismus spielt.The skin, especially the epidermis, as a barrier organ of the human organism, is particularly exposed to external influences. According to today's scientific understanding, the skin represents an immunological organ, which as an immunocompetent peripheral compartment plays its own role in inductive, effective and regulative immune processes of the whole organism.
Die Epidermis ist reich mit Nerven und Nervenendapparaten wie Vater-Pacini- Lamellenkörpern, Merkel-Zell-Neuritenkomplexen und freien Nervenendigungen für Schmerz-, Kälte-, Wärmeempfindung und Juckreiz ausgestattet.The epidermis is rich with nerves and nerve end devices such as Vater-Pacini lamellar bodies, Merkel-cell-neurite complexes and free ones Nerve endings equipped for pain, cold, warmth and itching.
Bei Menschen mit sensibler, empfindlicher oder verletzlicher Haut kann ein mit "Stinging" (<engl.> "to sting" = verletzen, brennen, schmerzen) bezeichnetes neurosensorisches Phänomen beobachtet werden. Diese "sensible Haut" unterscheidet sich grundsätzlich von "trockener Haut" mit verdickten und verhärteten Hornschichten.In people with sensitive, sensitive or vulnerable skin, a neurosensory phenomenon called "stinging" (<engl.> "To sting" = injure, burn, pain) can be observed. This "sensitive skin" differs fundamentally from "dry skin" with thickened and hardened horny layers.
Typische Reaktionen des "Stinging" bei sensibler Haut sind Rötung, Spannen und Brennen der Haut sowie Juckreiz.Typical reactions of "stinging" to sensitive skin are reddening, tension and burning of the skin as well as itching.
Typische, mit den Begriffen "Stinging" oder "empfindlicher Haut" in Verbindung gebrachte, störende neurosensorische Phänomene sind Hautrötung, Kribbeln, Prikkeln, Spannen und Brennen der Haut und Juckreiz. Sie können durch stimulierende Umgebungsbedingungen z.B. Massage, Tensideinwirkung, Wettereinfluß wie Sonne, Kälte, Trockenheit, aber auch feuchte Wärme, Wärmestrahlung und UV-Strahlung, z.B. der Sonne, hervorgerufen werden.Typical disturbing neurosensory phenomena associated with the terms "stinging" or "sensitive skin" are reddening of the skin, tingling, tingling, tensing and burning of the skin and itching. By stimulating environmental conditions e.g. Massage, surfactant, weather influences such as sun, cold, dryness, but also moist heat, heat radiation and UV radiation, e.g. the sun.
In "Journal of the Society of Cosmetic Chemists" 28, S.197 - 209 (Mai 1977) beschreiben P.J.Frosch und A.M.Kligman eine Methode zur Abschätzung des "Stinging-Potentials" topisch verabreichter Substanzen. Als positive Substanzen werden hier z.B. Milchsäure und Brenztraubensäure eingesetzt. Bei Messung nach dieser Methode wurden aber auch Aminosäuren, insbesondere Glycin, als neurosensorisch aktiv ermittelt (solche Substanzen werden "Stinger" genannt).In "Journal of the Society of Cosmetic Chemists" 28, pp. 197-209 (May 1977) P.J. Frosch and A.M. Kligman describe a method for estimating the "stinging potential" of topically administered substances. As positive substances, e.g. Lactic acid and pyruvic acid are used. When measured using this method, however, amino acids, in particular glycine, were also found to be neurosensory active (such substances are called "Stinger").
Nach bisherigen Erkenntnissen tritt eine derartige Empfindlichkeit gegenüber ganz bestimmten Substanzen individuell unterschiedlich auf. Dies bedeutet, eine Person, die bei Kontakt mit einer Substanz "Stingingeffekte" erlebt, wird sie mit hoher Wahrscheinlichkeit bei jedem weiteren Kontakt wiederholt erleben. Der Kontakt mit anderen "Stingern" kann aber ebensogut ohne jede Reaktion verlaufen.According to previous knowledge, such a sensitivity to very specific substances occurs individually in different ways. This means that a person who experiences "stinging effects" when in contact with a substance is very likely to be repeated with every further contact experience. Contact with other "Stingers" can just as easily be without any reaction.
Als neurosensorisches Phänomen ist der Juckreiz bei atopischer Haut anzusehen, sowie Juckreiz bei Hauterkrankungen, der aber nur ein Symptom dieser Erkrankungen ist und umgekehrt aber auch unspezifisch, d.h. ohne klinischen Befund einer Störung der Haut, einer Infektion oder Reizung entstehen kann. Zwar ist auch unspezifischer Juckreiz ein erstes Anzeichen einer möglichen verdeckten Allgemeinerkrankung, kann aber auch durch Streß oder andere Umwelteinflüsse ausgelöst werden.The itching in atopic skin is to be regarded as a neurosensory phenomenon, as well as itching in skin diseases, which is only a symptom of these diseases and vice versa but also unspecific, i.e. without a clinical finding of a skin disorder, infection or irritation. Although unspecific itching is a first sign of a possible hidden general illness, it can also be triggered by stress or other environmental influences.
Weiterhin kann Juckreiz ohne klar erkennbaren Grund, vorzugsweise bei eher sensiblen Personen, auftreten.Furthermore, itching can occur without a clearly recognizable reason, preferably in more sensitive people.
"Stinging"-Phänomene können generell also als kosmetisch zu behandelnde Störungen angesehen werden. Starker Juckreiz dagegen, insbesondere bei Atopie auftretendes starkes Hautjucken, kann auch als schwerwiegendere dermatologische Störung bezeichnet werden, während Juckreiz, der bei einem Stinging oder unspezifisch ohne Erkrankung auftritt auch als kosmetisch zu behandelnde Störung angesehen werden kann."Stinging" phenomena can therefore generally be regarded as disorders to be treated cosmetically. Severe itching, on the other hand, particularly severe itching of the skin that occurs in atopy, can also be described as a more serious dermatological disorder, while itching that occurs during stinging or nonspecifically without a disease can also be regarded as a cosmetically treatable disorder.
Weiterhin nimmt das Problem der empfindlichen oder sensiblen Haut immer mehr zu. Diese ist zum einen häufig gekennzeichnet durch eine erhöhte Suszeptibilität für Stinging, wie aber auch durch andere Kriterien gekennzeichnet wie: Zur Rötung neigende Haut, Haut des Phototyps I oder II, bekannte Allergie, eine dermatologische Grunderkrankung wie Atopische Dermatitis oder Psoriasis, bekannte Unverträglichkeiten von kosmetischen Produkten, das subjektive Gefühl von mangelndem Fett- und Feuchtigkeitsgehalt der Haut.Furthermore, the problem of sensitive or sensitive skin is increasing. On the one hand, this is often characterized by an increased susceptibility to stinging, but also by other criteria such as: skin prone to reddening, skin of type I or II, known allergy, a dermatological underlying disease such as atopic dermatitis or psoriasis, known intolerance to cosmetic Products, the subjective feeling of lack of fat and moisture content of the skin.
Zur weiteren Charakterisierung empfindlicher Haut wird eine „durchlässige" Barriere diskutiert, die sich in einem erhöhten TEWL niederschlägt. Zur Barriereregeneration werden okklusiv wirkende oder lipidsubstituierende Produkte empfohlen, die nach Applikation den TEWL senken. P.Elias beschreibt sogar verschiedene Lipid-Mischungen, die an Mäusehaut, die mit Aceton vorgeschädigt wurde eine Barriereregeneration bewirken. Auch die topische Applikation von RRR-a-Tocopherol verbessert nachweislich die Hautbarriere.For the further characterization of sensitive skin, a "permeable" barrier is discussed, which is reflected in an increased TEWL. For barrier regeneration, occlusive or lipid-substituting ones are used Products recommended that lower the TEWL after application. P.Elias even describes various lipid mixtures that cause barrier regeneration on mouse skin that has been damaged with acetone. The topical application of RRR-a-tocopherol has also been shown to improve the skin barrier.
Soll menschliches Haar dauerhaft gefärbt werden, kommen in der Praxis lediglich oxidierende Haarfärbeverfahren in Betracht. Beim oxidativen Haarfärben erfolgt die Ausbildung des Farbstoffchromophoren durch Reaktion von Präkursoren (Phenole, Aminophenole, seltener auch Diamine) und Basen (meistens p-Phenylendiamin) mit dem Oxidationsmittel, zumeist Wasserstoffperoxid. Wasserstoffperoxidkonzentrationen um 6% werden dabei gewöhnlich verwendet.If human hair is to be dyed permanently, in practice only oxidizing hair dyeing processes can be considered. In oxidative hair dyeing, the dye chromophore is formed by the reaction of precursors (phenols, aminophenols, more rarely diamines) and bases (mostly p-phenylenediamine) with the oxidizing agent, mostly hydrogen peroxide. Hydrogen peroxide concentrations around 6% are usually used.
Üblicherweise wird davon ausgegangen, daß neben der Färbewirkung auch eine Bleichwirkung durch das Wasserstoffperoxid erfolgt. In oxidativ gefärbtem menschlichem Haar sind, ähnlich wie bei gebleichtem Haar, mikroskopische Löcher an den Stellen, an denen Melaningranula vorlagen, nachweisbar.It is usually assumed that, in addition to the coloring effect, the hydrogen peroxide also has a bleaching effect. Similar to bleached hair, microscopic holes in the areas where melanin granules were present can be detected in oxidatively colored human hair.
Tatsache ist, daß das Oxidationsmittel Wasserstoffperoxid nicht nur mit den Farbvorstufen, sondern auch mit der Haarsubstanz reagieren und dabei unter Umständen eine Schädigung des Haares bewirken kann.The fact is that the oxidizing agent hydrogen peroxide not only reacts with the color precursors, but also with the hair substance and can cause damage to the hair.
Bei der Dauerwellbehandlung von Haaren kommen Derivate der Thioglycolsäure zum Einsatz, die die S-S-Bindung des Keratins reduziert und somit eine Verformung des Haares möglich macht. Anschließend müssen die S-S-Bindungen durch einen sogenannten Festiger wieder geschlossen werden, damit die Verformung erhalten bleibt. Die Dauerwellbehandlung findet im alkalischen, neutralen oder sauren Millieu statt, bei dem Haare und Kopfhaut aufquellen und sehr empfindlich reagieren.Derivatives of thioglycolic acid are used in the permanent wave treatment of hair, which reduces the S-S bond of keratin and thus enables the hair to be deformed. Then the S-S bonds must be closed again by a so-called strengthener so that the deformation is retained. The permanent wave treatment takes place in an alkaline, neutral or acidic environment, in which the hair and scalp swell and react very sensitively.
Weiterhin ist bekannt, daß beim Färbevorgang, sowie bei der Dauerwelle auch die Kopfhaut beeinflußt wird. Das Haut-Keratin wird ebenso angegriffen wie das Haar-Keratin. Ebenso beeinflußt werden kann die Haut der Hände, da trotz empfohlener Vorsichtsmaßnahnmen der Hersteller dieser Produkte keine Handschuhe getragen werden oder dennoch die Hände beim Ausspülen der Farben oder Dauerwellflüssigkeit damit in Berührung kommen.It is also known that the scalp is also influenced during the dyeing process and during the perm. The skin keratin is attacked as well as the hair keratin. The skin of the hands can also be affected, because despite the recommended precautionary measures taken by the manufacturers of these products Gloves are worn or your hands come into contact with them when you rinse out the colors or permanent wave liquid.
Weiterhin stellen Haar und Kopfhaut einen Teil des Körpers dar, der aufgrund seiner Position beim Aufenthalt im Freien einem erheblichen Anteil an UV- Strahlung ausgesetzt ist. Bisher gibt es nur wenige Produkte, die dem Haarschutz Rechnung tragen. Unbekannt sind Produkte, die nach der Lichtexpsoition auf Haar und Kopfhaut aufgetragen, die negativen Effekte lindern und so das Haar glänzend und glatt erhalten, sowie das Schuppen der Kopfhaut verhindern oder lindern.Furthermore, hair and scalp form a part of the body that is exposed to a considerable amount of UV radiation due to its position when staying outdoors. So far there are only a few products that take hair protection into account. Products that are applied to the hair and scalp after exposure to light, are known to alleviate the negative effects and thus keep the hair shiny and smooth, and to prevent or relieve scalp dandruff.
Antioxidantien sind Substanzen, welche Oxidationsprozesse verhindern bzw. welche die Autoxidation ungesättigte Verbindungen enthaltender Fette verhindern. Antioxidantien, welche auch auf dem Gebiete der Kosmetik und der Pharmazie Verwendung finden, sind beispielsweise α-Tocopherol, insbesondere in Form des α-Tocopheryiacetats, Sesamol, Gallensäurederivate, Butylhydroxyanisol und Butylhydroxytoluol.Antioxidants are substances which prevent oxidation processes or which prevent the autoxidation of fats containing unsaturated compounds. Antioxidants which are also used in the fields of cosmetics and pharmacy are, for example, α-tocopherol, in particular in the form of α-tocopheryiacetate, sesamol, bile acid derivatives, butylated hydroxyanisole and butylated hydroxytoluene.
Auch aus dem Grunde, solchen Reaktionen vorzubeugen, können kosmetischen Formulierungen zusätzlich Antioxidantien oder Radikalfänger einverleibt werden.Antioxidants or radical scavengers can also be incorporated into cosmetic formulations for the reason of preventing such reactions.
Zwar sind einige Antioxidantien und Radikalfänger bekannt. So ist bereits in den US-Patentschriften 4,144,325 und 4,248,861 sowie aus zahlreichen anderen Dokumenten vorgeschlagen worden, Vitamin E, eine Substanz mit be¬ kannter antioxidativer Wirkung in Lichtschutzformulierungen einzusetzen, den¬ noch bleibt auch hier die erzielte Wirkung weit hinter der erhofften zurück.Some antioxidants and radical scavengers are known. It has already been proposed in US Pat. Nos. 4,144,325 and 4,248,861 and from numerous other documents to use vitamin E, a substance with a known antioxidative action in light protection formulations, but the effect achieved here still falls far short of the hoped-for effect.
Eine Aufgabe der vorliegenden Erfindung war, die Nachteile des Standes der Technik zu beseitigen. Insbesondere sollten Wirkstoffe bzw. kosmetische und dermatologische Zubereitungen, solche Wirkstoffe enthaltend, zur Verfügung gestellt werden, bei deren Verwendung die Schädigung der Haut und/oder des Haares durch oxidativen Einfluß zumindest gemindert, wenn nicht gänzlich verhindert werden können. Eine weitere Aufgabe der vorliegenden Erfindung bestand darin, kosmetische Zubereitungen zur Verfügung zu stellen, welche vor oder nach Behandlung des Haars mit Haarfärbezubereitungen oder Dauerwellprodukten, selbst solcher mit einem Gehalt an starken Oxidationsmitteln wie z.B. Wasserstoffperoxid, deren schädigenden Oxidationswirkung entgegenwirken.An object of the present invention was to eliminate the disadvantages of the prior art. In particular, active ingredients or cosmetic and dermatological preparations containing such active ingredients should be made available, the use of which at least reduces, if not completely prevents, damage to the skin and / or hair by oxidative influence. Another object of the present invention was to provide cosmetic preparations which, before or after treatment of the hair with hair dye preparations or permanent wave products, even those containing strong oxidizing agents such as hydrogen peroxide, counteract their damaging oxidizing action.
Insbesondere sollten Wirkstoffe und Zubereitungen, solche Wirkstoffe enthaltend, zur kosmetischen und dermatologischen Behandlung und/oder Prophylaxe des Erscheinungsbildes des "Stingings" zur Verfügung gestellt werden.In particular, active ingredients and preparations containing such active ingredients should be made available for cosmetic and dermatological treatment and / or prophylaxis of the appearance of the "stinging".
Es war überraschend und für den Fachmann nicht vorauszusehen, daß erfindungsgemäße Zubereitungen und Wirkstoffkombinationen, enthaltend wirksame Mengen an Substanzen gewählt aus der Gruppe der Flavonoide oder ihrer Glycoside allein oder ihre Kombination mit Substanzen aus der Gruppe der Zimtsäurederivate oder Hydroxyzimtsäuren den Nachteilen des Standes der Technik abhilft.It was surprising and unforeseeable for the person skilled in the art that preparations and combinations of active substances according to the invention containing effective amounts of substances selected from the group of flavonoids or their glycosides alone or their combination with substances from the group of cinnamic acid derivatives or hydroxycinnamic acids remedies the disadvantages of the prior art .
Die vorstehenden Aufgaben werden gemäß der Erfindung gelöst.The above objects are achieved according to the invention.
Gegenstand der Erfindung sind kosmetische und dermatologische Zubereitungen mitThe invention relates to cosmetic and dermatological preparations
a) einem Gehalt an einer Verbindung oder mehreren Verbindungen aus der Gruppe der Flavonoide oder mita) a content of one or more compounds from the group of flavonoids or with
b) einem Gehalt an einer Wirkstoffkombination, enthaltend eine Verbindung oder mehrere Verbindungen ausgewählt aus der Gruppe der Flavonoide in Kombination mit einer Verbindung oder mehreren Verbindungen ausgewählt aus der Gruppe der Zimtsäurederivate undb) a content of an active ingredient combination comprising a compound or more compounds selected from the group of flavonoids in combination with a compound or more compounds selected from the group of cinnamic acid derivatives and
c) gegebenenfalls einem zusätzlichen Gehalt an einer Verbindung oder mehreren Verbindungen aus der Gruppe der Antioxidantien. Wirkstoffkombinationen b), deren Verwendung und Zubereitungen, die diese enthalten, werden bevorzugt.c) optionally an additional content of one or more compounds from the group of antioxidants. Active ingredient combinations b), their use and preparations containing them are preferred.
Topische Zubereitungen werden bevorzugt.Topical preparations are preferred.
Die erfindungsgemäßen Flavonoide werden im folgenden auch mit A), die erfindungsgemäßen Zimtsäurederivate auch mit B) und die erfindungsgemäßen Antioxidantien auch mit C) bezeichnet.The flavonoids according to the invention are also referred to below with A), the cinnamic acid derivatives according to the invention also with B) and the antioxidants according to the invention also with C).
Bevorzugte erfindungsgemäße Flavonoide sind beispielsweise hydroxylierte Flavone, Flavanone, Isoflavone oder Chalcone und jeweils auch deren Glycoside, aber auch diese nicht hydroxylierten Grundstrukturen bzw. Stammsubstanzen.Preferred flavonoids according to the invention are, for example, hydroxylated flavones, flavanones, isoflavones or chalcones and in each case also their glycosides, but also these non-hydroxylated basic structures or parent substances.
Erfindungsgemäß werden die Flavonoide A) bevorzugt gewählt aus der Gruppe der Substanzen der generischen StrukturformelnAccording to the invention, the flavonoids A) are preferably selected from the group of substances of the generic structural formulas
undand
wobei Zi - Z5 unabhängig voneinander gewählt werden aus der Gruppe H, OH und O-Alkyl, wobei die Alkylgruppen verzweigt und unverzweigt sein und 1 - 18 C-Atome aufweisen können, und wobei Gly gewählt wird aus der Gruppe der Mono-, Di- und Oligoglycosidreste oder auch H darstellen kann. Reste Gly können z.B. die für Gly1 - Gly 3 angegebenen Reste sein. Reste Gly können z.B. die für Glyi - Gly3 angegebenen Reste sein. where Zi - Z 5 are selected independently of one another from the group H, OH and O-alkyl, where the alkyl groups can be branched and unbranched and can have 1-18 C atoms, and wherein Gly is selected from the group of the mono-, di - And oligoglycoside residues or H can represent. Gly residues can be, for example, the residues specified for Gly1-Gly 3. Gly residues can be, for example, the residues specified for Glyi-Gly3.
Vorteilhaft im Sinne der vorliegenden Erfindung ist es, das oder die Flavonoide A) zu wählen aus der Gruppe Quercitin, Chrysin, Kaempferol, Myricetin, Apigenin, Naringenin, Hesperitin, Morin, Fisetin, Vitexin, Isovitexin, Flavon und Genistein.For the purposes of the present invention, it is advantageous to select the flavonoid (s) A) from the group quercitin, chrysin, kaempferol, myricetin, apigenin, naringenin, hesperitin, morin, fisetin, vitexin, isovitexin, flavon and genistein.
Ebenso vorteilhaft ist es die Flavonglycoside A) zu wählen aus der Gruppe Rutin, Rhamnetin, Luteolin, Naringin, Hesperidin, Phloridzin, Diosmin , Neohesperidin-Dihydrochalkon.It is also advantageous to choose the flavone glycosides A) from the group of rutin, rhamnetin, luteolin, naringin, hesperidin, phloridzin, diosmin, neohesperidin-dihydrochalcone.
Besonders bevorzugt sind Chrysin, Naringin, Hesperidin, Naringenin, Hesperetin, Morin, Phloridzin, Diosmin, Neohesperidin-Dihydrochalkon, Flavon.Chrysin, Naringin, Hesperidin, Naringenin, Hesperetin, Morin, Phloridzin, Diosmin, Neohesperidin-Dihydrochalkon, Flavon are particularly preferred.
Weitere erfindungsgemäße Flavonoide A) werden vorteilhaft gewählt aus der Gruppe der Substanzen mit den generischen Strukturformeln:Further flavonoids A) according to the invention are advantageously selected from the group of substances with the generic structural formulas:
sowie such as
worin Zi - Z5 die oben angegebene Bedeutung haben und Glyi , Gly2 und Gly 3 Monoglycosidreste darstellen.where Zi - Z5 have the meaning given above and represent Glyi, Gly2 and Gly 3 monoglycoside residues.
Bevorzugt werden Gly1t Gly2 und Gly3 unabhängig voneinander gewählt aus der Gruppe der Hexosylreste oder Pentosylreste. Reste wie Allosyl, Altrosyl, Apiosyl, Arabinosyl, Ascorbinyl, Biosidyl, Galactosyl, Gulosyl, Glucosyl, Glucoronidyl, Idosyl, Mannosyl, Talosyl, Dulcityl, Fructosyl, Mannityl, Rhamnosyl, Ribosyl, Sorbityl und Xylosyl sind vorteilhaft zu verwenden. Insbesondere vorteilhaft ist es, Rhamnosylreste oder Glucosylreste zu verwenden.Gly 1t Gly 2 and Gly 3 are preferably selected independently of one another from the group of the hexosyl radicals or pentosyl radicals. Residues such as allosyl, altrosyl, apiosyl, arabinosyl, ascorbinyl, biosidyl, galactosyl, gulosyl, glucosyl, glucoronidyl, idosyl, mannosyl, talosyl, dulcityl, fructosyl, mannityl, rhamnosyl, ribosyl, sorbityl and xylosyl are advantageous to use. It is particularly advantageous to use rhamnosyl residues or glucosyl residues.
Besonders vorteilhaft im Sinne der vorliegenden Erfindung ist, das oder die Flavonglycoside zu wählen aus der Gruppe alpha-Glucosylrutin, alpha- Glucosylmyrictrin, alpha-Glucosylisoquercitrin und alpha-Glucosylquercitrin.For the purposes of the present invention, it is particularly advantageous to select the flavone glycoside (s) from the group alpha-glucosylrutin, alpha-glucosylmyrictrin, alpha-glucosylisoquercitrin and alpha-glucosylquercitrin.
Darüberhinaus sind besonders bevorzugt Verbindungen wie alpha- Glycosylrutin, alpha-Glycosylhesperidin, alpha-Glycosylnaringin, alpha- Mannosylrutin, alpha-Rhamnosylrutin.In addition, compounds such as alpha-glycosyl rutin, alpha glycosyl hesperidine, alpha glycosyl naringin, alpha mannosyl rutin, alpha rhamnosyl rutin are particularly preferred.
Ebenso kann es von Vorteil sein, einen oder mehreren der Glyi, Gly2, Gly3- Reste aus der Gruppe der Oligo- oder Poly-a- oder ß-glycosidischen Verbindungen zu wählen, oder aus der Gruppe der Zuckersäuren oder Zuckerester. Ebenso können eine oder mehrere Glyi, Gly2, Gly3- Reste aus der Gruppe der substituierten Zucker gewählt werden, wie z.B. N- Acetylglucosamin. Ebenso kann es von Vorfeil sein Flavonoide A) zu verwenden, deren Glycosid- Rest über phenolische OH-Funktionen an 07, 04', 03' oder 05' gebunden ist.It may also be advantageous to choose one or more of the Glyi, Gly 2 , Gly 3 radicals from the group of the oligo- or poly-a- or β-glycosidic compounds, or from the group of the sugar acids or sugar esters. Likewise, one or more Glyi, Gly 2 , Gly 3 residues can be selected from the group of substituted sugars, such as N-acetylglucosamine. It can also be of advantage to use flavonoids A) whose glycoside residue is bonded to 07, 04 ' , 03 ' or 05 ' via phenolic OH functions.
Weiterhin kann es von Vorteil sein, Flavonoide A) und deren Glycoside zu verwenden, deren phenolische OH-Funktion an 09 frei vorliegt (sogenannte Chalkone). Insbesondere ist es vorteilhaft aus dieser Gruppe Neohesperidin- Dihydrochalkon zu verwenden.Furthermore, it may be advantageous to use flavonoids A) and their glycosides, the phenolic OH function of which is freely available at 09 (so-called chalcones). From this group it is particularly advantageous to use neohesperidine dihydrochalcone.
Besonders bevorzugte Flavonoide A) sind: Chrysin, Naringin, Hesperidin, Naringenin, Hesperetin, Morin, Phloridzin, Diosmin, Neohesperidin- Dihydrochalkon, Flavon und insbesondere alpha-Glucosylrutin der Formel:Particularly preferred flavonoids A) are: chrysin, naringin, hesperidin, naringenin, hesperetin, morin, phloridzin, diosmin, neohesperidin dihydrochalcone, flavone and in particular alpha-glucosylrutin of the formula:
Daruberhinaus kann es vorteilhaft sein im Sinne der Erfindung handelsübliche, flavonoidhaltige Pflanzenextrakte zu verwenden. Bei diesen kann es sich um nach den üblichen Methoden gewonnene wassrig-alkoholische bzw. wässrig- glykolische Extrakte sowie trockene Extrakte handeln. Insbesondere als vorteilhaft haben sich erwiesen: Zitrusfruchtschalen- oder - kernextrakt (z. B. Citricidal/Fa. Synthapharm), Soyaextrakt (z. B. Phytodermin/Fa. Chem. Laboratorium Dr. Kurt Richter GmbH), Sophora Japonica-Extrakt (z. B. Sophorine/Fa. Solabia), Frauendistelextrakt (z. B. Psoralen Silymarin/Fa. Mani GmbH Chemische Produkte), Katzenpfötchenblütenextrakt, Spinatextrakt und ein gemischter Pflanzenextrakt aus Passionsblumen, schwarzen Johannisbeeren und Weinbättern (AE Complex Fa. Solabia), Calendula-Extrakt (Pot Marigold AMI watersoluble/ Alban Muller).In addition, it may be advantageous to use commercially available flavonoid-containing plant extracts for the purposes of the invention. These can be aqueous-alcoholic or aqueous-glycolic extracts and dry extracts obtained by the usual methods. The following have proven to be particularly advantageous: citrus fruit peel or kernel extract (e.g. Citricidal / Synthapharm), soy extract (e.g. Phytodermin / Chem. Laboratorium Dr. Kurt Richter GmbH), Sophora Japonica extract (e.g. B. Sophorine / Solabia), women's thistle extract (e.g. Psoralen Silymarin / Mani GmbH Chemical Products), cat paw blossom extract, spinach extract and a mixed plant extract of passion flowers, black currants and vine leaves (AE Complex from Solabia), Calendula Extract (Pot Marigold AMI watersoluble / Alban Muller).
Geeignete Zimtsäurederivate sind z.B. Hydroxyzimtsauren und deren Derivate, wobei die Derivate z.B. die im folgenden definierten sein können.Suitable cinnamic acid derivatives are e.g. Hydroxycinnamic acids and their derivatives, the derivatives e.g. which can be defined below.
Erfindungsgemäß können vorzugsweise Zimtsäurederivate der allgemeinen FormelAccording to the invention, cinnamic acid derivatives of the general formula can preferably be used
und/oder wirksame Mengen an Zimtsäurederivaten der allgemeinen Formeland / or effective amounts of cinnamic acid derivatives of the general formula
verwendet werden, wobei die Gruppen X, Y und R unabhängig voneinander gewählt werden können aus der Gruppe H, verzweigtes bzw. unverzweigtes Alkyl mit 1 - 18 C-Atomen, insbesondere 1 - 6 C-Atomen. Es können die Säuren oder deren Salze verwendet werden, vorzugsweise die physiologisch verträgliche Salze, beispielsweise wasserlösliche Salze (Natrium-, Kaliumsalze).are used, the groups X, Y and R being able to be selected independently of one another from the group H, branched or unbranched alkyl having 1 to 18 carbon atoms, in particular 1 to 6 carbon atoms. The acids or their salts can be used, preferably the physiologically tolerable salts, for example water-soluble salts (sodium, potassium salts).
Als besonders vorteilhaftes Zimtsäurederivat im Sinne der vorliegenden Erfindung wird die Ferulasäure angesehen. Ferulasäure (4-Hydroxy-3- methoxyzimtsäure, Kaffeesäure-3-methylether) ist durch die StrukturformelFerulic acid is regarded as a particularly advantageous cinnamic acid derivative for the purposes of the present invention. Ferulic acid (4-hydroxy-3-methoxycinnamic acid, caffeic acid-3-methyl ether) is due to the structural formula
bzw.respectively.
gekennzeichnet. Sie ist in Pflanzen weit verbreitet und kommt z.B. in Rüben, Getreide und dem Milchsaft der namensgebenden Doldenblütlern Ferula asafoetida und Ferula nartex vor. Die E-Form ist unter Normalbedingungen ein farblos-kristalliner Festkörper, die Z-Form liegt unter Normalbedingungen als gelbliches Öl vor.characterized. It is widespread in plants and comes e.g. in beets, cereals and the milk juice of the umbelliferae Ferula asafoetida and Ferula nartex. Under normal conditions, the E form is a colorless, crystalline solid, and under normal conditions, the Z form is a yellowish oil.
Im Sinne der vorliegenden Erfindung ist bevorzugt E-Ferulasäure zu verwenden. Es ist jedoch gegebenenfalls auch von Vorteil, Z-Ferulasäure bzw. beliebige Gemische aus E- und Z-Ferulasäure einzusetzen.For the purposes of the present invention, preference is given to using E-ferulic acid. However, it may also be advantageous to use Z-ferulic acid or any mixtures of E- and Z-ferulic acid.
Eine weiteres erfindungsgemäß bevorzugtes Derivat der Zimtsäure ist die Kaffeesäure, welche sich durch die Struktur Another derivative of cinnamic acid preferred according to the invention is caffeic acid, which is distinguished by its structure
auszeichnet. Sie ist eine weit verbreitete Pflanzensäure und z.B. in Kaffee, Tabak, Mohn und Löwenzahn enthalten.distinguished. It is a widely used plant acid and e.g. contained in coffee, tobacco, poppy seeds and dandelions.
Es ist auch gegebenenfalls vorteilhaft Pflanzenextrakte mit einem Gehalt an erfindungsgemäßen Zimtsäurederivaten, insbesondere Ferulasäure und/oder Kaffeesäure, zu verwenden.It may also be advantageous to use plant extracts containing cinnamic acid derivatives according to the invention, in particular ferulic acid and / or caffeic acid.
Unter dem Begriff "Derivate der Kaffeesäure oder Ferulasäure" sind zu verstehen ihre kosmetisch oder pharmakologisch unbedenklichen Ester, Salze und Basenaddukte, insbesondere solche, wie sie bei den Zimtsäurederivaten vorstehend beschrieben sind.The term "derivatives of caffeic acid or ferulic acid" means their cosmetically or pharmacologically acceptable esters, salts and base adducts, in particular those as described above for the cinnamic acid derivatives.
Bevorzugte erfindungsgemäße Kombinationen sind Kombinationen von einem oder mehreren Stoffen aus der Gruppe der oben aufgeführten Flavonoide oder Kombinationen von einem oder mehrern Vertreten der Flavonoide mit einem Derivat der Zimtsäure oder auch die Kombination mit mehreren Zimtsäurederivaten.Preferred combinations according to the invention are combinations of one or more substances from the group of the flavonoids listed above or combinations of one or more representatives of the flavonoids with a derivative of cinnamic acid or the combination with several cinnamic acid derivatives.
Das Gewichtsverhältnis der Zimtsäurederivate zu dem oder den Flavonoiden beträgt vorteilhaft 25 : 1 bis 1 : 25, bevorzugt 5 : 1 bis 1 : 5, insbesondere be¬ vorzugt etwa 2 : 1 bis 1 : 2.The weight ratio of the cinnamic acid derivatives to the flavonoid (s) is advantageously 25: 1 to 1:25, preferably 5: 1 to 1: 5, particularly preferably about 2: 1 to 1: 2.
Erfindungsgemäß besonders bevorzugt sind die Kombinationen von Flavonoiden, Flavonglucosiden bzw. flavonoidhaltigen pflanzlichen Extrakten mit Ferulasäure sowie die Kombination von synthetisch modifizierten, insbesondere glykosylierten Flavonoiden wie alpha-Glukosylrutin mit Zimtsäurederivaten.The combinations of flavonoids, flavonglucosides or flavonoid-containing plant extracts with ferulic acid and the combination of synthetically modified, in particular glycosylated flavonoids such as alpha-glucosylrutin with cinnamic acid derivatives are particularly preferred according to the invention.
Besonders bevorzugt werden Zubereitungen mit Kombinationen b), die alpha- Glucocsylrutin und/oder Ferulasäure enthalten. In den erfindungsgemäßen Zubereitungen können als alleinige Wirkstoffe die Verbindungen der Gruppe A oder die der Kombination der Wirkstoffe A) und B) vorliegen.Preparations with combinations b) which contain alpha-glucocsylrutin and / or ferulic acid are particularly preferred. The compounds of group A or of the combination of the active compounds A) and B) can be present as the sole active compounds in the preparations according to the invention.
Die erfindungsgemäßen kosmetischen und dermatologischen Zubereitungen enthalten bevorzugt 0,001 Gew.-% bis 30 Gew.-%, vorzugsweise 0,01 Gew.-% bis 10 Gew.-%, insbesondere aber 0,1 Gew.-% bis 6 Gew.-%, bezogen auf das Gesamtgewicht der Zubereitung eines oder mehrerer erfindungsgemäßer Stoffe A) oder der Kombination von A) und B).The cosmetic and dermatological preparations according to the invention preferably contain 0.001% by weight to 30% by weight, preferably 0.01% by weight to 10% by weight, but in particular 0.1% by weight to 6% by weight , based on the total weight of the preparation of one or more substances A) according to the invention or the combination of A) and B).
Die erfindungsgemäßen Zubereitungen können aber bevorzugt neben den Wirkstoffen A) oder der Kombination von A) und B) auch noch einen Gehalt an einem Antioxidans oder mehreren Antioxidantien C) haben.In addition to the active ingredients A) or the combination of A) and B), the preparations according to the invention can preferably also have an antioxidant or more antioxidants C).
Besonders vorteilhaft können die erfindungsgemäßen Antioxidantien C) aus der Gruppe der Tocopherole und deren Derivaten ausgewählt werden. Die Tocopherole, auch Vitamin E genannt, leiten sich vom Grundkörper Tocol ((2- Methyl-2-(4,8,12-trimethyltridecyl)chroman-6-ol) ab. Dem natürlich am häufigsten vorkommenden und bedeutendsten -Tocopherol kommt die Konfiguration 2R,4'R,8'R zu. Es wird gelegentlich auch RRR-α-Tocopherol genannt.The antioxidants C) according to the invention can be selected particularly advantageously from the group of tocopherols and their derivatives. The tocopherols, also called vitamin E, are derived from the main body tocol ((2-methyl-2- (4,8,12-trimethyltridecyl) chroman-6-ol). The most common and most important tocopherol, of course, comes from the configuration 2R, 4'R, 8'R. It is sometimes called RRR-α-tocopherol.
Die erfindungsgemäß bevorzugten Tocopherolderivate sind das α-Tocopherol und seine Ester, insbesondere das α-Tocopherylacetat. Ester von Säuren mit 2 bis 18, insbesondere 2 bis 8 C-Atomen werden bevorzugt.The tocopherol derivatives preferred according to the invention are the α-tocopherol and its esters, in particular the α-tocopheryl acetate. Esters of acids with 2 to 18, in particular 2 to 8, carbon atoms are preferred.
Weiterhin ist es vorteilhaft Antioxidantien C) aus der Gruppe bestehend aus Aminosäuren (z.B. Glycin, Histidin, Tyrosin, Tryptophan) und deren Derivate, Imidazole (z.B. Urocaninsäure) und deren Derivate, Peptide wie D,L-Carnosin, D-Carnosin, L-Camosin und deren Derivate (z.B. Anserin), Carotinoide, Carotine (z.B. α-Carotin, ß-Carotin, Lycopin) und deren Derivate, Chlorogensäure und deren Derivate, Liponsäure und deren Derivate (z.B. Dihydroliponsäure), Aurothioglucose, Propylthiouracil und andere Thiole (z.B. Thioredoxin, Glutathion, Cystein, Cystin, Cystamin und deren Glycosyl-, N- Acetyl-, Methyl-, Ethyl-, Propyl-, Amyl-, Butyl- und Lauryl-, Palmitoyl-, Oleyl-, γ- Linoleyl-, Cholesteryl- und Glycerylester) sowie deren Salze sowie Sulfoximin- verbindungen (z.B. Buthioninsuffoximine, Homocysteinsulfoximin, Buthionin- sulfone, Penta-, Hexa-, Heptathioninsulfoximin) in sehr geringen verträglichenIt is also advantageous antioxidants C) from the group consisting of amino acids (eg glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (eg urocanic acid) and their derivatives, peptides such as D, L-carnosine, D-carnosine, L- Camosin and its derivatives (e.g. Anserin), carotenoids, carotenes (e.g. α-carotene, β-carotene, lycopene) and their derivatives, chlorogenic acid and their derivatives, lipoic acid and their derivatives (e.g. dihydroliponic acid), aurothioglucose, propylthiouracil and other thiols (e.g. Thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, γ-linoleyl, cholesteryl and glyceryl esters) as well as their salts and sulfoximine compounds (eg buthionine suffoximines, homocysteine sulfoximine, buthionine sulfones, penta-, hexa-, heptathioninsulfoximine) in very low tolerable
Dosierungen (z.B. pmol bis μmol/kg), ferner (Metall)-Chelatoren (z.B. α-Hydroxyfettsäuren, Palmitinsäure, Phytinsäure, Lactoferrin), α-Hydroxysäuren (z.B. Citronensäure, Milchsäure, Apfeisäure), Huminsäure,Dosages (e.g. pmol to μmol / kg), also (metal) chelators (e.g. α-hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), α-hydroxy acids (e.g. citric acid, lactic acid, malic acid), humic acid,
Gallensäure, Gallenextrakte, Bilirubin, Biliverdin, EDTA, EGTA und derenBile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and their
Derivate, ungesättigte Fettsäuren und deren Derivate (z.B. γ-Linolensäure,Derivatives, unsaturated fatty acids and their derivatives (e.g. γ-linolenic acid,
Linolsäure, ölsäure), Folsäure und deren Derivate, Ubichinon und Ubichinol und deren Derivate, Vitamin C und Derivate (z.B. Ascorbylpalmitat, Mg-Linoleic acid, oleic acid), folic acid and its derivatives, ubiquinone and ubiquinol and their derivatives, vitamin C and derivatives (e.g. ascorbyl palmitate, Mg-
Ascorbylphosphat, Ascorbylacetat), Vitamin A und Derivate (Vitamin-A- palmitat) sowie Koniferylbenzoat des Benzoeharzes, Butylhydroxytoluol,Ascorbyl phosphate, ascorbyl acetate), vitamin A and derivatives (vitamin A palmitate) and coniferyl benzoate of the benzoin, butylated hydroxytoluene,
Butylhydroxyanisol, Nordihydroguajakharzsäure, Nordihydroguajaretsäure,Butylated hydroxyanisole, nordihydroguajakarzarzäure, Nordihydroguajaretsäure,
Trihydroxybutyrophenon, Harnsäure und deren Derivate, Mannose und deren Derivate, Sesamol, Sesamolin, Zink und dessen Derivate (z.B. ZnO, ZnSO. )Trihydroxybutyrophenone, uric acid and its derivatives, mannose and its derivatives, sesamol, sesamolin, zinc and its derivatives (e.g. ZnO, ZnSO.)
Selen und dessen Derivate (z.B. Selenmethionin), Stilbene und deren Derivate (z.B. Stilbenoxid, Trans-Stilbenoxid) und die erfindungsgemäß geeigneten Derivate (Salze, Ester, Ether, Zucker, Nukleotide, Nukleoside, Peptide und Lipide) dieser genannten Wirkstoffe zu verwenden.Selenium and its derivatives (e.g. selenium methionine), stilbenes and their derivatives (e.g. stilbene oxide, trans-stilbene oxide) and the derivatives suitable according to the invention (salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids) of these active substances mentioned.
Die Menge der vorgenannten Antioxidantien C) (eine oder mehrere Verbindungen) in den Zubereitungen beträgt vorzugsweise 0,001 bis 30 Gew - %, besonders bevorzugt 0,05 - 20 Gew.-%, insbesondere 1 - 10 Gew.-%, bezogen auf das Gesamtgewicht der Zubereitung.The amount of the aforementioned antioxidants C) (one or more compounds) in the preparations is preferably 0.001 to 30% by weight, particularly preferably 0.05 to 20% by weight, in particular 1 to 10% by weight, based on the total weight the preparation.
Sofern Vitamin E und/oder dessen Derivate das oder die Antioxidantien darstellen, ist vorteilhaft, deren jeweilige Konzentrationen aus dem Bereich von 0,001 - 10 Gew.-%, bezogen auf das Gesamtgewicht der Formulierung, zu wählen.If vitamin E and / or its derivatives represent the antioxidant (s), it is advantageous to choose their respective concentrations from the range of 0.001-10% by weight, based on the total weight of the formulation.
Die erfindungsgemäßen kosmetischen und/oder dermatologischen Formulierungen können wie üblich zusammengesetzt sein und zur Prophylaxe und/oder zur Behandlung der Haut im Sinne einer dermatologischen Behandlung oder einer Prophylaxe und/oder Behandlung im Sinne der Kosmetik dienen. Sie können aber auch in Schminkprodukten in der dekorativen Kosmetik eingesetzt werden. Sie enthalten bevorzugt 0,001 Gew.-% bis 30 Gew.-%, vorzugsweise 0,01 Gew.-% bis 10 Gew.-%, insbesondere aber 0,1 Gew.-% bis 6 Gew.-%, bezogen auf das Gesamtgewicht, eines oder mehrerer erfindungsgemäßer Stoffe A) oder der Kombination von A) und B).The cosmetic and / or dermatological formulations according to the invention can be composed as usual and can be used for prophylaxis and / or for the treatment of the skin in the sense of a dermatological treatment or a prophylaxis and / or treatment in the sense of cosmetics. But they can also be used in make-up products in decorative cosmetics. They preferably contain 0.001% by weight to 30% by weight, preferably 0.01% by weight to 10% by weight, but in particular 0.1% by weight to 6% by weight, based on the Total weight, one or more substances A) according to the invention or the combination of A) and B).
Es ist erfindungsgemäß vorteilhaft, Kombinationen aus mehreren erfindungsgemäßen Substanzen zu verwenden, insbesondere, wenn wenigstens eine der Komponenten gewählt wird aus der Gruppe der Flavonoide bzw. deren Glucoside und der Zimtsäurederivate.It is advantageous according to the invention to use combinations of several substances according to the invention, in particular if at least one of the components is selected from the group of the flavonoids or their glucosides and the cinnamic acid derivatives.
Vorteilhaft ist es insbesondere, Kombinationen aus mindestens einer Verbindung aus den Flavonoiden A) bzw. deren Derivaten, mindestens einer Verbindung aus den Zimtsäurederivaten B) sowie Vitamin E bzw. seinen Derivate C) zu verwenden.It is particularly advantageous to use combinations of at least one compound from the flavonoids A) or their derivatives, at least one compound from the cinnamic acid derivatives B) and vitamin E or its derivatives C).
Zur Anwendung werden die erfindungsgemäßen Substanzen bzw. Zubereitungen, solche Substanzen enthaltend, vorzugsweise Kombinationen aus Flavonoiden bzw. deren Derivaten, Zimtsäurederivaten sowie gegebenenfalls Antioxidantien in der für Kosmetika oder Dermatika üblichen Weise auf die Haut in ausreichender Menge aufgebracht.For use, the substances or preparations according to the invention containing such substances, preferably combinations of flavonoids or their derivatives, cinnamic acid derivatives and, if appropriate, antioxidants are applied to the skin in a sufficient amount in the manner customary for cosmetics or dermatics.
Die Schrift JP-OS Hei-06-138,941 beschreibt zwar orale Zubereitungen mit einem Gehalt an wasserlöslichen Glycosiden, welche beispielsweise gewählt werden können aus der Gruppe α-Glucosylrutin, α-Glucosylmyrictrin, α- Glucosylisoquercitrin und α-Glucosylquercitrin. Die Schrift JP-OS Hei-04- 363,395 beschreibt ein Verfahren, die Zersetzung von Parfümbestandteilen zu verhindern, welche sich unter anderem durch einen Zusatz an α-Glucosylrutin zu den entsprechenden Zubereitungen auszeichnet. Ferner beschreiben die Schriften EP-OS 586 303 und EP-OS 595 694 die Verwendung von Flavonoiden als Antioxidantien bzw. Lichtschutzsubstanzen in Kosmetika. Weiterhin ist aus US-PS 4,144,325 und 4,248,861 sowie aus zahlreichen anderen Dokumenten bekannt, Vitamin E in kosmetischen und dermatologischen Lichtschutzformulierungen einzusetzen. Die erfindungsgemäße Verwendung des Vitamins E und seiner Derivate wurde indes nicht durch den Stand der Technik nahegelegt.The document JP-OS Hei-06-138,941 describes oral preparations containing water-soluble glycosides, which can be selected, for example, from the group α-glucosylrutin, α-glucosylmyrictrin, α-glucosylisoquercitrin and α-glucosylquercitrin. JP-OS Hei-04- 363,395 describes a process for preventing the decomposition of perfume components, which is characterized, inter alia, by the addition of α-glucosylrutin to the corresponding preparations. Furthermore, the documents EP-OS 586 303 and EP-OS 595 694 describe the use of flavonoids as antioxidants or light protection substances in cosmetics. Furthermore, it is known from US Pat. Nos. 4,144,325 and 4,248,861 and from numerous other documents to use vitamin E in cosmetic and dermatological light protection formulations. However, the use of vitamin E and its derivatives according to the invention has not been suggested by the prior art.
Kein Hinweis ist diesen Schriften aber zu entnehmen, welcher in die Richtung der vorliegenden Erfindung weisen könnte. Es war für den Fachmann daher nicht vorauszusehen gewesen, daß die erfindungsgemäßen Wirkstoffe und Wirkstoffkombinationen bzw. kosmetische oder dermatologische Zubereitungen, diese enthaltendHowever, there is no indication in these documents which could point in the direction of the present invention. It was therefore not foreseeable for the person skilled in the art that the active substances and active substance combinations according to the invention or cosmetic or dermatological preparations containing them
besser gegen die Hautalterung wirken besseren Schutz für Lippen geben besser die Haut und Haare gegen Photoreaktionen schützen besser Haare und Kopfhaut bei Haarfärbungen und Dauerwellen schützen würden bei empfindlicher Haut besser vor unangenehmem Stinging schützen gegen unspezifischen Juckreiz wirksam sindbetter work against aging better protection for lips give better protection of the skin and hair against photoreactions better protect hair and scalp against hair coloring and perms would protect sensitive skin better against unpleasant stinging against unspecific itching
als die Wirkstoffe, Wirkstoffkombinationen und Zubereitungen des Standes der Technik.as the active ingredients, combinations of active ingredients and preparations of the prior art.
Erfindungsgemäß sind daher die Verwendung der erfindungsggemäßen Wirkstoffe oder Wirkstoffkombinationen zur Bekämpfung und/oder Prophylaxe der durch oxidative Beanspruchung hervorgerufenen Hautalterung und entzündlicher Reaktionen sowie die vorstehend und im folgenden angegebenen Wirkungen und Verwendungen.According to the invention, therefore, are the use of the active substances or combinations of active substances according to the invention for combating and / or prophylaxis of skin aging and inflammatory reactions caused by oxidative stress, and the effects and uses indicated above and below.
Gegenstand der Erfindung ist daher auch die Verwendung der kosmetischen und dermatologischen Zubereitungen mitThe invention therefore also relates to the use of the cosmetic and dermatological preparations
a) einem Gehalt an einer Verbindung oder mehreren Verbindungen aus der Gruppe der Flavonoidea) a content of one or more compounds from the group of flavonoids
oder mitor with
b) einem Gehalt an einer Wirkstoffkombination, enthaltend eine Verbindung oder mehrere Verbindungen ausgewählt aus der Gruppe der Flavonoide A) in Kombination mit einer Verbindung oder mehreren Verbindungen ausgewählt aus der Gruppe der Zimtsäurederivate und c) gegebenenfalls einem zusätzlichen Gehalt an einer Verbindung oder mehreren Verbindungen aus der Gruppe der Antioxidantien zur Behandlung und prophylaktische Behandlung der Hautalterung, zur Vorbehandlung oder Nachbehandlung der Haare oder der Kopfhaut oder des Haarwurzelbereiches, insbesondere vor oder nach der Haarbehandlung, z.B. bei der Haarfärbung oder Dauerwelle, zum Schutz der Lippen insbesondere vor exogenen Noxen, zur Behandlung und zur prophylaktischen Behandlung von Stinging oder unspezifischem Juckreiz, zur Stabilisierung oder Wiederherstellung der epidermalen Barrierefunktion, zur Verringerung oder Verhinderung der Schädigung der Haut und des Haares durch oxidative Einflüsse, zum Schutz der Haut oder der Haare gegen Photoreaktionen und zur Behandlung oder prophylaktischen Behandlung der durch oxidative Beanspruchung hervorgerufenen Hautalterung und entzündlicher Reaktionen.b) a content of an active ingredient combination containing one or more compounds selected from the group of flavonoids A) in combination with one or more compounds selected from the group of cinnamic acid derivatives and c) if appropriate, an additional content of one or more compounds from the group of antioxidants for the treatment and prophylactic treatment of skin aging, for the pretreatment or aftertreatment of the hair or the scalp or the hair root area, in particular before or after the hair treatment, for example in the hair coloring or Perm, to protect the lips, in particular from exogenous noxae, to treat and prophylactically treat stinging or non-specific itching, to stabilize or restore the epidermal barrier function, to reduce or prevent damage to the skin and hair by oxidative influences, to protect the skin or hair against photoreactions and for the treatment or prophylactic treatment of skin aging and inflammatory reactions caused by oxidative stress.
Bevorzugt wird für diese Verwendung die topische Anwendung.Topical application is preferred for this use.
Die erfindungsgemäßen kosmetischen oder dermatologischen Formulierungen können für diese Verwendungen wie üblich zusammengesetzt sein und z.B. zur Behandlung, der Pflege und der Reinigung der Haut und/oder der Haare und als Schminkprodukt in der dekorativen Kosmetik dienen. Sie enthalten bevorzugt 0,001 Gew.-% bis 30 Gew.-%, vorzugsweise 0,01 Gew.-% bis 10 Gew.-%, insbesondere aber 0,1 Gew.-% bis 6 Gew.-%, bezogen auf das Gesamtgewicht des Mittels, an den erfindungsgemäßen Wirkstoffen oder ihren Wirkstoffkombinationen.The cosmetic or dermatological formulations according to the invention can be composed as usual for these uses and e.g. for the treatment, care and cleaning of the skin and / or hair and as a make-up product in decorative cosmetics. They preferably contain 0.001% by weight to 30% by weight, preferably 0.01% by weight to 10% by weight, but in particular 0.1% by weight to 6% by weight, based on the total weight of the agent, on the active substances according to the invention or their combinations of active substances.
Zur Anwendung werden die erfindungsgemäßen kosmetischen und dermatolo¬ gischen Zubereitungen in der für Kosmetika vorzugsweise auf die Haut und/oder die Haare in ausreichender Menge aufgebracht.For use, the cosmetic and dermatological preparations according to the invention are preferably applied in a sufficient amount to the skin and / or the hair for cosmetics.
Erfindungsgemäße kosmetische und dermatologische Zubereitungen können in verschiedenen Formen vorliegen. So können sie z.B. eine Lösung, eine wasserfreie Zubereitung, eine Emulsion oder Mikroemulsion vom Typ Wasser¬ in-Öl (W/O) oder vom Typ Öl-in-Wasser (O/W), eine multiple Emulsionen, beispielsweise vom Typ Wasser-in-ÖI-in-Wasser (W/O/W), ein Gel, einen festen Stift, eine Salbe oder auch ein Aerosol darstellen. Es ist auch vorteilhaft, die erfindungsgemäßen Wirkstoffkombinationen in verkapselter Form darzureichen, z.B. in Kollagenmatrices und anderen üblichen Verkapselungsmaterialien, z.B. als Celluloseverkapselungen, in Gelatine, Wachsmatrices oder liposomal verkapselt. Insbesondere Wachsmatrices wie sie in der DE-OS 43 08282 beschrieben werden, haben sich als günstig herausgestellt.Cosmetic and dermatological preparations according to the invention can be in various forms. For example, they can be a solution, an anhydrous preparation, an emulsion or microemulsion of the water-in-oil (W / O) or oil-in-water (O / W) type, multiple emulsions, for example of the water- in-oil-in-water (W / O / W), a gel, a solid stick, an ointment or an aerosol. It is also beneficial to present the active compound combinations according to the invention in encapsulated form, for example in collagen matrices and other customary encapsulation materials, for example in the form of cellulose encapsulations, in gelatin, wax matrices or liposomally encapsulated. In particular, wax matrices as described in DE-OS 43 08282 have proven to be favorable.
Es ist auch möglich und vorteilhaft im Sinne der vorliegenden Erfindung, die er¬ findungsgemäßen Wirkstoffkombinationen in wäßrige Systeme bzw. Tensid- zubereitungen zur Reinigung der Haut und der Haare einzufügen.It is also possible and advantageous for the purposes of the present invention to insert the active compound combinations according to the invention into aqueous systems or surfactant preparations for cleaning the skin and hair.
Als vorteilhafte Verkörperung der vorliegenden Erfindung wird daher auch die Verwendung erfindungsgemäßer Wirkstoffkombinationen zum Schütze der Haut und/oder der Haare vor oxidativer Beanspruchung angesehen, insbesondere diese Verwendung der erfindungsgemäßen Wirkstoffkombinationen in Shampoos und Waschformulierungen.The use of active ingredient combinations according to the invention for protecting the skin and / or hair from oxidative stress is therefore also regarded as an advantageous embodiment of the present invention, in particular this use of the active ingredient combinations according to the invention in shampoos and wash formulations.
Die erfindungsgemäßen kosmetischen und dermatologischen Zubereitungen können kosmetische Hilfsstoffe enthalten, wie sie üblicherweise in solchen Zubereitungen verwendet werden, z.B. Konservierungsmittel, Bakterizide, Parfüme, Substanzen zum Verhindern des Schäumens, Farbstoffe, Pigmente, die eine färbende Wirkung haben, Verdickungsmittel, oberflächenaktive Substanzen, Emulgatoren, weichmachende, anfeuchtende und/oder feuchhaltende Substanzen, Fette, öle, Wachse oder andere übliche Bestandteile einer kosmetischen oder dermatologischen Formulierung wie Al¬ kohole, Polyole, Polymere, Schaumstabilisatoren, Elektrolyte, organische Löse¬ mittel oder Silikonderivate.The cosmetic and dermatological preparations according to the invention can contain cosmetic auxiliaries as are usually used in such preparations, e.g. Preservatives, bactericides, perfumes, anti-foaming substances, dyes, pigments that have a coloring effect, thickeners, surface-active substances, emulsifiers, softening, moisturizing and / or moisturizing substances, fats, oils, waxes or other common components of a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
Insbesondere können die erfindungsgemäßen Zubereitungen auch Antioxidantien enthalten.In particular, the preparations according to the invention can also contain antioxidants.
Erfindungsgemäß können als günstige Antioxidantien alle für kosmetische und/oder dermatologische Anwendungen geeigneten oder gebräuchlichen Antioxidantien verwendet werden. Vorteilhaft werden die Antioxidantien gewählt aus der Gruppe bestehend ausAccording to the invention, all the antioxidants suitable or customary for cosmetic and / or dermatological applications can be used as favorable antioxidants. The antioxidants are advantageously selected from the group consisting of
Aminosäuren (z.B. Glycin, Histidin, Tyrosin, Tryptophan) und deren Derivate,Amino acids (e.g. glycine, histidine, tyrosine, tryptophan) and their derivatives,
Imidazole (z.B. Urocaninsäure) und deren Derivate, Peptide wie D,L-Camosin,Imidazoles (e.g. urocanic acid) and their derivatives, peptides such as D, L-camosine,
D-Carnosin, L-Carnosin und deren Derivate (z.B. Anserin), Carotinoide, Caro- tine (z.B. α-Carotin, ß-Carotin, Lycopin) und deren Derivate, Chlorogensäure und deren Derivate, Liponsäure und deren Derivate (z.B. Dihydroliponsäure),D-carnosine, L-carnosine and their derivatives (e.g. anserine), carotenoids, carotenes (e.g. α-carotene, ß-carotene, lycopene) and their derivatives, chlorogenic acid and its derivatives, lipoic acid and its derivatives (e.g. dihydroliponic acid),
Aurothioglucose, Propylthiouracil und andere Thiole (z.B. Thioredoxin, Gluta- thion, Cystein, Cystin, Cystamin und deren Glycosyl-, N-Acetyl-, Methyl-, Ethyl-Aurothioglucose, propylthiouracil and other thiols (e.g. thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl
, Propyl-, Amyl-, Butyl- und Lauryl-, Palmitoyl-, Oleyl-, γ-Linoleyl-, Cholesteryl- und Glycerylester) sowie deren Salze, Dilaurylthiodipropionat, Distearylthio- dipropionat, Thiodipropionsäure und deren Derivate (Ester, Ether, Peptide,, Propyl, amyl, butyl and lauryl, palmitoyl, oleyl, γ-linoleyl, cholesteryl and glyceryl esters) and their salts, dilauryl thiodipropionate, distearylthio dipropionate, thiodipropionic acid and their derivatives (esters, ethers, peptides,
Lipide, Nukleotide, Nukleoside und Salze) sowie Sulfoximinverbindungen (z.B.Lipids, nucleotides, nucleosides and salts) and sulfoximine compounds (e.g.
Buthioninsulfoximine, Homocysteinsulfoximin, Buthioninsulfone, Penta-, Hexa-,Buthioninsulfoximine, Homocysteinsulfoximin, Buthioninsulfone, Penta-, Hexa-,
Heptathioninsulfoximin) in sehr geringen verträglichen Dosierungen (z.B. pmol bis μmol/kg), ferner (Metall)-Chelatoren (z.B. α-Hydroxyfettsäuren, Palmitinsäu- re, Phytinsaure, Lactoferrin), α-Hydroxysäuren (z.B. Citronensäure, Milchsäure,Heptathioninsulfoximine) in very low tolerable doses (e.g. pmol to μmol / kg), also (metal) chelators (e.g. α-hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), α-hydroxy acids (e.g. citric acid, lactic acid,
Apfelsäure), Huminsäure, Gallensäure, Gallenextrakte, Bilirubin, Biliverdin,Malic acid), humic acid, bile acid, bile extracts, bilirubin, biliverdin,
EDTA, EGTA und deren Derivate, ungesättigte Fettsäuren und deren DerivateEDTA, EGTA and their derivatives, unsaturated fatty acids and their derivatives
(z.B. γ-Linolensäure, Linolsäure, ölsäure), Folsäure und deren Derivate, Ubi- chinon und Ubichinol und deren Derivate, Vitamin C und Derivate (z.B.(e.g. γ-linolenic acid, linoleic acid, oleic acid), folic acid and its derivatives, ubiquinone and ubiquinol and their derivatives, vitamin C and derivatives (e.g.
Ascorbylpalmitat, Mg-Ascorbylphosphat, Ascorbylacetat), Tocopherole undAscorbyl palmitate, Mg ascorbyl phosphate, ascorbyl acetate), tocopherols and
Derivate (z.B. Vitamin-E-acetat), Vitamin A und Derivate (Vitamin-A-palmitat) sowie Koniferylbenzoat des Benzoeharzes, Rutinsäure und deren Derivate,Derivatives (e.g. vitamin E acetate), vitamin A and derivatives (vitamin A palmitate) and coniferyl benzoate of benzoin, rutinic acid and their derivatives,
Butylhydroxytoluol, Butylhydroxyanisol, Nordihydroguajakharzsäure, Nordihy- droguajaretsäure, Trihydroxybutyrophenon, Harnsäure und deren Derivate,Butylated hydroxytoluene, butylated hydroxyanisole, nordihydroguajak resin acid, nordihydroguajaretic acid, trihydroxybutyrophenone, uric acid and their derivatives,
Mannose und deren Derivate, Sesamol, Sesamolin, Zink und dessen Derivate (z.B. ZnO, ZnSO- ) Selen und dessen Derivate (z.B. Selenmethionin), Stilbene und deren Derivate (z.B. Stilbenoxid, Trans-Stilbenoxid) und die erfindungsge¬ mäß geeigneten Derivate (Salze, Ester, Ether, Zucker, Nukleotide, Nukleoside, Peptide und Lipide) dieser genannten Wirkstoffe.Mannose and its derivatives, sesamol, sesamolin, zinc and its derivatives (e.g. ZnO, ZnSO-) selenium and its derivatives (e.g. selenomethionine), stilbenes and their derivatives (e.g. stilbene oxide, trans-stilbene oxide) and the derivatives (salts , Esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids) of these active ingredients.
Die Menge der vorgenannten Antioxidantien (eine oder mehrere Verbindun¬ gen), welche nicht mit den erfindungsgmäßen Wirkstoffkombinationen identisch sind, in den Zubereitungen beträgt vorzugsweise 0,001 bis 30 Gew.-%, besonders bevorzugt 0,05 - 20 Gew.-%, insbesondere 1 - 10 Gew.-%, bezogen auf das Gesamtgewicht der Zubereitung. Sofern Vitamin E und/oder dessen Derivate das oder die Antioxidantien darstellen, ist vorteilhaft, deren jeweilige Konzentrationen aus dem Bereich von 0,001 - 10 Gew.-%, bezogen auf das Gesamtgewicht der Formulierung, zu wählen.The amount of the aforementioned antioxidants (one or more compounds), which are not identical to the active ingredient combinations according to the invention, in the preparations is preferably 0.001 to 30% by weight, particularly preferably 0.05-20% by weight, in particular 1 - 10 wt .-%, based on the total weight of the preparation. If vitamin E and / or its derivatives represent the antioxidant (s), it is advantageous to choose their respective concentrations from the range of 0.001-10% by weight, based on the total weight of the formulation.
Sofern Vitamin A, bzw. Vitamin-A-Derivate, bzw. Carotine bzw. deren Derivate das oder die Antioxidantien darstellen, ist vorteilhaft, deren jeweilige Konzentrationen aus dem Bereich von 0,001 - 10 Gew.-%, bezogen auf das Gesamtgewicht der Formulierung, zu wählen.If vitamin A or vitamin A derivatives or carotenes or their derivatives represent the antioxidant or antioxidants, it is advantageous to use their respective concentrations in the range from 0.001-10% by weight, based on the total weight of the formulation, to choose.
Erfindungsgemäße Emulsionen sind vorteilhaft und enthalten z.B. die ge¬ nannten Fette, öle, Wachse und anderen Fettkörper, sowie Wasser und einen Emulgator, wie er üblicherweise für einen solchen Typ der Formulierung ver¬ wendet wird.Emulsions according to the invention are advantageous and contain e.g. the said fats, oils, waxes and other fat bodies, as well as water and an emulsifier, as is usually used for such a type of formulation.
Die Lipidphase kann dabei vorteilhaft gewählt werden aus folgender Substanz¬ gruppe:The lipid phase can advantageously be selected from the following group of substances:
natürliche, synthetische und/oder partialsynthetische öle, wie Triglyceride der Caprin- oder der Caprylsäure, vorzugsweise aber Rizinusöl;natural, synthetic and / or partially synthetic oils, such as triglycerides of capric or caprylic acid, but preferably castor oil;
Fette, Wachse und andere natürliche synthetische und/oder partialsynthetische Fettkörper, vorzugsweise Ester von Fettsäuren mit Alkoholen niedriger C-Zahl, z.B. mit Isopropanol, Propyienglykol oder Gly- cerin, oder Ester von Fettalkoholen mit Alkansäuren niedriger C-Zahl oder mit Fettsäuren;Fats, waxes and other natural synthetic and / or partially synthetic fat bodies, preferably esters of fatty acids with alcohols of low C number, e.g. with isopropanol, propylene glycol or glycerin, or esters of fatty alcohols with low C number alkanoic acids or with fatty acids;
Silikonöle wie Dimethylpolysiloxane, Diethylpoiysiloxane, Diphenylpolysiloxane sowie Mischformen daraus.Silicone oils such as dimethylpolysiloxanes, diethylpolysiloxanes, diphenylpolysiloxanes and mixed forms thereof
gesättigte Verbindungen wie Kohlenwasserstoffe natürlichen oder synthe¬ tischen Ursprungs (Vaseline, Squalan)saturated compounds such as hydrocarbons of natural or synthetic origin (petroleum jelly, squalane)
Die wäßrige Phase der erfindungsgemäßen Zubereitungen enthält gegebenenfalls vorteilhaft Alkohole, Diole oder Polyole niedriger C-Zahl, sowie deren Ether, vorzugsweise Ethanol, Isopropanol, Propylenglykol, Glycerin, Ethylenglykol, Ethylenglykolmonoethyl- oder -monobutylether, Pro- pylenglykolmonomethyl, -monoethyl- oder -monobutylether, Diethylengly- kolmonomethyl- oder -monoethylether und analoge Produkte, ferner Alkohole niedriger C-Zahl, z.B. Ethanol, Isopropanol, 1 ,2-Propandiol, Glycerin sowie ins¬ besondere ein oder mehrere Verdickungsmittel, welches oder welche vorteilhaft gewählt werden können aus der Gruppe Siliciumdioxid, Aluminium¬ silikate, Polysaccharide bzw. deren Derivate, z.B. Hyaluronsäure, Xanthangum- mi, Hydroxypropylmethylcellulose, besonders vorteilhaft aus der Gruppe der Polyacrylate, bevorzugt ein Polyacrylat aus der Gruppe der sogenannten Carbopole, beispielsweise Carbopole der Typen 980, 981 , 1382, 2984, 5984, oder auch der Typen ETD (Easy-to-disperse) 2001, 2020, 2050, jeweils einzeln oder in beliebigen Kombinationen untereinander.Kombination.The aqueous phase of the preparations according to the invention optionally advantageously contains alcohols, diols or polyols of low C number, and whose ethers, preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ether and similar products, furthermore alcohols of low C number, for example Ethanol, isopropanol, 1, 2-propanediol, glycerol and in particular one or more thickeners, which one or more can advantageously be selected from the group consisting of silicon dioxide, aluminum silicates, polysaccharides or their derivatives, for example hyaluronic acid, xanthan gum, hydroxypropylmethyl cellulose , particularly advantageously from the group of polyacrylates, preferably a polyacrylate from the group of so-called carbopoles, for example carbopoles of types 980, 981, 1382, 2984, 5984, or also of types ETD (easy-to-disperse) 2001, 2020, 2050 , individually or in any combination with each other.
Insbesondere werden Gemische der vorstehend genannten Lösemittel verwendet. Bei alkoholischen Lösemitteln kann Wasser ein weiterer Bestandteil sein.Mixtures of the abovementioned solvents are used in particular. Water can also be a component of alcoholic solvents.
Erfindungsgemäße Emulsionen sind vorteilhaft und enthalten z.B. die genannten Fette, öle, Wachse und anderen Fettkörper, sowie Wasser und einen Emuigator, wie er üblicherweise für einen solchen Typ der Formulierung verwendet wird.Emulsions according to the invention are advantageous and contain e.g. the fats, oils, waxes and other fat bodies mentioned, as well as water and an emuigator, as is usually used for such a type of formulation.
Gele gemäß der Erfindung enthalten üblicherweise Alkohole niedriger C-Zahl, z.B. Ethanol, Isopropanol, 1,2-Propandiol, Glycerin und Wasser bzw. ein vorstehend genanntes Öl in Gegenwart eines Verdickungsmittels, das bei ölig- alkoholischen Gelen vorzugsweise Siliciumdioxid oder ein Aluminiumsilikat, bei wäßrig-alkoholischen oder alkoholischen Gelen vorzugweise ein Polyacrylat ist.Gels according to the invention usually contain low C number alcohols, e.g. Ethanol, isopropanol, 1,2-propanediol, glycerol and water or an oil mentioned above in the presence of a thickening agent which is preferably silicon dioxide or an aluminum silicate in the case of oleo-alcoholic gels and preferably a polyacrylate in the case of aqueous-alcoholic or alcoholic gels.
Als Treibmittel für erfindungsgemäße, aus Aerosolbehältern versprühbare Zu¬ bereitungen sind die üblichen bekannten leichtflüchtigen, verflüssigten Treibmittel, beispielsweise Kohlenwasserstoffe (Propan, Butan, Isobutan) ge¬ eignet, die allein oder in Mischung miteinander eingesetzt werden können. Auch Druckluft ist vorteilhaft zu verwenden. Vorteilhaft können erfindungsgemäße Zubereitungen außerdem Substanzen enthalten, die UV-Strahlung im UVB-Bereich absorbieren, wobei die Gesamt¬ menge der Filtersubstanzen z.B. 0,1 Gew.-% bis 30 Gew.-%, vorzugsweise 0,5 bis 10 Gew.-%, insbesondere 1,0 bis 6,0 Gew.-% beträgt, bezogen auf das Gesamtgewicht der Zubereitungen, um kosmetische Zubereitungen zur Verfügung zu stellen, die das Haar bzw. die Haut vor dem gesamten Bereich der ultravioletten Strahlung schützen. Sie können auch als Sonnenschutzmittel fürs Haar oder die Haut dienen.Suitable propellants for preparations according to the invention which can be sprayed from aerosol containers are the customary, known volatile, liquefied propellants, for example hydrocarbons (propane, butane, isobutane), which can be used alone or in a mixture with one another. Compressed air can also be used advantageously. Preparations according to the invention can also advantageously contain substances which absorb UV radiation in the UVB range, the total amount of the filter substances being, for example, 0.1% by weight to 30% by weight, preferably 0.5 to 10% by weight. , in particular 1.0 to 6.0% by weight, based on the total weight of the preparations, in order to provide cosmetic preparations which protect the hair or the skin from the entire range of ultraviolet radiation. They can also serve as a sunscreen for the hair or skin.
Enthalten die erfindungsgemäßen Emulsionen UVB-Filtersubstanzen, können diese öllöslich oder wasserlöslich sein. Erfindungsgemäß vorteilhafte öllösliche UVB-Filter sind z.B.:If the emulsions according to the invention contain UVB filter substances, they can be oil-soluble or water-soluble. Oil-soluble UVB filters which are advantageous according to the invention are, for example:
3-Benzyiidencampher-Derivate, vorzugsweise 3-(4-Methylben- zyliden)campher, 3-Benzylidencampher;3-benzylidene camphor derivatives, preferably 3- (4-methylbenzylidene) camphor, 3-benzylidene camphor;
4-Aminobenzoesäure-Derivate, vorzugsweise 4-(Dimethylamino)-benzoe- säure(2-ethylhexyl)ester, 4-(Dimethylamino)benzoesäureamylester;4-aminobenzoic acid derivatives, preferably 4- (dimethylamino) benzoic acid (2-ethylhexyl) ester, 4- (dimethylamino) benzoic acid amyl ester;
Ester der Zimtsäure, vorzugsweise 4-Methoxyzimtsäure(2- ethylhexyl)ester, 4-Methoxyzimtsäureisopentyiester;Esters of cinnamic acid, preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-methoxycinnamic acid isopentiester;
Ester der Salicylsäure, vorzugsweise Salicylsäure(2-ethylhexyl)ester, Salicylsäure(4-isopropylbenzyl)ester, Salicylsäurehomomenthylester,Esters of salicylic acid, preferably salicylic acid (2-ethylhexyl) ester, salicylic acid (4-isopropylbenzyl) ester, salicylic acid homomethyl ester,
Derivate des Benzophenons, vorzugsweise 2-Hydroxy-4-methoxybenzo- phenon, 2-Hydroxy-4-methoxy-4'-methylbenzophenon, 2,2'-Dihydroxy-4- methoxybenzophenon;Derivatives of benzophenone, preferably 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone;
Ester der Benzalmalonsäure, vorzugsweise 4-Methoxybenzal- malonsäuredi(2-ethylhexyl)ester, - 2,4,6-Trianilino-(p-carbo-2'-ethyl-1 '- hexyloxy) -1 ,3,5-triazin.Esters of benzalmalonic acid, preferably 4-methoxybenzalmalonic acid di (2-ethylhexyl) ester, 2,4,6-trianilino- (p-carbo-2'-ethyl-1 '- hexyloxy) -1, 3,5-triazine.
Vorteilhafte wasserlösliche UVB-Filter sind z.B.: Salze der 2-Phenylbenzimidazol-5-sulfonsäure wie ihr Natrium-, Kalium¬ oder ihr Triethanoiammonium-Salz, sowie die Sulfonsäure selbst;Examples of advantageous water-soluble UVB filters are: Salts of 2-phenylbenzimidazole-5-sulfonic acid such as its sodium, potassium or triethanoiammonium salt, and the sulfonic acid itself;
Sulfonsäure-Derivate von Benzophenonen, vorzugsweise 2-Hydroxy-4- methoxybenzophenon-5-sulfonsäure und ihre Salze;Sulfonic acid derivatives of benzophenones, preferably 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid and its salts;
Sulfonsäure-Derivate des 3-Benzylidencamphers, wie z.B. 4-(2-Oxo-3- bornylidenmethyl)benzolsulfonsäure, 2-Methyl-5-(2-oxo-3-bornylidenme- thyl)sulfonsäure und ihre Salze.Sulfonic acid derivatives of 3-benzylidene camphor, e.g. 4- (2-oxo-3-bornylidene methyl) benzenesulfonic acid, 2-methyl-5- (2-oxo-3-bornylidene methyl) sulfonic acid and their salts.
Die Liste der genannten UVB-Filter, die in Kombination mit den erfindungsgemäßen Wirkstoffkombinationen verwendet werden können, soll selbstverständlich nicht limitierend sein.The list of UVB filters mentioned, which can be used in combination with the active compound combinations according to the invention, is of course not intended to be limiting.
Gegenstand der Erfindung ist auch die Verwendung einer Kombination der er¬ findungsgemäßen Wirkstoffe mit mindestens einem UVB-Filter als Antioxidans bzw. die Verwendung einer Kombination der erfindungsgemäßen Wirkstoffe mit mindestens einem UVB-Filter als Antioxidans in einer kosmetischen oder dermatologischen Zubereitung.The invention also relates to the use of a combination of the active compounds according to the invention with at least one UVB filter as an antioxidant or the use of a combination of the active compounds according to the invention with at least one UVB filter as an antioxidant in a cosmetic or dermatological preparation.
Es kann auch von Vorteil sein, erfindungsgemäße Wirkstoffe mit UVA-Filtern zu kombinieren, die bisher üblicherweise in kosmetischen Zubereitungen ent¬ halten sind. Bei diesen Substanzen handelt es sich vorzugsweise um Derivate des Dibenzoylmethans, insbesondere um 1-(4'-tert.Butylphenyl)-3-(4'- methoxyphenyl)propan-1 ,3-dion und um 1 -Phenyl-3-(4'- isopropylphenyl)propan-1,3-dion. Auch diese Kombinationen bzw. Zubereitungen, die diese Kombinationen enthalten, sind Gegenstand der Erfindung. Es können die für die UVB-Kombination verwendeten Mengen ein¬ gesetzt werden.It can also be advantageous to combine active ingredients according to the invention with UVA filters which have hitherto usually been contained in cosmetic preparations. These substances are preferably derivatives of dibenzoylmethane, in particular 1- (4'-tert-butylphenyl) -3- (4'-methoxyphenyl) propane-1, 3-dione and 1-phenyl-3- (4 '- isopropylphenyl) propane-1,3-dione. These combinations or preparations containing these combinations are also the subject of the invention. The amounts used for the UVB combination can be used.
Gegenstand der Erfindung ist auch die Verwendung einer Kombination der er¬ findungsgemäßen Wirkstoffe mit mindestens einem UVA-Filter als Antioxidans bzw. die Verwendung einer Kombination der erfindungsgemäßen Wirkstoffe mit mindestens einem UVA-Filter als Antioxidans in einer kosmetischen oder der¬ matologischen Zubereitung. Gegenstand der Erfindung ist auch die Verwendung einer Kombination der er¬ findungsgemäßen Wirkstoffe mit mindestens einem UVA-Filter und mindestens einem UVB-Filter als Antioxidans bzw. die Verwendung einer Kombination der erfindungsgemäßen Wirkstoffe mit mindestens einem UVA-Filter und minde¬ stens einem UVB-Filter als Antioxidans in einer kosmetischen oder derma¬ tologischen Zubereitung.The invention also relates to the use of a combination of the active compounds according to the invention with at least one UVA filter as an antioxidant or the use of a combination of the active compounds according to the invention with at least one UVA filter as an antioxidant in a cosmetic or dermatological preparation. The invention also relates to the use of a combination of the active compounds according to the invention with at least one UVA filter and at least one UVB filter as an antioxidant or the use of a combination of the active compounds according to the invention with at least one UVA filter and at least one UVB filter. Filters as an antioxidant in a cosmetic or dermatological preparation.
Kosmetische und dermatologische Zubereitungen mit einem wirksamen Gehalt an erfindungsgemäßen Wirkstoffen können auch anorganische Pigmente ent¬ halten, die üblicherweise in der Kosmetik zum Schütze der Haut vor UV- Strahlen verwendet werden. Dabei handelt es sich um Oxide des Titans, Zinks, Eisens, Zirkoniums, Siliciums, Mangans, Aluminiums, Cers und Mischungen davon, sowie Abwandlungen, bei denen die Oxide die aktiven Agentien sind. Besonders bevorzugt handelt es sich um Pigmente auf der Basis von Titandioxid.Cosmetic and dermatological preparations with an effective content of active substances according to the invention can also contain inorganic pigments which are usually used in cosmetics to protect the skin from UV rays. These are oxides of titanium, zinc, iron, zirconium, silicon, manganese, aluminum, cerium and mixtures thereof, as well as modifications in which the oxides are the active agents. It is particularly preferred to use pigments based on titanium dioxide.
Auch diese Kombinationen von UVA-Filter und Pigment bzw. Zubereitungen, die diese Kombination enthalten, sind Gegenstand der Erfindung. Es können die für die vorstehenden Kombinationen genannten Mengen verwendet werden.These combinations of UVA filter and pigment or preparations containing this combination are also the subject of the invention. The amounts given for the above combinations can be used.
Bei kosmetischen und dermatologischen Zubereitungen zum Schütze der Haare vor UV-Strahlen gemäß der Erfindung handelt es sich beispielsweise um Shampoonierungsmittel, Zubereitungen, die beim Spülen der Haare vor oder nach der Shampoonierung, vor oder nach der Dauerwellbehandlung, vor oder nach der Färbung oder Entfärbung der Haare angewendet werden, um Zubereitungen zum Fönen oder Einlegen der Haare, Zubereitungen zum Färben oder Entfärben, um eine Frisier- und Behandlungslotion, einen Haarlack oder um Dauerwellmittel.Cosmetic and dermatological preparations for protecting the hair from UV rays according to the invention are, for example, shampooing agents, preparations which are used when rinsing the hair before or after the shampooing, before or after the permanent wave treatment, before or after the coloring or discoloration of the Hair is applied to preparations for blow-drying or pickling hair, preparations for coloring or decolouring, to a styling and treatment lotion, a hair lacquer or to permanent waving agents.
Die kosmetischen und dermatologischen Zubereitungen enthalten Wirkstoffe und Hilfsstoffe, wie sie üblicherweise für diesen Typ von Zubereitungen zur Haarpflege und Haarbehandlung verwendet werden. Als Hilfsstoffe dienen Konservierungsmittel, oberflächenaktive Substanzen, Substanzen zum Verhindern des Schäumens, Verdickungsmittel, Emulgatoren, Fette, Öle, Wachse, organische Lösungsmittel, Bakterizide, Parfüme, Farbstoffe oder Pig- mente, deren Aufgabe es ist, die Haare oder die kosmetische oder dermato¬ logische Zubereitung selbst zu färben, Elektroyte, Substanzen gegen das Fetten der Haare.The cosmetic and dermatological preparations contain active substances and auxiliaries as are usually used for this type of preparations for hair care and hair treatment. Preservatives, surface-active substances, substances to prevent foaming, thickeners, emulsifiers, fats, oils, waxes, organic solvents, bactericides, perfumes, dyes or pigments serve as auxiliary substances. elements whose task it is to dye the hair or the cosmetic or dermatological preparation itself, electrophoresis, substances for greasing the hair.
Unter Elektrolyten im Sinne der vorliegenden Erfindung sind wasserlösliche Al¬ kali-, Ammonium-, Erdalkali- (unter Einbeziehung des Magnesiums) und Zinksalze anorganischer Anionen und beliebige Gemische aus solchen Salzen zu verstehen, wobei gewährleistet sein muß, daß sich diese Salze durch pharmazeutische oder kosmetische Unbedenklichkeit auszeichnen.For the purposes of the present invention, electrolytes are understood to mean water-soluble alkali metal, ammonium, alkaline earth metal (including magnesium) and zinc salts of inorganic anions and any mixtures of such salts, it being necessary to ensure that these salts are pharmaceutical or distinguish cosmetic harmlessness.
Die erfindungsgemäßen Anionen werden bevorzugt gewählt aus der Gruppe der Chloride, der Sulfate und Hydrogensulfate, der Phosphate, Hydrogenphosphate und der linearen und cyclischen Oligophosphate sowie der Carbonate und Hydrogencarbonate.The anions according to the invention are preferably selected from the group of chlorides, sulfates and hydrogen sulfates, phosphates, hydrogen phosphates and linear and cyclic oligophosphates as well as carbonates and hydrogen carbonates.
Kosmetische Zubereitungen, die ein Hautreinigungsmittel oder Shampoonie¬ rungsmittel darstellen, enthalten vorzugsweise mindestens eine anionische, nicht-ionische oder amphotere oberflächenaktive Substanz, oder auch Gemische aus solchen Substanzen, erfindungsgemäße Wirkstoffe im wäßrigen Medium und Hilfsmittel, wie sie üblicherweise dafür verwendet werden. Die oberflächenaktive Substanz bzw. die Gemische aus diesen Substanzen können in einer Konzentration zwischen 1 Gew.-% und 50 Gew.-% in dem Shampoonierungsmittel vorliegen.Cosmetic preparations which are a skin cleansing agent or shampoo contain preferably at least one anionic, non-ionic or amphoteric surface-active substance, or else mixtures of such substances, active substances according to the invention in an aqueous medium and auxiliaries as are usually used therefor. The surface-active substance or the mixtures of these substances can be present in the shampoo in a concentration of between 1% and 50% by weight.
Liegen die kosmetischen oder dermatologischen Zubereitungen in Form einer Lotion vor, die ausgespült und z.B. vor oder nach der Entfärbung, vor oder nach der Shampoonierung, zwischen zwei Shampoonierungsschritten, vor oder nach der Dauerwellbehandlung angewendet wird, so handelt es sich dabei z.B. um wäßrige oder wäßrig-alkoholische Lösungen, die gegebenenfalls ober¬ flächenaktive Substanzen enthalten, deren Konzentration zwischen 0,1 und 10 Gew.-%, vorzugsweise zwischen 0,2 und 5 Gew.-%, liegen kann.Are the cosmetic or dermatological preparations in the form of a lotion that is rinsed out and e.g. before or after decolorization, before or after shampooing, between two shampooing steps, before or after permanent waving, these are e.g. around aqueous or aqueous-alcoholic solutions, which may contain surface-active substances, the concentration of which may be between 0.1 and 10% by weight, preferably between 0.2 and 5% by weight.
Diese kosmetischen oder dermatologischen Zubereitungen können auch Aerosole mit den üblicherweise dafür verwendeten Hilfsmitteln darstellen. Eine kosmetische Zubereitung in Form einer Lotion, die nicht ausgespült wird, insbesondere eine Lotion zum Einlegen der Haare, eine Lotion, die beim Fönen der Haare verwendet wird, eine Frisier- und Behandlungslotion, stellt im allgemeinen eine wäßrige, alkoholische oder wäßrig-alkoholische Lösung dar und enthält mindestens ein kationisches, anionisches, nicht-ionisches oder amphoteres Polymer oder auch Gemische derselben, sowie erfindungsgemäße Wirkstoffkombinatonen in wirksamer Konzentration. Die Menge der verwen¬ deten Polymeren liegt z.B. zwischen 0,1 und 10 Gew.-%, bevorzugt zwischen 0,1 und 3 Gew.-%.These cosmetic or dermatological preparations can also be aerosols with the auxiliaries usually used for them. A cosmetic preparation in the form of a lotion that is not rinsed out, in particular a lotion for inlaying the hair, a lotion used for blow-drying the hair, a styling and treatment lotion, generally provides an aqueous, alcoholic or aqueous-alcoholic solution represents and contains at least one cationic, anionic, non-ionic or amphoteric polymer or mixtures thereof, as well as active ingredient combinations according to the invention in effective concentration. The amount of the polymers used is, for example, between 0.1 and 10% by weight, preferably between 0.1 and 3% by weight.
Kosmetische Zubereitungen zur Behandlung und Pflege der Haare, die erfindungsgemäße Wirkstoffe enthalten, können als Emulsionen vorliegen, die vom nicht-ionischen oder anionischen Typ sind. Nicht-ionische Emulsionen enthalten neben Wasser öle oder Fettalkohole, die beispielsweise auch polyethoxyliert oder polypropoxyliert sein können, oder auch Gemische aus den beiden organischen Komponenten. Diese Emulsionen enthalten gegebenenfalls kationische oberflächenaktive Substanzen.Cosmetic preparations for the treatment and care of the hair, which contain active ingredients according to the invention, can be present as emulsions which are of the non-ionic or anionic type. In addition to water, non-ionic emulsions contain oils or fatty alcohols, which can also be polyethoxylated or polypropoxylated, for example, or also mixtures of the two organic components. These emulsions may contain cationic surface-active substances.
Erfindungsgemäß können kosmetische Zubereitungen zur Behandlung und Pflege der Haare als Gele vorliegen, die neben einem wirksamen Gehalt an er¬ findungsgemäßen Wirkstoffkombinationen und dafür üblicherweise verwendeten Lösungsmitteln, bevorzugt Wasser, noch organische Verdickungsmittel, z.B. Gummiarabikum, Xanthangummi, Natriumalginat, Cellu- lose-Derivate, vorzugsweise Methylcellulose, Hydroxymethylcellulose, Hydro- xyethylcellulose, Hydroxypropylcellulose, Hydroxypropylmethylcellulose oder anorganische Verdickungsmittel, z.B. Aluminiumsilikate wie beispielsweise Bentonite, oder ein Gemisch aus Polyethylenglykol und Polyethylenglycol- stearat oder -distearat, enthalten. Das Verdickungsmittel ist in dem Gel z.B. in einer Menge zwischen 0,1 und 30 Gew.-%, bevorzugt zwischen 0,5 und 15 Gew.-%, enthalten.According to the invention, cosmetic preparations for the treatment and care of the hair can be in the form of gels which, in addition to an effective content of active compound combinations according to the invention and solvents conventionally used for this, preferably water, or organic thickeners, e.g. Gum arabic, xanthan gum, sodium alginate, cellulose derivatives, preferably methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose or inorganic thickeners, e.g. Aluminum silicates such as bentonites, or a mixture of polyethylene glycol and polyethylene glycol stearate or distearate, contain. The thickener is in the gel e.g. in an amount between 0.1 and 30% by weight, preferably between 0.5 and 15% by weight.
Vorzugsweise beträgt die Menge der erfindungsgemäßen Wirkstoffe in einem für die Haare bestimmten Mittel 0,05 Gew.-% bis 10 Gew.-%, insbesondere 0,5 Gew.-% bis 5 Gew.-%, bezogen auf das Gesamtgewicht des Mittels. Erfindungsgemäße wäßrige kosmetische Reinigungsmittel oder für die wäßrige Reinigung bestimmte wasserarme oder wasserfreie Reinigungsmittelkonzentra¬ te können anionische, nichtionische und/oder amphotere Tenside enthalten, beispielsweiseThe amount of the active compounds according to the invention in an agent intended for the hair is preferably 0.05% by weight to 10% by weight, in particular 0.5% by weight to 5% by weight, based on the total weight of the agent. Aqueous cosmetic detergents according to the invention or low-water or water-free detergent concentrations intended for aqueous cleaning can contain anionic, nonionic and / or amphoteric surfactants, for example
herkömmliche Seifen, z.B. Fettsäuresalze des Natriumsconventional soaps, e.g. Fatty acid salts of sodium
Alkylsulfate, Alkylethersulfate, Alkan- und AlkylbenzolsulfonateAlkyl sulfates, alkyl ether sulfates, alkane and alkyl benzene sulfonates
SulfoacetateSulfoacetates
SulfobetaineSulfobetaines
SarcosinateSarcosinate
AmidosulfobetaineAmidosulfobetaines
SulfosuccinateSulfosuccinates
SulfobernsteinsäurehalbesterSulfosuccinic acid semiesters
AlkylethercarboxylateAlkyl ether carboxylates
Eiweiß-Fettsäure-KondensateProtein fatty acid condensates
Alkylbetaine und AmidobetaineAlkyl betaines and amido betaines
FettsäurealkanolamideFatty acid alkanolamides
Polyglycolether-DerivatePolyglycol ether derivatives
Kosmetische Zubereitungen, die kosmetische Reinigungszubereitungen für die Haut darstellen, können in flüssiger oder fester Form vorliegen. Sie enthalten neben erfindungsgemäßen Wirkstoffen vorzugsweise mindestens eine anioni¬ sche, nicht-ionische oder amphotere oberflächenaktive Substanz oder Gemische daraus, gewünschtenfalls einen oder mehrere Elektrolyten und Hilfsmittel, wie sie üblicherweise dafür verwendet werden. Die oberflächen¬ aktive Substanz kann in einer Konzentration zwischen 1 und 94 Gew.-% in den Reinigungszubereitungen vorliegen, bezogen auf das Gesamtgewicht der Zubereitungen.Cosmetic preparations, which are cosmetic cleaning preparations for the skin, can be in liquid or solid form. In addition to the active compounds according to the invention, they preferably contain at least one anionic, nonionic or amphoteric surface-active substance or mixtures thereof, if desired one or more electrolytes and auxiliaries of the kind normally used for this purpose. The surface-active substance can be present in the cleaning preparations in a concentration of between 1 and 94% by weight, based on the total weight of the preparations.
Kosmetische Zubereitungen, die ein Shampoonierungsmittel darstellen, enthal¬ ten neben einem wirksamen Gehalt an erfindungsgemäßen Wirkstoffen vorzugsweise mindestens eine anionische, nicht-ionische oder amphotere oberflächenaktive Substanz oder Gemische daraus, gegebenenfalls einen erfindungsgemäßes Elektrolyten und Hilfsmittel, wie sie üblicherweise dafür verwendet werden. Die oberflächenaktive Substanz kann in einer Konzentration zwischen 1 Gew.-% und 94 Gew.-% in dem Shampoonierungsmittel vorliegen.Cosmetic formulations which are shampoos s t hal¬ th preferably adjacent an effective content of novel active compounds thereof, an inventive electrolytes and auxiliaries as are customarily used for this purpose at least one anionic, nonionic or amphoteric surfactant or mixtures thereof, if necessary. The surface-active substance can be in a Concentration between 1 wt .-% and 94 wt .-% are present in the shampoo.
Die erfindungsgemäßen Zusammensetzungen enthalten außer den vorgenannten Tensiden Wasser und gegebenenfalls die in der Kosmetik üblichen Zusatzstoffe, beispielsweise Parfüm, Verdicker, Farbstoffe, Desodorantien, antimikrobielle Stoffe, rückfettende Agentien, Komplexierungs- und Sequestrierungsagentien, Perlglanzagentien, Pflanzenextrakte, Vitamine, Wirkstoffe und dergleichen.In addition to the aforementioned surfactants, the compositions according to the invention contain water and, if appropriate, the additives customary in cosmetics, for example perfume, thickeners, dyes, deodorants, antimicrobial substances, lipid-replenishing agents, complexing and sequestering agents, pearlescent agents, plant extracts, vitamins, active ingredients and the like.
Die vorliegende Erfindung umfaßt auch ein kosmetisches Verfahren zum Schütze der Haut und der Haare vor oxidativen bzw. photooxidativen Prozessen, das dadurch gekennzeichnet ist, daß man ein kosmetisches Mittel, welches eine wirksame Konzentration an erfindungsgemäßen Wirkstoffen enthält, in ausreichender Menge auf die Haut oder Haare aufbringt.The present invention also encompasses a cosmetic method for protecting the skin and hair from oxidative or photooxidative processes, which is characterized in that a cosmetic agent which contains an effective concentration of active compounds according to the invention is applied to the skin or hair in a sufficient amount applies.
Ebenso umfaßt die vorliegende Erfindung auch ein Verfahren zum Schütze kosmetischer oder dermatologischer Zubereitungen gegen Oxidation oder Pho- tooxidation, wobei diese Zubereitungen z.B. Zubereitungen zur Behandlung und Pflege der Haare darstellen, insbesondere Haarfärbemittel, Haarlacke, Shampoonierungsmittel, Farbshampoonierungsmittel, ferner Schminkprodukte wie z.B. Nagellacke, Lippenstifte, Teintgrundlagen, Wasch- und Duschzuberei¬ tungen, Cremes zur Behandlung oder Pflege der Haut oder um sämtliche anderen kosmetischen Zubereitungen handelt, deren Bestandteile Stabilitätsprobleme aufgrund von Oxidation bzw. Photooxidation bei der Lage¬ rung mit sich bringen können, dadurch gekennzeichnet, daß die kosmetischen Zubereitungen einen wirksamen Gehalt an erfindungsgemäßen Wirkstoffen aufweisen.The present invention also includes a method for protecting cosmetic or dermatological preparations against oxidation or photo-oxidation, these preparations being e.g. Represent preparations for the treatment and care of the hair, in particular hair colorants, hair lacquers, shampooing agents, color shampooing agents, and also make-up products such as e.g. Nail polishes, lipsticks, complexion bases, washing and shower preparations, creams for the treatment or care of the skin or all other cosmetic preparations, the components of which can cause stability problems due to oxidation or photooxidation during storage, characterized in that that the cosmetic preparations have an effective content of active ingredients according to the invention.
Vorzugsweise beträgt die Menge an erfindungsgemäßen Wirkstoffen in diesen Zubereitungen 0,001 Gew.-% bis 10 Gew.-%, insbesondere 0,01 Gew.-% bis 6 Gew.-%, bezogen auf das Gesamtgewicht der Zubereitungen.The amount of active compounds according to the invention in these preparations is preferably 0.001% by weight to 10% by weight, in particular 0.01% by weight to 6% by weight, based on the total weight of the preparations.
Gegenstand der Erfindung ist auch das Verfahren zur Herstellung der erfindungsgemäßen Zubereitungen, das dadurch gekennzeichnet ist, daß man in an sich bekannter Weise erfindungsgemäße Wirkstoffe in kosmetische und dermato logische Formulierungen einarbeitet.The invention also relates to the process for the preparation of the preparations according to the invention, which is characterized in that Active ingredients according to the invention are incorporated into cosmetic and dermatological logical formulations in a manner known per se.
Alle Mengenangaben, Anteile und Prozentanteile sind, soweit nicht anders angegeben, auf das Gewicht und die Gesamtmenge bzw. auf das Gesamt¬ gewicht der Zubereitungen bezogen.Unless otherwise stated, all quantities, proportions and percentages are based on the weight and the total amount or on the total weight of the preparations.
Die nachfolgenden Beispiele sollen die vorliegende Erfindung verdeutlichen, ohne sie einzuschränken.The following examples are intended to illustrate the present invention without restricting it.
Beispiel 1example 1
W/O CremeW / O cream
Gew.-%% By weight
Paraffinöl 10 ,00Paraffin oil 10.00
Petrolatum 4 ,00Petrolatum 4, 00
Wollwachsalkohol 1 ,00Wool wax alcohol 1.00
PEG-7 Hydriertes Rizinusöl 3,00PEG-7 hydrogenated castor oil 3.00
Aluminumstearat 0,40Aluminum stearate 0.40
Rutin 0,50Rutin 0.50
Ferulasäure 0,50Ferulic acid 0.50
Glycerin 2,00Glycerin 2.00
Wasser, Konservierungsmittel und Parfüm ad 100,00Water, preservatives and perfume ad 100.00
Beispiel 2Example 2
W/O LotionW / O lotion
Gew.-%% By weight
Paraffinöl 20,00Paraffin oil 20.00
Petrolatum 4,00Petrolatum 4.00
Glucosesesqiisostearat 2,00Glucose Seqiisostearate 2.00
Aluminumstearat 0,40Aluminum stearate 0.40
Naringin 1 ,00Naringin 1, 00
Ferulasäure 0,25 Vitamin E Acetat 2,00Ferulic acid 0.25 Vitamin E acetate 2.00
Vitamin C Palmitat 0,20Vitamin C palmitate 0.20
Glycerin 5,00Glycerin 5.00
Wasser, Konservierungsmittel und Parfüm ad 100,00 Water, preservatives and perfume ad 100.00
Beispiel 3Example 3
O/W LotionO / W lotion
Gew.-%% By weight
Paraffinöl 8,00Paraffin oil 8.00
Isopropylpalmitat 3,00Isopropyl palmitate 3.00
Petrolatum 4,00,Petrolatum 4.00,
Cetearylalkohol 2,00Cetearyl alcohol 2.00
PEG-40 Rizinusöl 0,50PEG-40 castor oil 0.50
Natriumcetearylsulfat 0,50Sodium cetearyl sulfate 0.50
Natrium Carbomer 0,40Sodium carbomer 0.40
Hesperidin 0,50Hesperidin 0.50
Naringin 0,20Naringin 0.20
Ferulasäure 0,25Ferulic acid 0.25
Glycerin 3,00 α-Tocopherol 0,20Glycerin 3.00 α-tocopherol 0.20
Octylmethoxycinnamat 5,00Octyl methoxycinnamate 5.00
Butylmethoxydibenzoylmethan 1 ,00Butyl methoxydibenzoyl methane 1.00
Wasser, Konservierungsmittel und Parfüm ad 100,00Water, preservatives and perfume ad 100.00
Beispiel 4Example 4
O/W CremeO / W cream
Gew.-%% By weight
Paraffinöl 7,00Paraffin oil 7.00
Avocadoöl 4,00Avocado oil 4.00
Glycerylmonostearat 2,00Glyceryl monostearate 2.00
Natriumstearat 1 ,00Sodium stearate 1, 00
Kaffeesäure 0,50 α-Glucosylrutin 0,20Caffeic acid 0.50 α-glucosylrutin 0.20
Natriumphytat 1 ,00Sodium phytate 1, 00
Titandioxid 1 ,00 Natriumlactat 3,00Titanium dioxide 1.00 Sodium lactate 3.00
Glycerin 3,00Glycerin 3.00
Wasser, Konservierungsmittel und Parfüm ad 100,00Water, preservatives and perfume ad 100.00
Beispiel 5Example 5
LippenpflegestiftLip balm
Gew.-%% By weight
Hydriertes Rizinusöl 4,00Hydrogenated castor oil 4.00
Ceresin 8,00Ceresin 8.00
Bienenwachs 4,00Beeswax 4.00
Carnaubawachs 2,00Carnauba wax 2.00
Petrolatum 40,00 α-Glucosylhesperidin 1,00 ß-Carotin 0,10Petrolatum 40.00 α-glucosyl hesperidin 1.00 β-carotene 0.10
Kaffeesäure 0,30Caffeic acid 0.30
Paraffinöl, Pigmente und Farbstoffe ad 100,00Paraffin oil, pigments and dyes ad 100.00
Beispiel 6Example 6
Liposomenhaltiges GelGel containing liposomes
Gew.-%% By weight
Lecithin 6,00Lecithin 6.00
Schibutter 3,00Ski butter 3.00
Ferulasäure 0,50Ferulic acid 0.50
Chrysin 0,10Chrysin 0.10
Vitamin A Palmitat 0,20Vitamin A palmitate 0.20
Biotin 0,08Biotin 0.08
Natriumeitrat 0,50Sodium citrate 0.50
Glycin 0,20Glycine 0.20
Harnstoff 0,20Urea 0.20
Natrium PCA 0,50 Hydrolysiertes Kollagen 2,00Sodium PCA 0.50 Hydrolyzed collagen 2.00
Xanthan Gummi 1 ,40Xanthan gum 1, 40
Sorbitol 3,00Sorbitol 3.00
Wasser, Konservierungsmittel und Parfüm ad 100,00Water, preservatives and perfume ad 100.00
Beispiel 7Example 7
HaarkurHair treatment
Gew.-%% By weight
Paraffinöl 3,00Paraffin oil 3.00
Mandelöl 3,00Almond oil 3.00
Cetostearylalcohol 5,00Cetostearyl alcohol 5.00
PEG - 40 Rizinusöl 1 ,00PEG - 40 castor oil 1, 00
Natriumcetearylsulfate 0,50Sodium cetearyl sulfate 0.50
Sorbitol 5,00Sorbitol 5.00
Glycerin 5,00Glycerin 5.00
Ferulasäure 0,50Ferulic acid 0.50
Citricidal 0,80Citricidal 0.80
Dilaurylthiodipropionat 0,05Dilauryl thiodipropionate 0.05
L- Arginin 0,10L-arginine 0.10
Wasser, Konservierungsmittel und Parfüm ad 100,00Water, preservatives and perfume ad 100.00
Beispiel 8Example 8
MassagecremeMassage cream
Gew.-%% By weight
Stearylalkohol 2,00Stearyl alcohol 2.00
Petrolatum 4,00Petrolatum 4.00
Dimethicon 2,00Dimethicone 2.00
Isopropylpalmitat 6,00Isopropyl palmitate 6.00
Cetearylalkohol 4,00 PEG- 40 Hydriertes Rizinusöl 2,00Cetearyl alcohol 4.00 PEG-40 hydrogenated castor oil 2.00
Ferulasäure 0,50 α-Glucosylrutin 0,30Ferulic acid 0.50 α-glucosylrutin 0.30
Glycerin 3,00Glycerin 3.00
Wasser, Konservierungsmittel und Parfüm ad 100,00 Water, preservatives and perfume ad 100.00

Claims

Patentansprüche claims
1. Kosmetische und dermatologische Zubereitungen mit1. Cosmetic and dermatological preparations with
a) einem Gehalt an einer Verbindung oder mehreren Verbindungen aus der Gruppe der Flavonoide oder mita) a content of one or more compounds from the group of flavonoids or with
b) einem Gehalt an einer Wirkstoffkombination, enthaltend eine Verbindung oder mehrere Verbindungen ausgewählt aus der Gruppe der Flavonoide in Kombination mit einer Verbindung oder mehreren Verbindungen ausgewählt aus der Gruppe der Zimtsäurederivate undb) a content of an active ingredient combination comprising a compound or more compounds selected from the group of flavonoids in combination with a compound or more compounds selected from the group of cinnamic acid derivatives and
c) gegebenenfalls einem zusätzlichen Gehalt an einer Verbindung oder mehreren Verbindungen aus der Gruppe der Antioxidantien.c) optionally an additional content of one or more compounds from the group of antioxidants.
2. Verwendung der kosmetischen und dermatologischen Zubereitungen gemäß Anspruch 1 mit2. Use of the cosmetic and dermatological preparations according to claim 1 with
a) einem Gehalt an einer Verbindung oder mehreren Verbindungen aus der Gruppe der Flavonoidea) a content of one or more compounds from the group of flavonoids
oder mitor with
b) einem Gehalt an einer Wirkstoffkombination, enthaltend eine Verbindung oder mehrere Verbindungen ausgewählt aus der Gruppe der Flavonoide A) in Kombination mit einer Verbindung oder mehreren Verbindungen ausgewählt aus der Gruppe der Zimtsäurederivate undb) a content of an active ingredient combination containing one or more compounds selected from the group of flavonoids A) in combination with one or more compounds selected from the group of cinnamic acid derivatives and
c) gegebenenfalls einem zusätzlichen Gehalt an einer Verbindung oder mehreren Verbindungen aus der Gruppe der Antioxidantien zur Behandlung und prophylaktische Behandlung der Hautalterung, zur Vorbehandlung oder Nachbehandlung der Haare oder der Kopfhaut oder des Haarwurzelbereiches, insbesondere vor oder nach der Haarbehandlung, z.B. bei der Haarfärbung oder Dauerwelle, zum Schutz der Lippen insbesondere vor exogenen Noxen, zur Behandlung und zur prophylaktischen Behandlung von Stinging oder unspezifischem Juckreiz, zur Stabilisierung oder Wiederherstellung der epidermalen Barrierefunktion, zur Verringerung oder Verhinderung der Schädigung der Haut und des Haares durch oxidative Einflüsse, zum Schutz der Haut oder der Haare gegen Photoreaktionen und zur Behandlung oder prophylaktischen Behandlung der durch oxidative Beanspruchung hervorgerufenen Hautalterung und entzündlicher Reaktionen.c) if appropriate, an additional content of one or more compounds from the group of antioxidants for the treatment and prophylactic treatment of skin aging, for the pretreatment or aftertreatment of the hair or the scalp or the hair root area, in particular before or after the hair treatment, for example in the hair coloring or perm, to protect the lips especially from exogenous noxious agents, to treat and prophylactically treat stinging or non-specific itching, to stabilize or restore the epidermal barrier function, to reduce or prevent damage to the skin and hair by oxidative influences, to protect the Skin or hair against photoreactions and for the treatment or prophylactic treatment of skin aging and inflammatory reactions caused by oxidative stress.
3. Zubereitungen gemäß Anspruch 1 , dadurch gekennzeichnet, daß sie eine oder mehrere Verbindungen aus der Gruppe der Flavonoide Quercitin, Chrysin, Kaempferol, Myricetin, Apigenin, Naringenin, Hesperitin, Morin, Fisetin, Vitexin, Isovitexin, Flavon, Genistein, Rutin, Rhamnetin, Luteolin, Naringin, Hesperidin, Phloridzin, Diosmin, Neophesperidin-Dihydrochalkan, alpha-Glucosylrutin, alpha-Glucosylmytrictrin, alpha-Gisoquercitrintin und alpha-Glucosylquercitrin, alpha-Glycosylrutin, alpha-Glycosylhesperidin, alpha-Glycosylnaringin, alpha- Mannosylrutin, alpha-Rhamnosylrutin enthalten.3. Preparations according to claim 1, characterized in that they contain one or more compounds from the group of the flavonoids quercitin, chrysin, kaempferol, myricetin, apigenin, naringenin, hesperitin, morin, fisetin, vitexin, isovitexin, flavon, genistein, rutin, rhamnetin , luteolin, naringin, hesperidin, phloridzin, diosmin, Neophesperidin-Dihydrochalkan, alpha-glucosylrutin, alpha-Glucosylmytrictrin, alpha-Gisoquercitrintin and alpha-Glucosylquercitrin, alpha-glycosyl rutin, alpha-glycosyl hesperidin, alpha-glycosyl naringin, alpha Mannosylrutin, alpha-Rhamnosylrutin contain.
4. Zubereitungen gemäß Anspruch 1 , dadurch gekennzeichnet, daß sie die Kombination b) enthalten.4. Preparations according to claim 1, characterized in that they contain the combination b).
5. Zubereitungen gemäß Anspruch 1 , dadurch gekennzeichnet, daß sie eine oder mehrere Hydroxyzimtsauren enthalten.5. Preparations according to claim 1, characterized in that they contain one or more hydroxycinnamic acids.
6. Zubereitungen gemäß Anspruch 1 , dadurch gekennzeichnet, daß Zimtsäurederivate der allgemeinen Formel6. Preparations according to claim 1, characterized in that cinnamic acid derivatives of the general formula
und/oder wirksame Mengen an Zimtsäurederivaten der allgemeinen Formel and / or effective amounts of cinnamic acid derivatives of the general formula
verwendet werden, wobei die Gruppen X, Y und R unabhängig voneinander gewählt werden können aus der Gruppe H, verzweigtes bzw. unverzweigtes Alkyl mit 1 - 18 C-Atomen, insbesondere 1 - 6 C-Atomen.are used, the groups X, Y and R being able to be selected independently of one another from the group H, branched or unbranched alkyl having 1 to 18 carbon atoms, in particular 1 to 6 carbon atoms.
7. Zubereitungen gemäß Anspruch 1 , dadurch gekennzeichnet, daß sie Kaffeesäure und/oder Ferulasäure enthalten.7. Preparations according to claim 1, characterized in that they contain caffeic acid and / or ferulic acid.
8. Zubereitungen mit Kombinationen b), die alpha-Glucosylrutin und/oder Ferulasäure enthalten. 8. Preparations with combinations b) which contain alpha-glucosylrutin and / or ferulic acid.
EP95941094A 1994-12-13 1995-12-12 Cosmetic and dermatological preparations with flavonoids Ceased EP0799020A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE29522372U DE29522372U1 (en) 1994-12-13 1995-12-12 Cosmetic and dermatological preparations with flavonoids

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4444238A DE4444238A1 (en) 1994-12-13 1994-12-13 Cosmetic or dermatological drug combinations of cinnamic acid derivatives and flavone glycosides
DE4444238 1994-12-13
PCT/EP1995/004905 WO1996018379A1 (en) 1994-12-13 1995-12-12 Cosmetic and dermatological preparations with flavonoids

Publications (1)

Publication Number Publication Date
EP0799020A1 true EP0799020A1 (en) 1997-10-08

Family

ID=6535603

Family Applications (7)

Application Number Title Priority Date Filing Date
EP95118438A Withdrawn EP0716847A1 (en) 1994-12-13 1995-11-23 Cosmetic or dermatologic compositions containing cinnamic acid derivatives and a flavonoid
EP01123102A Withdrawn EP1201227A3 (en) 1994-12-13 1995-12-12 Use of flavonoids as immunomodulating or immunoprotecting agents in cosmetic and dermatological compositions
EP95942129A Revoked EP0797427B1 (en) 1994-12-13 1995-12-12 Agents acting against hyperreactive and hypoactive, deficient skin conditions and manifest dermatitides
EP02025465A Withdrawn EP1300138A3 (en) 1994-12-13 1995-12-12 Agents effective against hyperreactive and hypoactive deficient skin conditions as well as manifest dermatitis
EP95941094A Ceased EP0799020A1 (en) 1994-12-13 1995-12-12 Cosmetic and dermatological preparations with flavonoids
EP95942128A Withdrawn EP0799022A1 (en) 1994-12-13 1995-12-12 Use of flavonoids for protecting unstable cosmetic active substances and constituents in cosmetic and dermatological formulations
EP95942130A Revoked EP0799023B1 (en) 1994-12-13 1995-12-12 Use of flavonoids as immunomodulating or immuno-protective agents in cosmetic and dermatological preparations

Family Applications Before (4)

Application Number Title Priority Date Filing Date
EP95118438A Withdrawn EP0716847A1 (en) 1994-12-13 1995-11-23 Cosmetic or dermatologic compositions containing cinnamic acid derivatives and a flavonoid
EP01123102A Withdrawn EP1201227A3 (en) 1994-12-13 1995-12-12 Use of flavonoids as immunomodulating or immunoprotecting agents in cosmetic and dermatological compositions
EP95942129A Revoked EP0797427B1 (en) 1994-12-13 1995-12-12 Agents acting against hyperreactive and hypoactive, deficient skin conditions and manifest dermatitides
EP02025465A Withdrawn EP1300138A3 (en) 1994-12-13 1995-12-12 Agents effective against hyperreactive and hypoactive deficient skin conditions as well as manifest dermatitis

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP95942128A Withdrawn EP0799022A1 (en) 1994-12-13 1995-12-12 Use of flavonoids for protecting unstable cosmetic active substances and constituents in cosmetic and dermatological formulations
EP95942130A Revoked EP0799023B1 (en) 1994-12-13 1995-12-12 Use of flavonoids as immunomodulating or immuno-protective agents in cosmetic and dermatological preparations

Country Status (7)

Country Link
US (8) US6121243A (en)
EP (7) EP0716847A1 (en)
JP (5) JPH08259421A (en)
AT (2) ATE218059T1 (en)
DE (5) DE4444238A1 (en)
ES (2) ES2199260T3 (en)
WO (4) WO1996018381A1 (en)

Families Citing this family (308)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE32570T1 (en) * 1981-12-10 1988-03-15 Revlon PROCESS FOR MAKING METALLIC LEAF-FORMING PIGMENTS.
DE4444238A1 (en) * 1994-12-13 1996-06-20 Beiersdorf Ag Cosmetic or dermatological drug combinations of cinnamic acid derivatives and flavone glycosides
JPH1053515A (en) * 1996-08-09 1998-02-24 Ajinomoto Co Inc Skin lotion
US8039026B1 (en) * 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
DE19742025A1 (en) * 1997-09-24 1999-03-25 Beiersdorf Ag Use of flavone or flavanone derivatives to treat or prevent undesirable skin pigmentation
US6239114B1 (en) * 1997-09-26 2001-05-29 Kgk Synergize Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols
KR20010031501A (en) * 1997-10-31 2001-04-16 추후제출 Methods and compositions for regulation of 5-alpha reductase activity
US6696484B2 (en) 1997-10-31 2004-02-24 University Of Chicago Office Of Technology And Intellectual Property Method and compositions for regulation of 5-alpha reductase activity
ES2175820T3 (en) * 1997-11-19 2002-11-16 Flavone Sunproducts As COMPOSITION CONTAINING ONE OR MORE FLAVONOIDS, PROCEDURE FOR OBTAINING SUCH COMPOSITION AND ITS USE AS A UV ABSORBING AGENT.
JPH11180885A (en) * 1997-12-18 1999-07-06 Noevir Co Ltd Antiallergic skin preparation for external use
FR2772612B1 (en) * 1997-12-19 2003-01-10 Oreal USE OF CINNAMIC ACID OR DERIVATIVES THEREOF IN A FIRMING COSMETIC COMPOSITION
FR2772610B1 (en) * 1997-12-19 2006-06-02 Oreal USE OF CINNAMIC ACID OR AT LEAST ONE OF ITS DERIVATIVES IN A COSMETIC COMPOSITION
FR2772613B1 (en) * 1997-12-19 2003-05-09 Oreal USE OF PHLOROGLUCINOL IN A COSMETIC COMPOSITION
US6660283B2 (en) 1997-12-19 2003-12-09 Societe L'oreal S.A. Use of cinnamic acid, or of at least one of its derivatives in a cosmetic composition
DE19807774A1 (en) * 1998-02-24 1999-08-26 Beiersdorf Ag Use of flavone, flavanone or flavonoid compound for protection of ascorbic acid or ascorbyl compound against oxidation, especially in cosmetic and dermatological preparations,
BR9908870A (en) * 1998-03-16 2000-11-21 Procter & Gamble Processes to regularize the appearance of the skin
DE19811692A1 (en) * 1998-03-18 1999-09-23 Merck Patent Gmbh Sunscreen formulation containing filters preventing herpes virus activation and herpetic skin disease
FR2778560B1 (en) * 1998-05-12 2001-06-01 Oreal USE OF CINNAMIC ACID OR AT LEAST ONE OF ITS DERIVATIVES IN A COMPOSITION FOR PROMOTING DEQUAMATION OF THE SKIN, AND COMPOSITION COMPRISING SAME
US6750229B2 (en) 1998-07-06 2004-06-15 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin pigmentation
US8093293B2 (en) 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
US8106094B2 (en) 1998-07-06 2012-01-31 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for treating skin conditions
FR2781156B1 (en) * 1998-07-20 2001-06-29 Lafon Labor PHARMACEUTICAL COMPOSITION FOR PARTICULARLY FOR THE PREVENTION AND TREATMENT OF RADIOMUCITES AND CHEMOMUCITES
DE19837758A1 (en) * 1998-08-20 2000-02-24 Beiersdorf Ag Use of active ingredient combinations of flavonoids and UV filter substances as antiviral principle of action
CA2309179A1 (en) * 1998-09-10 2000-03-16 Avon Products, Inc. Method and composition for reducing dermatological aging and for reduci ng bruising
DE19845324A1 (en) * 1998-10-01 2000-04-06 Beiersdorf Ag Use of nitrilotriacetic acid for stabilizing flavone, flavanone and/or flavonoid useful in cosmetic and dermatological formulations
DE19845305A1 (en) * 1998-10-01 2000-04-06 Beiersdorf Ag Active combination, useful in cosmetic and dermatological formulations, contains saturated fatty acid mono- and/or diglyceride esters partly neutralized with citric acid and flavone, flavanone and/or flavonoid
DE19845271A1 (en) * 1998-10-01 2000-04-06 Beiersdorf Ag Cosmetic or dermatological formulation containing flavone, flavanone and/or flavonoid, useful e.g. in skin and hair cosmetics, contains alkylglucoside and optionally alkanol
DE19845319A1 (en) * 1998-10-01 2000-04-06 Beiersdorf Ag Use of mono-, oligo- and polymeric ethers, esters and ether-ester surfactants for stabilizing flavone, flavanone and/or flavonoid useful in cosmetic and dermatological formulations
DE19845266A1 (en) * 1998-10-01 2000-04-06 Beiersdorf Ag Use of butylhydroxytoluene for stabilizing flavone, flavanone and/or flavonoid useful in cosmetic and dermatological formulations
DE19845322A1 (en) * 1998-10-01 2000-04-06 Beiersdorf Ag Active combination based on flavone, flavanone and/or flavonoid, useful in cosmetic and dermatological formulations, contains 2-tert.-butyl hydroquinone
US20020197244A1 (en) * 1998-12-07 2002-12-26 Miri Seiberg Compositions and methods for regulating phagocytosis and ICAM-1 expression
DE19903241A1 (en) * 1999-01-28 2000-08-03 Merck Patent Gmbh Galenic wording
DE19904703A1 (en) * 1999-02-05 2000-08-24 Georg Noga Aqueous plant strengthening composition containing tocopherol and methoxycinnamic acid, providing protection against damage by e.g. heat, frost, drought or especially ultraviolet light
JP2000239144A (en) * 1999-02-22 2000-09-05 Kose Corp Langerhans cell decrease inhibitor and preparation which contain the inhibitor and is useful for external use for skin
US6440432B1 (en) * 1999-03-18 2002-08-27 Unilever Home & Personal Care Usa, A Division Of Conopco, Inc. Skin cosmetic compositions containing dextran or maltodextrin and a weak carboxylic acid
AU3913800A (en) * 1999-03-26 2000-10-16 Lipogenics, Inc. Novel antioxidant formulations and methods for using them
US7268148B2 (en) * 1999-05-20 2007-09-11 Regents Of The University Of Michigan Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes
US20040235950A1 (en) * 1999-05-20 2004-11-25 Voorhees John J. Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes
DE19923772A1 (en) * 1999-05-22 2000-11-23 Beiersdorf Ag Active substance combinations of boron nitride and flavone derivatives and / or flavanone derivatives, in particular of flavonoids, and cosmetic preparations containing such active substance combinations
DE19923713A1 (en) * 1999-05-22 2000-11-23 Beiersdorf Ag Cosmetic or dermatological sunscreen preparations containing flavone derivatives and / or flavanone derivatives, in particular flavonoids and benzotriazole, and the use of UV filter substances having the structural motif of benzotriazole for stabilizing flavone derivatives and / or flavanone derivatives, in particular flavonoids
DE19923712A1 (en) * 1999-05-22 2000-11-23 Beiersdorf Ag Active substance combination of sulfonated UV filter substances and flavone derivatives and / or flavanone derivatives, in particular flavonoids, and cosmetic preparations containing such active substance combinations
DE19923715A1 (en) * 1999-05-22 2000-11-23 Beiersdorf Ag Cosmetic or dermatological sunscreen preparations containing flavone derivatives and / or flavanone derivatives, in particular flavonoids and s-triazine, and the use of UV filter substances having the structural motif of s-triazine for stabilizing flavone derivatives and / or flavanone derivatives, in particular flavonoids
DE19925499A1 (en) * 1999-06-04 2000-12-07 Beiersdorf Ag Use of ascorbic acid and one or more flavone derivatives and / or flavonone derivatives, in particular flavonoids, for the preparation of cosmetic or dermatological preparations for the prophylaxis or relief of sunburn
DE19939849A1 (en) * 1999-07-20 2001-01-25 Beiersdorf Ag Emulsifier-free, finely dispersed water-in-oil systems
DE50011516D1 (en) * 1999-07-20 2005-12-08 Beiersdorf Ag EMULSIFY FREE WATER-IN-OIL WATER-DISPERSED SYSTEMS
US6864274B2 (en) 1999-07-23 2005-03-08 Alwyn Company, Inc. Allantoin-containing skin cream
US20020054895A1 (en) 1999-07-23 2002-05-09 Alwyn Company, Inc. Allantoin-containing skin cream
US6896897B2 (en) 1999-07-23 2005-05-24 Alwyn Company, Inc. Flexible applicator for applying oil-in-water emulsion with improved stability
US6329413B1 (en) 1999-07-23 2001-12-11 Alwyn Company, Inc. Allantoin-containing skin cream
US6281236B1 (en) 1999-07-23 2001-08-28 Alwyn Company, Inc. Oil-in-water emulsion with improved stability
US6673826B2 (en) 1999-07-23 2004-01-06 Alwyn Company, Inc. Methods for treatment of inflammatory diseases
US6531500B2 (en) 1999-07-23 2003-03-11 Alwyn Company, Inc. Methods for treatment of inflammatory diseases
WO2001007004A1 (en) * 1999-07-26 2001-02-01 Unilever Plc Stabilization of ferulic acid in cosmetic compositions
US7985404B1 (en) 1999-07-27 2011-07-26 Johnson & Johnson Consumer Companies, Inc. Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
DE19938404A1 (en) * 1999-08-13 2001-02-22 Clariant Gmbh Cosmetic preparations
JP3470182B2 (en) * 1999-08-27 2003-11-25 リアル化学株式会社 Novel hair dye and hair dyeing method using the same
US6667045B2 (en) * 1999-10-01 2003-12-23 Joseph Scott Dahle Topical applications for skin treatment
US6528042B1 (en) 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
US6426362B1 (en) * 1999-10-08 2002-07-30 Galileo Laboratories, Inc. Formulations of tocopherols and methods of making and using them
EP1408930A1 (en) * 1999-10-20 2004-04-21 Vesifact Ag Microemulsion preconcentrates which contain cyclosporines and corresponding microemulsions
US7309688B2 (en) 2000-10-27 2007-12-18 Johnson & Johnson Consumer Companies Topical anti-cancer compositions and methods of use thereof
EP1104672A1 (en) * 1999-12-02 2001-06-06 Laboratoires Serobiologiques(Societe Anonyme) Cosmetic and/or pharmaceutical compositions
US6521668B2 (en) * 1999-12-14 2003-02-18 Avon Products, Inc. Cosmetic composition and methods of use
AU1889901A (en) * 1999-12-15 2001-06-25 Kyowa Hakko Kogyo Co. Ltd. Stabilizers for l-ascorbic acid-2-sodium phosphate
DE10003786A1 (en) * 2000-01-28 2001-08-02 Merck Patent Gmbh Galenic formulation
GB0004686D0 (en) * 2000-02-28 2000-04-19 Aventis Pharma Ltd Chemical compounds
TWI233353B (en) * 2000-04-11 2005-06-01 Takara Bio Inc Therapeutic or preventive agents containing polyphenols
AU2001212734B2 (en) * 2000-04-18 2005-01-20 Ceteris Holding B.V. -Amsterdam (Olanda)-Succursale Di Lugano A composition based on natural extracts useful in the prevention and treatment of cutaneous wrinkles
DE10025558A1 (en) * 2000-05-24 2001-11-29 Merck Patent Gmbh Topical composition containing at least one aryloxime and process for its preparation
DE10025553A1 (en) * 2000-05-24 2001-11-29 Merck Patent Gmbh Composition containing at least one aryloxime and at least one active ingredient for the treatment of acne and their use
WO2002000239A1 (en) * 2000-06-28 2002-01-03 Kikkoman Corporation Antiallergic agents, drugs, foods, drinks or cosmetics containing them and process for producing the same
DE10031457C2 (en) * 2000-06-28 2002-12-12 Jean Krutmann Use of O-beta-hydroxyethylrutoside or its aglycon for the systemic treatment and prophylaxis of UV-induced dermatoses and undesirable long-term consequences of UV radiation
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
DE10035071A1 (en) * 2000-07-17 2002-01-31 Cognis Deutschland Gmbh Decorative cosmetic preparations
FR2811892B1 (en) * 2000-07-18 2003-04-18 Oreal COMPOSITION COMPRISING SOPHORA JAPONICA EXTRACT AND USE THEREOF
JP3548102B2 (en) * 2000-08-07 2004-07-28 花王株式会社 Antihypertensive agent
GB2368012A (en) * 2000-10-19 2002-04-24 Nicholas John Larkins Preparation for the relief of inflammatory disease
FR2815859B1 (en) * 2000-10-26 2003-02-28 Oreal USE OF THE COMBINATION OF AT LEAST ONE CAROTENOID WITH PROVITAMIN ACTIVITY WITH AND AT LEAST ONE CAROTENOID WITHOUT PROVITAMIN ACTIVITY TO TREAT THE SIGNS OF AGING
FR2815861B1 (en) * 2000-10-26 2003-02-28 Oreal USE OF THE COMBINATION OF AT LEAST ONE CAROTENOID AND AT LEAST ONE ISOFLAVONOID FOR TREATING SKIN SIGNS OF AGING
US8431550B2 (en) 2000-10-27 2013-04-30 Johnson & Johnson Consumer Companies, Inc. Topical anti-cancer compositions and methods of use thereof
US6630158B2 (en) 2000-10-31 2003-10-07 Stiefel Laboratories, Inc. Dietary supplement composition and method for improving and maintaining healthy skin
AUPR549901A0 (en) * 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
DE10056400A1 (en) 2000-11-14 2002-05-23 Merck Patent Gmbh Galenic formulation
ATE444756T1 (en) * 2000-11-14 2009-10-15 Vital Health Sciences Pty Ltd COMPOSITIONS COMPRISING COMPLEXES OF TOCOPHEROL PHOSPHATE DERIVATIVES
FR2816838B1 (en) * 2000-11-17 2004-12-03 Oreal USE OF DERIVATIVES OF 2-OXOTHIAZOLIDINE-4-CARBOXYLIC ACID AS PRODESQUAMANTS
DE10062401A1 (en) * 2000-12-14 2002-06-20 Beiersdorf Ag Use of folic acid and / or derivatives thereof for the preparation of cosmetic or dermatological preparations for the prophylaxis of damage to the skin's own DNA and / or to repair damage already occurred to the skin's own DNA
FR2818148B1 (en) * 2000-12-15 2005-06-24 Oreal COMPOSITION, ESPECIALLY COSMETIC, CONTAINING 7-HYDROXY DHEA AND / OR 7-KETO DHEA AND AT LEAST ONE ISOFLAVONOID
FR2818135B1 (en) * 2000-12-15 2003-02-14 Oreal COMPOSITION, ESPECIALLY COSMETIC, CONTAINING 7-HYDROXY DHEA AND / OR 7-CETO DHEA AND AT LEAST ONE CAROTENOID
US20040067245A1 (en) * 2000-12-20 2004-04-08 Harish Mahalingam Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin
US6555573B2 (en) 2000-12-21 2003-04-29 The Quigley Corporation Method and composition for the topical treatment of diabetic neuropathy
JP4197091B2 (en) * 2000-12-27 2008-12-17 花王株式会社 Cosmetics
WO2002062978A1 (en) * 2001-02-05 2002-08-15 David Holzer Method and composition for in situ metabolizing of glutathione and nad
FR2820974B1 (en) * 2001-02-21 2004-02-13 Pharmascience Lab TOPICAL COMPOSITION COMPRISING A TRUE SOLUTION CONTAINING A CHROMANE OR CHROMENE DERIVATIVE, ITS PREPARATION METHOD AND ITS COSMETIC AND THERAPEUTIC USE
US6638543B2 (en) 2001-02-27 2003-10-28 Regents Of The University Of Michigan Use of natural EGFR inhibitors to prevent side effects due to retinoid therapy, soaps, and other stimuli that activate the epidermal growth factor receptor
US6555143B2 (en) 2001-02-28 2003-04-29 Johnson & Johnson Consumer Products, Inc. Legume products
US7192615B2 (en) 2001-02-28 2007-03-20 J&J Consumer Companies, Inc. Compositions containing legume products
US20020127256A1 (en) * 2001-03-01 2002-09-12 Howard Murad Compositions and methods for treating dermatological disorders
WO2002069926A1 (en) * 2001-03-02 2002-09-12 Merck Patent Gmbh Cosmetic formulations containing flavonoid derivatives
FR2822466B1 (en) * 2001-03-23 2004-07-02 Diana Ingredients PHLORIDZINE-RICH PHENOLIC FRACTION AND ITS USE AS A COSMETIC, FOOD OR NUTRACEUTICAL AGENT
EP1287816B1 (en) * 2001-03-30 2010-08-04 Shiseido Co., Ltd. Cosmetic preparation and method for using a color-developing composition as a cosmetic preparation
DE50100901D1 (en) * 2001-04-12 2003-12-11 Vesifact Ag Baar Microemulsion preconcentrates and microemulsions containing coenzyme Q10
EP1260212A1 (en) * 2001-05-21 2002-11-27 Cognis France S.A. Cosmetic composition
CA2449671A1 (en) * 2001-06-06 2002-12-12 The Regents Of The University Of Michigan Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enyzmes
DE10133201A1 (en) * 2001-07-07 2003-01-23 Beiersdorf Ag Use of topical compositions containing electrolytes in combination with polyols and/or urea to, e.g. improve skin condition or to treat or prevent skin disorders
DE10133202A1 (en) * 2001-07-07 2003-01-16 Beiersdorf Ag Topical compositions containing osmolytes, useful e.g. for treating or preventing dry skin or inflammatory conditions of the skin, e.g. eczema, polymorphic light dermatosis or psoriasis
US20060194773A1 (en) * 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
AU2002317053B2 (en) * 2001-07-27 2004-08-05 Vital Health Sciences Pty Ltd Dermal therapy using phosphate derivatives of electron transfer agents
CA2357053A1 (en) * 2001-09-04 2003-03-04 Unknown Effectiveness of a combination of antioxidant substances for the treatment of alzheimer's disease
US20030118536A1 (en) * 2001-11-06 2003-06-26 Rosenbloom Richard A. Topical compositions and methods for treatment of adverse effects of ionizing radiation
US6696082B2 (en) * 2002-01-08 2004-02-24 Mccully Kilmer S. Enhanced liposomal thioretinaco ozonide compositions and liposomal carrier
US20030224075A1 (en) * 2002-02-21 2003-12-04 Jue-Chen Liu Soy composition for balancing combination skin
FR2836336B1 (en) 2002-02-26 2004-08-27 Diana Ingredients USE IN A COSMETIC TREATMENT OF A PHENOLIC FRACTION RICH IN DIHYDROCHALCONES
GB0209254D0 (en) * 2002-04-23 2002-06-05 Larkins Nicholas J Preparation for the relief of disease
US20030212127A1 (en) * 2002-05-09 2003-11-13 Bradley Pharmaceuticals, Inc. Method of treating actinic keratosis
DE10225772A1 (en) * 2002-06-10 2003-12-24 Beiersdorf Ag Cosmetic or dermatological formulations for skin care after sunbathing or shaving
AU2003240300A1 (en) * 2002-06-25 2004-01-06 Cosmeceutic Solutions Pty Ltd Topical cosmetic compositions
AU2002950308A0 (en) * 2002-07-23 2002-09-12 Phoenix Eagle Company Pty Ltd Topically applied composition
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
AU2002950713A0 (en) * 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
US6793193B2 (en) * 2002-08-20 2004-09-21 Dart Industries Inc. Adjustable mold for forming shaped food
JP3926711B2 (en) * 2002-08-30 2007-06-06 株式会社ファンケル Composition for preventing skin aging to prevent, prevent and improve flattening of the epidermis
DE10240923A1 (en) * 2002-09-02 2004-03-04 Merck Patent Gmbh Flavonoid derivatives for eczema treatment
US20040063593A1 (en) * 2002-09-30 2004-04-01 Wu Jeffrey M. Compositions containing a cosmetically active organic acid and a legume product
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US20160158261A1 (en) * 2002-10-25 2016-06-09 Foamix Pharmaceuticals Ltd. Antibiotic Kit and Composition and Uses Thereof
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
AU2003279493B2 (en) 2002-10-25 2009-08-20 Foamix Pharmaceuticals Ltd. Cosmetic and pharmaceutical foam
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US7241456B2 (en) * 2002-10-25 2007-07-10 Australian Importers Ltd. Formulations for topical delivery of bioactive substances and methods for their use
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
NZ539871A (en) * 2002-10-30 2008-06-30 Asat Ag Applied Science & Tech Daily melatonin dosing units of 0.01 to 0.2 mg of melatonin or melatonin derivative, for promoting hair growth
DE20217814U1 (en) * 2002-11-18 2004-04-08 Asat Ag Applied Science & Technology Melatonin daily dosage units
DE10250646A1 (en) * 2002-10-30 2004-05-13 Asat Ag Applied Science & Technology Cosmetic and/or pharmaceutical hair treatment compositions, especially for promoting hair growth, containing melatonin (or derivative) and Gingko biloba and biotin as potentiating agents
US7083813B2 (en) * 2002-11-06 2006-08-01 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
US20040205904A1 (en) * 2002-12-13 2004-10-21 L'oreal Dye composition comprising a cationic tertiary para-phenylenediamine and a vitamin derivative, processes therefor and uses thereof
DE10308162A1 (en) * 2003-02-26 2004-09-09 Universitätsklinikum Freiburg Process for the preparation of flavonoid-containing compositions and their use
JP2006519866A (en) * 2003-03-04 2006-08-31 スリーエム イノベイティブ プロパティズ カンパニー Prophylactic treatment of UV-induced epidermal neoplasia
US20050036972A1 (en) * 2003-03-10 2005-02-17 Hy-Gene Biomedical Corporation System for managing pathogens and irritants and monitoring usage of anti-bacterial formulations
JP4481928B2 (en) * 2003-03-11 2010-06-16 株式会社カネカ Oil-in-water emulsified composition containing coenzyme Q10 and method for producing the same
ITFI20030070A1 (en) * 2003-03-18 2004-09-19 Berlin Chemie Ag STABILIZED TOPICAL FORMULATIONS CONTAINING KETOPROFENE
ITMI20030661A1 (en) * 2003-04-04 2004-10-05 Indena Spa PROCESS FOR THE PREPARATION OF FERUTININ FROM PLANTS OF THE GENE FERULA
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US20050008588A1 (en) * 2003-06-05 2005-01-13 L'oreal Aminoarylvinyl-s-triazine compounds and uses thereof
US20040258765A1 (en) * 2003-06-23 2004-12-23 Gee Gilbert C. Method for treatment of sores and lesions of the skin
US7001622B1 (en) * 2003-06-30 2006-02-21 Robert Berndt Composition and method for treatment and prevention of pruritis
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
JP2007530417A (en) * 2003-07-01 2007-11-01 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ Composition for manipulating the longevity and stress response of cells and organisms
US20050004561A1 (en) * 2003-07-01 2005-01-06 Lynn Halas Method for removing hair
WO2005007676A2 (en) * 2003-07-10 2005-01-27 Rajadhyaksha V J Glycopeptides for the treatment of als and other metabolic and autoimmune disorders
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US7546987B2 (en) * 2003-08-20 2009-06-16 Howard Sinkoff Cable tray assemblies
US7999003B2 (en) * 2003-08-26 2011-08-16 Mannatech, Incorporated Antioxidant compositions and methods thereto
US20050048012A1 (en) * 2003-08-26 2005-03-03 Roland Jermann Use of biotin or a biotin derivative for skin lightening purposes and for the treatment of senile lentigines
US20050214413A1 (en) * 2003-08-26 2005-09-29 Mannatech, Inc. Methods and compositions for modified release of nutritional supplements
US8211873B2 (en) * 2003-08-29 2012-07-03 Island Kinetics, Inc. Antiaging chirally-correct mitoprotectant amino acid and peptide complexes
EP1677748A1 (en) * 2003-10-29 2006-07-12 Johnson & Johnson Consumer France SAS Compositions comprising soy products and dioic acids
KR100449887B1 (en) * 2003-10-31 2004-09-22 주식회사 렉스진바이오텍 Preparation method of extract of Sophorae Fructus containing isoflavone
NZ547628A (en) * 2003-11-06 2010-07-30 Univ New York State Res Found Methods of treating eczema
ES2232302B1 (en) * 2003-11-07 2006-08-01 Universitat De Les Illes Balears MYO-INOSITOL HEXAFOSFATO FOR TOPICAL USE.
ES2381359T3 (en) * 2003-11-17 2012-05-25 Sederma Compositions containing mixtures of tetrapeptides and tripeptides
US7176185B2 (en) * 2003-11-25 2007-02-13 Tsrl, Inc. Short peptide carrier system for cellular delivery of agent
US20050152996A1 (en) * 2003-12-01 2005-07-14 BUTLER Donald Extracts of Mimulus aurantiacus for treating psoriasis and repelling insects
US8017634B2 (en) * 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
JP2007527418A (en) 2003-12-29 2007-09-27 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ Composition for treating or preventing obesity and insulin resistance disorders
US20090017146A1 (en) * 2003-12-31 2009-01-15 Yossi Shevach Beta Vulgaris-Based Products
EP1720551B9 (en) * 2004-03-03 2011-09-21 Vital Health Sciences Pty Ltd. Alkaloid formulations
FR2869229B1 (en) * 2004-04-26 2006-08-25 Sederma Soc Par Actions Simpli USE OF A INDUCER OF UGT BY TOPIC
US20060084085A1 (en) * 2004-06-16 2006-04-20 Sinclair David A Methods and compositions for modulating Bax-mediated apoptosis
US20060014705A1 (en) * 2004-06-30 2006-01-19 Howitz Konrad T Compositions and methods for selectively activating human sirtuins
US7399493B2 (en) * 2004-07-16 2008-07-15 Wille John J Anti-irritant botanicals
US20060018861A1 (en) * 2004-07-23 2006-01-26 Minghua Chen Skin care composition
WO2006020164A1 (en) * 2004-07-23 2006-02-23 The Procter & Gamble Company Skin care composition containing a flavonoid and vitamin b3
JP2008507525A (en) * 2004-07-23 2008-03-13 ザ プロクター アンド ギャンブル カンパニー Substrate-based skin care device
CN1988881A (en) * 2004-07-23 2007-06-27 宝洁公司 Skin care composition containing a flavonoid and vitamin b3
JP2008507522A (en) * 2004-07-23 2008-03-13 ザ プロクター アンド ギャンブル カンパニー Skin care composition containing flavonoids and vitamin B3
JP4672303B2 (en) * 2004-08-02 2011-04-20 丸善製薬株式会社 Fibroblast growth promoter, skin cosmetics and cosmetics
US20090004166A1 (en) * 2004-08-03 2009-01-01 Simon Michael West Carrier For Enternal Administration
US7368133B2 (en) * 2004-08-23 2008-05-06 Yu Ching Wu Medicinal drug and methods of manufacturing the same
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
JP5254616B2 (en) 2004-09-13 2013-08-07 クロノ セラピューティクス、インコーポレイテッド Biosynchronous transdermal drug delivery
US9089494B2 (en) 2004-09-14 2015-07-28 Coty S.A. Ultra-violet inhibition system
JP2008513378A (en) * 2004-09-14 2008-05-01 アジノモト オムニケム エッス.アー. Topical composition containing phosphorylated polyphenols
JPWO2006038656A1 (en) * 2004-10-05 2008-05-15 国立大学法人九州大学 Allergy suppressant
US20060120980A1 (en) * 2004-12-02 2006-06-08 Eberl James J Novel dermatological composition using bio-activating organocatalysts
KR20070090237A (en) * 2004-12-07 2007-09-05 액세스 비지니스 그룹 인터내셔날 엘엘씨 Methods for scavenging oxidizing nitrogen and oxygen species with fragrances having antioxidative properties
CA2593537A1 (en) * 2005-01-12 2006-07-20 S.U.L.V.E. Ltd. Methods and pharmaceutical compositions useful for treating psoriasis
JP2008526963A (en) * 2005-01-14 2008-07-24 リポ ケミカルズ インコーポレイテッド Compositions and methods for treating overpigmented skin
EP1858508A4 (en) * 2005-03-03 2009-01-07 Vital Health Sciences Pty Ltd Compounds having anti-cancer properties
US20090239827A1 (en) * 2005-03-03 2009-09-24 Esra Ogru Compounds having lipid lowering properties
US20070042026A1 (en) * 2005-03-17 2007-02-22 Wille John J Prophylactic and therapeutic treatment of topical and transdermal drug-induced skin reactions
WO2006127905A2 (en) 2005-05-24 2006-11-30 Chrono Therapeutics, Inc. Portable drug delivery device
DE102005026002A1 (en) * 2005-06-03 2006-12-14 Beiersdorf Ag Cosmetic preparations containing an aqueous aniseed extract and one or more polymeric thickening agents selected from the group of cellulose derivatives
WO2006138418A2 (en) * 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
EP2548581A3 (en) 2005-06-17 2013-02-20 Vital Health Sciences Pty Ltd. A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
US7700083B2 (en) * 2005-10-24 2010-04-20 Kevin Meehan Skin care composition for accelerated production of collagen proteins and method of fabricating same
US7767238B2 (en) 2005-11-04 2010-08-03 Pepsico, Inc. Beverage composition and method of preventing degradation of vitamins in beverages
EP1797861A1 (en) * 2005-12-16 2007-06-20 KPSS-Kao Professional Salon Services GmbH Composition for the permanent shaping of human hair
DE102006010870A1 (en) * 2006-03-07 2007-09-13 Henkel Kgaa Cosmetic agents with purine and / or purine derivatives I
DE102006010869A1 (en) * 2006-03-07 2007-09-20 Henkel Kgaa Cosmetic agents with purine and / or purine derivatives II
US20070225360A1 (en) * 2006-03-22 2007-09-27 L'oreal Anti-aging composition containing phloretin
US20080008818A1 (en) * 2006-06-23 2008-01-10 Miri Seiberg Partially denatured whole soybean extracts and methods of use thereof
KR100808552B1 (en) * 2007-02-01 2008-02-29 한국원자력연구원 Therapeutic hydrogels for atopic dermatitis containing covering layer to prevent water loss
KR100772494B1 (en) * 2006-08-09 2007-11-01 한국원자력연구원 Therapeutic hydrogels for atopic dermatitis using irradiation
US20080131496A1 (en) * 2006-09-22 2008-06-05 Guilford F Timothy Topical application of melatonin directly or in liposomes for the amelioration of itching and histamine and non histamine related inflammatory skin changes
FR2906716B1 (en) * 2006-10-06 2013-05-17 Clarins Lab USE OF A COSMETIC COMPOSITION FOR THE CARE OF OIL SKIN.
US20080089960A1 (en) * 2006-10-16 2008-04-17 Miri Seiberg Use of Legume Products for the Treatment and Prevention of Radiotherapy-Induced Skin Damage
JP2007056035A (en) * 2006-10-19 2007-03-08 Fancl Corp Differentiation inhibiting agent for normal keratinized human epithelium cell
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US20080135643A1 (en) * 2006-12-08 2008-06-12 Kimberly-Clark Worldwide, Inc. Pulsating spray dispensers
US20080147734A1 (en) * 2006-12-18 2008-06-19 Cuticeuticals, Inc Method of topical steroidal organization
DE102006061828A1 (en) * 2006-12-21 2008-06-26 Henkel Kgaa Oxidative Hair Treatment with Litchi Extract
WO2008083389A1 (en) * 2006-12-29 2008-07-10 Moleculin, L.L.C. Methods of treating skin disorders with caffeic acid analogs
EP2011478A1 (en) * 2007-06-26 2009-01-07 KPSS-Kao Professional Salon Services GmbH Composition for the permanent shaping of human hair
EP2011479A1 (en) * 2007-06-26 2009-01-07 KPSS-Kao Professional Salon Services GmbH Composition for the permanent shaping of human hair
EP2011543A1 (en) * 2007-06-26 2009-01-07 KPSS-Kao Professional Salon Services GmbH Composition for the permanent shaping of human hair
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US20090130128A1 (en) * 2007-08-17 2009-05-21 Alberte Randall S Antiinfective Proanthocyanidin Compounds and Methods of Use Thereof
US7802314B2 (en) * 2007-10-31 2010-09-28 Kimberly-Clark Worldwide, Inc. Hand-wear article with cutaneous sensory elements
US8221370B2 (en) * 2007-10-31 2012-07-17 Kimberly-Clark Worldwide, Inc. Personal care article with substrate surface topography for evoking a neurosensory skin response
WO2009060017A1 (en) * 2007-11-09 2009-05-14 Henkel Ag & Co. Kgaa Hair treatment agent comprising tiliroside and vitamin b
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
JP5227016B2 (en) * 2007-12-28 2013-07-03 ライオン株式会社 Itching inhibitor and itch inhibiting composition
EP2242476A2 (en) 2008-01-14 2010-10-27 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US20090324705A1 (en) * 2008-02-13 2009-12-31 Nina Vikhrieva Phytonutrient compositions for topical use
US20090215924A1 (en) * 2008-02-26 2009-08-27 Momentive Performance Materials Inc. Silicone rubber exhibiting effective antimicrobial activity
CA2722895C (en) * 2008-04-30 2014-05-27 The Procter & Gamble Company Hair care compositions for preventing oxidative damage to hair, methods of use, and methods of marketing such compositions
US8450337B2 (en) * 2008-09-30 2013-05-28 Moleculin, Llc Methods of treating skin disorders with caffeic acid analogs
US8357407B2 (en) * 2009-01-30 2013-01-22 Manuel Gidekel Agent for cutaneous photoprotection against UVA/UVB rays
FR2942961B1 (en) * 2009-03-11 2011-04-22 Oreal COSMETIC COMPOSITION CONTAINING A DIBENZOYLMETHANE DERIVATIVE AND DIHYDROCHALCONE; METHOD FOR PHOTOSTABILIZATION OF THE DIBENZOYLMETHANE DERIVATIVE
CA2760186C (en) 2009-04-28 2019-10-29 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
GB2471135A (en) * 2009-06-19 2010-12-22 H D S Ltd Hair dye composition and use in reducing contact allergy
BRPI1011464A8 (en) * 2009-06-22 2019-01-29 Donaldson Co Inc filter element holder assembly, quick install system, and methods
CA2769625C (en) 2009-07-29 2017-04-11 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
KR20110012148A (en) * 2009-07-30 2011-02-09 서울대학교산학협력단 Hydroxycinnamoyl-peptide derivatives, process for producing the same and cosmetic composition comprising the same
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
MX359879B (en) 2009-10-02 2018-10-12 Foamix Pharmaceuticals Ltd Topical tetracycline compositions.
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US8174881B2 (en) 2009-11-24 2012-05-08 Micron Technology, Inc. Techniques for reducing disturbance in a semiconductor device
JP2011148708A (en) * 2010-01-19 2011-08-04 Noevir Co Ltd Moisturizing agent, anti-ageing agent, antioxidative agent, slimming agent, beautifying and whitening agent, anti-inflammatory agent, immunoactivating agent, skin care preparation for external use and functional oral administration composition
US20140135372A1 (en) 2010-02-02 2014-05-15 Elliott Farber Compositions and methods of treatment of inflammatory skin conditions using allantoin
AU2011213557B2 (en) 2010-02-05 2015-05-07 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
JP2011168559A (en) * 2010-02-22 2011-09-01 Noevir Co Ltd Antioxidant, anti-inflammatory agent, anti-aging agent, skin care preparation for external use and functional oral composition
US8652511B2 (en) 2010-03-30 2014-02-18 Phosphagenics Limited Transdermal delivery patch
ES2582859T3 (en) 2010-05-28 2016-09-15 Galderma S.A. Compositions and methods for treating bruises
JP2012082183A (en) * 2010-10-06 2012-04-26 Masaaki Ishiwatari Surfactant free oil-in-water type emulsified composition, and surfactant free cosmetic
US9561243B2 (en) 2011-03-15 2017-02-07 Phosphagenics Limited Composition comprising non-neutralised tocol phosphate and a vitamin A compound
ITCN20110006A1 (en) * 2011-06-16 2012-12-17 Alpiflor S R L NUTRITIONAL COMPOSITION IN WHICH THEY ARE ASSOCIATED IN A TWO PREPARED KIT, ONE WITH A PREBIOTIC, D-MANNOSE AND CITRATES AND THE OTHER WITH D-MANNOSE AND BIOFLAVONOIDS.
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
JP2013018720A (en) * 2011-07-08 2013-01-31 Kao Corp Hair treatment composition
US10111821B2 (en) 2011-11-03 2018-10-30 Applied Biology, Inc. Methods and compositions for administering a specific wavelength phototherapy
US20130115180A1 (en) * 2011-11-03 2013-05-09 Andy Ofer GOREN Methods And Compositions For Administering A Specific Wavelength Phototherapy
WO2013091684A1 (en) * 2011-12-20 2013-06-27 Oriflame Research And Development Ltd. Compounds with anti-aging activities
JP2012092138A (en) * 2011-12-27 2012-05-17 Maruzen Pharmaceut Co Ltd Skin cosmetic and hair cosmetic
JP5324000B1 (en) * 2012-03-08 2013-10-23 サントリーホールディングス株式会社 Composition containing imidazole peptide and quercetin glycoside
CN102659876B (en) * 2012-05-14 2014-06-11 河南中医学院 Flavonoid glycoside extracted from cardamine tangutorum and preparation method thereof
US9072919B2 (en) * 2012-10-12 2015-07-07 L'oreal S.A. Synergistic antioxidant cosmetic compositions containing at least one of baicalin and taxifolin, at least one of caffeine and nicotinamide, at least one of vitamin C and resveratrol and ferulic acid
US10105487B2 (en) 2013-01-24 2018-10-23 Chrono Therapeutics Inc. Optimized bio-synchronous bioactive agent delivery system
EP2769708A1 (en) * 2013-02-21 2014-08-27 Symrise AG Inhibition of skin ageing induced by IR radiation
MX2015013422A (en) * 2013-03-20 2016-07-07 Procter & Gamble Articles of manufacture comprising water-soluble polymer particles and processes for making same.
JP6209360B2 (en) * 2013-05-14 2017-10-04 森永製菓株式会社 Piceatannol solution and method for stabilizing piceatannol solution
JP6343126B2 (en) * 2013-05-14 2018-06-13 森永製菓株式会社 Method for stabilizing stilbenes contained in plant extract or solution thereof, and plant extract containing stilbenes or solution thereof
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
WO2015083554A1 (en) * 2013-12-02 2015-06-11 株式会社林原 4G-O-α-D-GLUCOPYRANOSYLRUTIN CRYSTAL AND APPLICATION THEREOF
DK3089737T3 (en) 2013-12-31 2021-12-13 Rapamycin Holdings Llc ORAL RAPAMYCIN NANOPARTICLE PREPARATIONS AND USE.
DE102014104254A1 (en) * 2014-03-26 2015-10-01 Beiersdorf Ag Active ingredient combinations of 4-hydroxyacetophenone and one or more cinnamic acid derivatives, as well as cosmetic or dermatological preparations containing these active ingredient combinations
CA2968049A1 (en) * 2014-04-16 2015-10-22 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US10213586B2 (en) 2015-01-28 2019-02-26 Chrono Therapeutics Inc. Drug delivery methods and systems
JP2018511127A (en) 2015-03-12 2018-04-19 クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. Craving input and support system
ES2882588T3 (en) * 2015-03-31 2021-12-02 Turtle Bear Holdings Llc Antiviral activity of medicinal mushrooms and their active constituents
JP6882321B2 (en) 2015-12-09 2021-06-02 フォスファージニクス リミテッド Pharmaceutical product
ES2941698T3 (en) * 2015-12-29 2023-05-24 Oreal Stable antioxidant compositions
US10253090B2 (en) 2016-03-22 2019-04-09 Avicenna Nutraceutical, Llc Hydrolyzed collagen compositions and methods of making thereof
US10695278B2 (en) 2016-03-31 2020-06-30 L'oreal Photo-stabilized compositions and methods of use
US20170326062A1 (en) 2016-05-13 2017-11-16 Yi-Chun Lin Compositions for skin application
US20190142726A1 (en) * 2016-06-29 2019-05-16 Nikko Chemicals Co., Ltd. Damaged hair improving agents and damaged hair improving cosmetics containing the same
CA2978573A1 (en) 2016-09-08 2018-03-08 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
CA3038697A1 (en) * 2016-10-13 2018-04-19 Unilever Plc Anti-dandruff composition
BR112019012946A2 (en) 2016-12-21 2019-11-26 Avecho Biotechnology Ltd process
JP2020503950A (en) 2017-01-06 2020-02-06 クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. Device and method for transdermal drug delivery
DE102017201306A1 (en) 2017-01-27 2018-08-02 Beiersdorf Ag Stabilization of preparations containing alpha-glucosylrutin
EP3158989A3 (en) * 2017-02-01 2017-10-11 SanderStrothmann GmbH Cosmetic skin treatment composition
KR101782966B1 (en) * 2017-03-14 2017-09-28 전북대학교산학협력단 A Composition for Preventing or Treating Pruritus
JP6482604B2 (en) * 2017-06-22 2019-03-13 教裕 南郷 Inner skin dissolution type needle and needle device
US10722465B1 (en) 2017-12-08 2020-07-28 Quicksilber Scientific, Inc. Transparent colloidal vitamin supplement
US11344497B1 (en) 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
JP7406688B2 (en) 2018-01-29 2023-12-28 ファンクション インコーポレイテッド Systems and methods for formulating personalized skin care products
US10729633B2 (en) * 2018-03-29 2020-08-04 L'oreal Methods for boosting UVA photo-protection using antioxidants
WO2019232077A1 (en) 2018-05-29 2019-12-05 Chrono Therapeutics Inc. Drug delivery methods and systems
JP7292866B2 (en) * 2018-12-11 2023-06-19 ロレアル Less Odorless Composition
KR20200091271A (en) * 2019-01-22 2020-07-30 조선대학교산학협력단 Composition for regulating skin hypersensitivity comprising hesperetin
US11291702B1 (en) 2019-04-15 2022-04-05 Quicksilver Scientific, Inc. Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method
CN116437894A (en) * 2020-08-31 2023-07-14 莱雅公司 Composition for caring keratin materials
WO2023018959A1 (en) * 2021-08-12 2023-02-16 Roc Opco Llc Composition of hyaluronic acid and use alone and in combination with retinoids to improve skin
WO2023220103A1 (en) * 2022-05-10 2023-11-16 Melaleuca, Inc. Dietary supplement compositions
US11878036B2 (en) * 2022-05-25 2024-01-23 Neuvian LLC Vaginal care compositions and methods of improving vaginal health

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US504323A (en) * 1893-09-05 btje kle
DE2529511A1 (en) * 1975-07-02 1977-01-20 Henkel & Cie Gmbh SUN PROTECTION FOR HUMAN SKIN
US4297348A (en) * 1980-04-11 1981-10-27 Rush-Hampton Industries, Inc. Composition and method for the treatment of acne
US4774229A (en) * 1982-04-05 1988-09-27 Chemex Pharmaceuticals, Inc. Modification of plant extracts from zygophyllaceae and pharmaceutical use therefor
DE3314895A1 (en) * 1983-04-25 1984-10-25 Blendax-Werke R. Schneider Gmbh & Co, 6500 Mainz DENTAL AND ORAL CARE PRODUCTS
FR2556969B1 (en) * 1983-12-27 1986-04-25 Oreal COSMETIC OR PHARMACEUTICAL COMPOSITION BASED ON PLANT EXTRACTS HAVING ACTION ON HAIR FRAGILITY
JPH0623089B2 (en) * 1986-05-15 1994-03-30 株式会社資生堂 External skin preparation
LU86601A1 (en) * 1986-09-22 1988-04-05 Oreal PHOTOSTABLE COSMETIC COMPOSITION CONTAINING AN ETHYLRUTINE DERIVATIVE AS A PROTECTIVE AGENT AGAINST SALARY LIGHT AND ITS USE FOR PROTECTING THE SKIN AND HAIR
IT1201149B (en) * 1987-01-14 1989-01-27 Indena Spa BIOFLAVONOID COMPLEXES WITH PHOSPHOLIPIDS, THEIR PREPARATION, USE AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS
FR2610626B1 (en) * 1987-02-09 1989-05-19 Oreal NOVEL ANTI-OXIDIZER SYSTEM BASED ON A STABILIZED ASCORBYL ESTER, COMPRISING AT LEAST ONE COMPLEXING AGENT AND AT LEAST ONE THIOL, AND COMPOSITIONS CONTAINING SUCH ANTI-OXIDIZING SYSTEM
JPS63208506A (en) * 1987-02-24 1988-08-30 Nonogawa Shoji:Kk Cosmetic
US5008441A (en) * 1987-08-04 1991-04-16 The Trustees Of Columbia University In The City Of New York Caffeic acid esters and methods of producing and using same
JPH0196106A (en) * 1987-10-09 1989-04-14 Shiseido Co Ltd External drug for skin
FR2634779B1 (en) * 1988-07-29 1994-05-27 Oreal NOVEL ANTI-OXIDIZING SYSTEM BASED ON A STABILIZED ASCORBYL ESTER, CONTAINING, AT LEAST ONE TOCOPHEROL OR A MIXTURE OF TOCOPHEROLS OR CAFEIC ACID OR A DERIVATIVE THEREOF, AT LEAST ONE COMPLEX AGENT AND AT LEAST ONE NON-THIOLE POLYPEPTIDE, AND COMPOSITIONS CONTAINING SUCH ANTI-OXIDIZING SYSTEM
US5153000A (en) * 1988-11-22 1992-10-06 Kao Corporation Phosphate, liposome comprising the phosphate as membrane constituent, and cosmetic and liposome preparation comprising the liposome
CA2011618A1 (en) * 1989-03-08 1990-09-08 Yukio Suzuki Preparation and uses of alpha-glycosyl rutin
JP3060227B2 (en) * 1989-06-03 2000-07-10 株式会社林原生物化学研究所 α-Glycosyl hesperidin, its production method and use
JPH03255013A (en) * 1990-03-01 1991-11-13 San Ei Chem Ind Ltd Cosmetic
FR2671724A1 (en) * 1991-01-22 1992-07-24 Synthelabo EXTRACTS OF HAMAMELIS LEAVES, THEIR PREPARATION AND THEIR APPLICATIONS.
WO1992016544A1 (en) * 1991-03-21 1992-10-01 Parfums Christian Dior Novel derivative of caffeic acid, oraposide, cosmetic or pharmaceutical, particularly dermatological, composition containing it
US5561116A (en) * 1991-04-11 1996-10-01 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Solid product containing propolis components, and preparation and uses thereof
JP3134233B2 (en) * 1991-07-26 2001-02-13 株式会社林原生物化学研究所 α-Glycosyl quercetin, its production method and use
IL99291A (en) * 1991-08-23 1997-04-15 Fischer Pharma Ltd Cosmetic preparations
US5494667A (en) * 1992-06-04 1996-02-27 Kabushiki Kaisha Hayahibara Topically applied hair restorer containing pine extract
US5340568A (en) * 1992-07-01 1994-08-23 The Procter & Gamble Company Topical composition and method containing deoxy and halo derivatives of lysophosphatidic acids for regulating skin wrinkles
JP3241440B2 (en) * 1992-07-02 2001-12-25 有限会社野々川商事 Cosmetics
EP0577143B1 (en) * 1992-07-03 1999-01-27 ALFATEC-PHARMA GmbH Solid and liquid solutions of flavonoids
FR2697159B1 (en) * 1992-10-22 1995-01-13 Oreal Cosmetic or dermo-pharmaceutical composition containing in combination a lauroylmethionate of a basic amino acid and at least one polyphenol.
FR2699818B1 (en) * 1992-12-24 1995-02-03 Oreal Cosmetic or pharmaceutical composition containing in combination a polyphenol and an extract of gingko.
US5446452A (en) * 1993-02-05 1995-08-29 Litton; Charles J. Temperature monitoring system
US5358752A (en) * 1993-02-23 1994-10-25 Norac Technologies Inc. Skin care composition
DE4307983A1 (en) * 1993-03-13 1994-09-15 Beiersdorf Ag Active ingredients and cosmetic and dermatological preparations
AU6666594A (en) * 1993-04-20 1994-11-08 Procter & Gamble Company, The Methods of using hesperetin for sebum control and treatment of acne
FR2707491B1 (en) * 1993-07-02 1995-12-01 Oreal Cosmetic composition containing in combination a superoxide dismutase and a melanin pigment.
FR2718022B1 (en) * 1994-04-01 1996-04-26 Roussel Uclaf Cosmetic or dermatological compositions and their preparation.
DE4444238A1 (en) * 1994-12-13 1996-06-20 Beiersdorf Ag Cosmetic or dermatological drug combinations of cinnamic acid derivatives and flavone glycosides
FR2736829B1 (en) * 1995-07-20 1997-09-12 Oreal COMPOSITION FOR FIGHTING AGAINST SPOTS AND / OR AGING OF THE SKIN, USES THEREOF

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9618379A1 *

Also Published As

Publication number Publication date
WO1996018379A1 (en) 1996-06-20
ATE218059T1 (en) 2002-06-15
US6121243A (en) 2000-09-19
WO1996018382A1 (en) 1996-06-20
DE59510219D1 (en) 2002-07-04
EP1201227A3 (en) 2003-05-28
EP1300138A2 (en) 2003-04-09
JPH10510523A (en) 1998-10-13
EP0716847A1 (en) 1996-06-19
JPH10510522A (en) 1998-10-13
US20090131340A1 (en) 2009-05-21
US6423747B1 (en) 2002-07-23
ATE240092T1 (en) 2003-05-15
EP0799023A1 (en) 1997-10-08
DE29522371U1 (en) 2002-09-12
DE29522375U1 (en) 2002-08-22
EP0799023B1 (en) 2002-05-29
US20020160965A1 (en) 2002-10-31
US5952373A (en) 1999-09-14
JPH08259421A (en) 1996-10-08
US20020099095A1 (en) 2002-07-25
WO1996018381A1 (en) 1996-06-20
DE4444238A1 (en) 1996-06-20
JPH10510802A (en) 1998-10-20
US6180662B1 (en) 2001-01-30
DE59510687D1 (en) 2003-06-18
ES2199260T3 (en) 2004-02-16
US20020142012A1 (en) 2002-10-03
EP1300138A3 (en) 2003-05-28
ES2177673T3 (en) 2002-12-16
EP0799022A1 (en) 1997-10-08
US6562794B1 (en) 2003-05-13
EP1201227A2 (en) 2002-05-02
EP0797427A1 (en) 1997-10-01
WO1996018380A1 (en) 1996-06-20
EP0797427B1 (en) 2003-05-14
US6596761B2 (en) 2003-07-22
JPH10510803A (en) 1998-10-20

Similar Documents

Publication Publication Date Title
EP0799020A1 (en) Cosmetic and dermatological preparations with flavonoids
EP1296642B1 (en) Use of creatine and/or creatine derivatives in dermatological preparations
EP0945126B1 (en) Cosmetic or dermatologic composition containing carnitine and/or an acylcarnitine and at least an antioxidant
EP1594455B1 (en) Cosmetic or dermatological preparations containing creatine, creatinine and/or the derivatives thereof combined with soya bean extracts
EP1194115A1 (en) Topically applied idebenone-containing agent with protective and regenerative effect
WO2002009652A2 (en) Cosmetic or dermatological active ingredient combinations containing carnitine and the use thereof
DE102004032837A1 (en) Use of active compound combinations of one or more biochinones and one or more isoflavones for improving the skin contours
DE10136076A1 (en) Cosmetic or dermatological preparations containing creatinine or its derivative, useful e.g. for combating skin aging symptoms or treating inflammatory conditions such as eczema or psoriasis
EP1000603B1 (en) Use of surface-active citric acid esters for stabilizing flavones, flavanones or flavonoids, and synergistic mixtures, cosmetic and dermatological preparations containing them
DE19806946A1 (en) Combination of (acyl) carnitine and retinoid for use in skin care, effective e.g. against light-induced damage and inflammation
EP0998898B1 (en) Use of alkylglycosides for stabilizing of flavones, flavanones or flavonoids, and synergistic mixtures, cosmetic and dermatological preparations containing them
EP0995422A1 (en) Use of nitrilotriacetic acid for stabilizing of flavones, flavanones or flavonoids, and synergistic mixtures, cosmetic and dermatological preparations containing them
DE10316666B4 (en) Cosmetic or dermatological preparations with a combination of creatinine with creatine and coenzyme Q10
EP0995432A1 (en) Use of surfactants for stabilizing flavones, flavanones, flavanoids, synergistic compositions of flavones, flavanones, flavanoides and surfactants, use of said compositions in cosmetic or dermatological formulations
DE19845266A1 (en) Use of butylhydroxytoluene for stabilizing flavone, flavanone and/or flavonoid useful in cosmetic and dermatological formulations
DE19739044A1 (en) Use of di:hydro-robinetin as antioxidant and/or radical scavenger
EP0997133A1 (en) Use of 2-tert-butylhydroquinone for stabilizing of flavones, flavanones or flavonoids, and synergistic mixtures, cosmetic and dermatological preparations containing them
DE10127432A1 (en) Cosmetic or dermatological preparations for combating undesirable skin pigmentation, containing synergistic combination of tyrosine-O-sulfate ester (or analog) and alpha-lipoic acid

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970606

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20000203

APAB Appeal dossier modified

Free format text: ORIGINAL CODE: EPIDOS NOAPE

APAB Appeal dossier modified

Free format text: ORIGINAL CODE: EPIDOS NOAPE

APAD Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOS REFNE

APAB Appeal dossier modified

Free format text: ORIGINAL CODE: EPIDOS NOAPE

APAD Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOS REFNE

APBX Invitation to file observations in appeal sent

Free format text: ORIGINAL CODE: EPIDOSNOBA2E

APBX Invitation to file observations in appeal sent

Free format text: ORIGINAL CODE: EPIDOSNOBA2E

APBZ Receipt of observations in appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNOBA4E

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20040514

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE